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Chapter1
Elastin as a biomaterial for tissue engineering
     Willeke Daamen, 
     Jan van Hest,
     Jacques Veerkamp, 
     Toin van Kuppevelt. 
     Biomaterials, invited review.
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ABSTRACT
Biomaterials based upon elastin and elastin-derived molecules are increasingly 
investigated for their application in tissue engineering. This interest is fuelled by the 
remarkable properties of this structural protein, such as elasticity, self-assembly, long-
term stability, and biological activity.  Elastin can be applied in biomaterials in various 
forms, including insoluble elastin ﬁ bres, hydrolysed soluble elastin, recombinant 
tropoelastin (fragments), repeats of synthetic peptide sequences and as block 
copolymers of elastin, possibly in combination with other biopolymers. In this chapter, 
the properties of various elastin-based materials will be discussed, and their current 
and future applications evaluated.
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INTRODUCTION
Elastin-based materials are becoming more and more popular as biomaterials for tissue 
engineering. This interest is established by its remarkable properties. Elastin is an 
extracellular matrix protein that provides elasticity to tissues and organs. Therefore, 
elastin is most abundant in organs where elasticity is of major importance, like in 
blood vessels, which stretch and relax more than a billion times during life, in elastic 
ligaments, in lung and in skin [1-3]. Another important property of tropoelastin, the 
precursor protein of elastin, and elastin-like peptides is their potential to self-assemble 
under physiological conditions. This is the basis of the process of coacervation, which 
probably leads to alignment of tropoelastin molecules previous to intermolecular 
crosslinking [4,5]. The resulting insoluble elastin has a half-life of 70 years in men 
and is one of the most stable proteins known [6]. It is furthermore not just a structural 
protein. The biological activity of peptides derived from insoluble elastin has long been 
established and there is growing evidence for its biological role [7,8].
This chapter will ﬁ rst explain some basic aspects of elastin and elastic ﬁ bres, i.e. 
biochemistry, biophysics, elastic ﬁ bre morphology, elastic ﬁ bre assembly and 
physiological function of elastin. After that, we will discuss the use of elastin-based 
materials in biomaterials for tissue engineering applications. Exploitation of elastin in 
biomaterials is generally based on the before-mentioned characteristics. The properties 
of the different elastin preparations and materials prepared thereof will be reviewed 
and current and future applications in biomaterials will be evaluated as well.
BIOCHEMISTRY OF ELASTIN
Elastin is encoded by a single copy gene. Alternative splicing of transcripts results 
in various tropoelastin isoforms. The small exons of the elastin gene (up to 36) are 
interspersed by large introns [9,10]. Strong similarity exists between tropoelastins of 
different species, more than 70% on average. Perfect alignment is generally found 
in crosslinking domains and domains 33 and 36 (coding for the basic C-terminus) 
[11,12]. Some variations, however, exist among species. Bovine exons 34 and 35, for 
instance, are absent from the human gene, while this gene contains exon 26A coding 
for an unusual hydrophilic and charged domain, not described in other species. This 
exon is rarely expressed except in certain pathologies such as pulmonary hypertension 
[13,14]. Human elastin is synthesised as a ~72 kDa soluble precursor (tropoelastin) 
by a variety of cells including smooth muscle cells, endothelial cells, ﬁ broblasts and 
chondrocytes [15-19]. Elastin has an uncommon amino acid composition, with about 
75% hydrophobic residues (Gly, Val, Ala), and is highly insoluble due to interchain 
crosslinks [20]. As is the case in collagen, glycine accounts for one third of the amino 
acid residues and proline is present in high amounts. Most of the other amino acid 
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residues in collagen, however, are hydrophilic. The tropoelastin molecule typically 
consists of two types of domains encoded for by separate exons: hydrophobic domains 
with many Gly, Val, Ala and Pro residues which often occur in repeats of several 
amino acids, like Gly-Val-Gly-Val-Pro, Gly-Val-Pro-Gly-Val and Gly-Val-Gly-Val-Ala-Pro, 
and hydrophilic domains with many Lys and Ala residues which are important in 
crosslinking. Lys residues are often interspersed between Ala residues (e.g. Ala-Ala-Ala-
Lys-Ala-Ala-Lys-Ala-Ala) (Fig. 1) and are important in the formation of tetrafunctional 
crosslinks, since the hydrophobic domains of the elastin molecule juxtapose lysine 
residues involved in crosslinking. 
Figure 1. Primary structure of human tropoelastin represented as a block copolymer with hydrophobic and 
crosslinking domains. The amino acid composition is based on the cDNA of tropoelastin, and posttranslational 
modiﬁ cations are therefore not taken into account. Domains for hydrophobic and crosslink repeats were from 
[20], splice variants from the NCBI Entrez Protein website for human tropoelastin (accession no. P15502).
Three hydrophobic domains ﬂ anking two crosslinking domains are sufﬁ cient to support 
this self-assembly process [21]. Four Lys residues from two tropoelastin molecules react 
with each other to form desmosine and isodesmosine (Fig. 2), but other Lys-based 
crosslinks are found as well [22-26]. Recently, a transglutaminase crosslink between 
tropoelastin and ﬁ brillin-1 has been identiﬁ ed, too [27]. Intermolecular crosslinking 
results in an highly insoluble polymer with crosslinks at roughly every 65-70 residues 
[28].
Figure 2. Speciﬁ c elastin intermolecular crosslinks include the tetrafunctional desmosine and isodesmosine 
formed from four Lys residues from two different tropoelastin molecules.
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BIOPHYSICS OF ELASTIN
A number of biophysical properties is crucial for the biomechanical/physiological role 
of elastin in the body. Elasticity, glass transition and coacervation will be discussed here 
only brieﬂ y, and the reader is referred to some excellent reviews on the subject: theories 
on the molecular mechanism of the elasticity of elastin [11,29,30], elasticity and glass 
transition [31] and coacervation [32]. With regard to elasticity, it is generally accepted 
that the driving force for the spontaneous recoil of stretched elastin is entropic in origin 
[33]. For an ideal elastomer in the extended mode, all the energy is taken up by the 
backbone and can be recovered upon relaxation [29]. The glass transition temperature 
(Tg) is an important characteristic of polymers. Below the Tg, a polymer will generally 
behave as a rigid/brittle material, whereas above the Tg the polymer behaves as an 
elastomer or a viscous ﬂ uid. Elastin undergoes a glass transition in a temperature range 
that depends on its water content [34,35]. In the dehydrated state, Tg is about 200°C, 
at 30% hydration it is about 30°C [36]. A second phase transition that can occur 
with tropoelastin as well as with elastin-based materials is coacervation. At ambient 
temperature, tropoelastin is soluble in aqueous solutions. However, upon raising the 
temperature, the solution becomes cloudy due to self-aggregation of the molecules as a 
result of interactions between hydrophobic domains. Elastin-based polypeptides lacking 
hydrophobic domains, e.g. those based on crosslinking domains, cannot coacervate 
[37-39]. After centrifuging, a liquid-liquid phase separation occurs with on the bottom 
a highly-viscous, highly-concentrated tropoelastin or peptide fraction, and on top an 
aqueous solution. Temperature, protein concentration, salt concentration and pH all 
have an effect on coacervation behaviour as does the presence of other molecules like 
glycosaminoglycans [5,38,40]. Coacervation is a lower critical solution temperature 
(LCST) phenomenon, which means that the protein forms ordered structures upon 
raising temperature. The loss of entropy from the protein chain is compensated by the 
release of water [40,41]. Coacervation is a self-assembly process [42] thought to align 
tropoelastin molecules in vivo prior to crosslinking [4,5,43].
MORPHOLOGY OF ELASTIC FIBRES
Elastin comprises up to 70% of the dry weight in elastic ligaments, about 50% in 
large arteries, 30% in lung, and 2-4% in skin [20,44,45]. In general, elastic ﬁ bres 
are present as rope-like structures like in ligaments,  in the media of elastic arteries 
and in skin [1]. Fig. 3 shows light microscopical and scanning/transmission electron 
microscopical pictures of bovine aorta and ligament. The media is separated from the 
intima (lumen-side) by the lamina elastica interna, a layer that is formed by fusion of 
mainly longitudinally directed elastic ﬁ bres (insert in Fig. 3E). The lamina elastica is 
important for the resilience of blood vessels, its pores allowing exchange of nutrients/
metabolites. In ligaments, elastin ﬁ bres are generally present as parallel-oriented 
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structures. In elastic cartilage, present in e.g. auricle (external ear) and epiglottis, 
elastic ﬁ bres are oriented into honeycomb structures [46].
ELASTIC FIBRE ASSEMBLY
Elastic ﬁ bres are essentially composed of two elements: amorphous elastin and 
microﬁ brils, which are 10-12 nm in diameter and primarily composed of ﬁ brillin-
1 [47]. Fibre assembly is a complicated process and many different molecules are 
Figure 3. Light microscopical (LM) staining (Verhoeff - Van Gieson) of bovine aorta (A) and ligament (B) 
show elastic ﬁ bres in black and collagenous material in grey. Transmission electron micrographs (TEM) 
of bovine aorta (C) and ligament (D) and scanning electron micrographs (SEM) of partly puriﬁ ed bovine 
aorta (E) and ligament (F) reveal elastic ﬁ bre ultrastructure and clearly show differences in elastic ﬁ bre 
organisation and elastic ﬁ bre diameter between the two organs. Insert in E shows lamina elastica of aorta. 
Arrows indicate microﬁ brils. Bar represents 10 µm in A, B, E, F, and 1 µm in C, D.
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involved in its development. Tropoelastin is synthesised in the rough endoplasmatic 
reticulum and undergoes few intracellular posttranslational modiﬁ cations, including 
release of the signal peptide and hydroxylation of some Pro residues by the enzyme 
prolyl hydroxylase. Intracellularly, tropoelastin is immediately bound to the 67 kDa 
elastin-binding protein to prevent intracellular aggregation [48]. This chaperone is also 
a sub-unit of the elastin-laminin receptor (Fig. 4) which is present on many cell types, 
including ﬁ broblasts, vascular smooth muscle cells, endothelial cells, chondrocytes, 
monocytes, lymphocytes and polymorphonuclear leukocytes [49]. The receptor is 
composed of two transmembrane subunits of 61 and 55 kDa and the 67 kDa elastin 
binding protein and has a binding site for elastin or laminin and for a galactoside 
(e.g. lactose or a glycosaminoglycan like chondroitin sulphate or dermatan sulphate) 
[50,51]. The elastin-binding protein only releases tropoelastin upon binding of the 
galactosugars of the microﬁ brillar component in the extracellular space. The binding 
for both tropoelastin and its membrane-bound 55 kDa subunit is then dramatically 
reduced resulting in the release of tropoelastin from the elastin-binding protein and 
the release of the elastin-binding protein from the transmembrane subunit after which 
this is recycled [48,52]. Outside the cell, the microﬁ brillar components act as a scaffold 
onto which elastin is deposited, the microﬁ brils ultimately ending up in and around 
the elastic ﬁ bre. Tropoelastin molecules are crosslinked to each other involving the 
copper and vitamin B6-requiring enzyme lysyl oxidase, resulting in the formation of 
speciﬁ c interchain crosslinks like (iso)desmosine [13,45,53]. Crosslinking results in 
mature elastin which is insoluble and extremely stable. Once microﬁ brils are present, 
ﬁ bre formation can occur without the presence of cells [54].
Figure 4. A model for the elastin-laminin receptor which is comprised of three subunits (55, 61 and 67 kDa). 
Tropoelastin binds to the complex via the elastin-binding protein (A). Upon binding of a galactosugar, the 67 
kDa subunit and tropoelastin are released (B). Figure reproduced from [32] with permission.
16
ch
ap
te
r 
1
el
as
ti
n 
as
 a
 b
io
m
at
er
ia
l f
or
 t
is
su
e 
en
gi
ne
er
in
g
Next to elastin, the elastic ﬁ bre contains or is associated with a variety of molecules 
including ﬁ brillins, microﬁ bril-associated (glyco)proteins (MAGPs), latent TGFβ-
binding proteins, ﬁ bulins, emilins, proteoglycans and lysyl oxidases [55]. Recent 
research indicates that the proteins ﬁ bulin-1, ﬁ bulin-5 and lysyl oxidase-like 1 (LOXL-
1) are involved in elastogenesis [56-59]. Heparan sulfate, a glycosaminoglycan, also 
plays a role in elastic ﬁ bre formation and was found to interact with tropoelastin and 
to be present in human dermis elastic ﬁ bres [54,60].
PHYSIOLOGICAL FUNCTION OF ELASTIN
Not only tropoelastin is capable to interact with the elastin-laminin receptor; elastin 
degradation products and synthetic polypeptides are also able to bind [50,61-64]. 
Effects of elastin(like) molecules mediated by the receptor include elastin synthesis [7], 
chemotaxis [65,66], inhibition of vascular calciﬁ cation [67], proliferation of ﬁ broblasts 
[68], astrocytes [69], glioma cells [70], arterial smooth muscle cells [63], keratinocyte 
migration and differentiation [71], vasorelaxant activity [72], and regulation of matrix 
protease activity [73]. Other receptors may be of importance as well, e.g. integrins 
[74]. Tissue regeneration can thus be inﬂ uenced by the presence of these molecules. 
Especially, induction of elastin synthesis may accelerate tissue healing since this key 
element in e.g. skin is difﬁ cult to restore when damaged. However, the presence of 
elastin (peptides) may also result in adverse effects, since an indirect role in tumour 
progression by upregulation of matrix metalloproteinases has been reported [75].
Mutations involving elastic ﬁ bres are important in understanding the function of 
elastin and the process of elastogenesis. Here, we will give some examples of elastic 
ﬁ bre-associated diseases and corresponding mouse models. Additional information 
can be found elsewhere [76-79]. Congenital supravalvular aortic stenosis (SVAS) is 
a pathological condition associated with a mutation in the elastin gene, resulting 
in left ventrical outﬂ ow obstruction and narrowing of the arterial lumen due to a 
failure to regulate cellular proliferation and matrix deposition of elastin [80-84]. It is 
caused by truncation and lack of some crosslink domains and the C-terminal region, 
or deﬁ cient coacervation of tropoelastin molecules [81,85]. Elastin hemizygosity is 
used as a mouse model for SVAS [83]. Elastin null mice die within 4 days after birth 
from a subendothelial accumulation of proliferating vascular smooth muscle cells that 
obstruct the vascular lumen [8,86]. SVAS can be inherited autosomal dominantly or as 
a part of the Williams’ syndrome [87]. Another pathology linked to the elastin gene is 
the rare autosomal dominant disease cutis laxa [88-90] which is caused by a frameshift 
mutation characterised by inelastic loose-hanging skin, hernias, and emphysema due 
to abnormally branched and fragmented elastic ﬁ bres with reduced elastin deposition 
in the elastic ﬁ bres and fewer microﬁ brils in the dermis [91,92]. Elastin is not the 
only molecule to cause the autosomal dominant form of cutis laxa, since mutations 
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in ﬁ bulin-5 also result in cutis laxa [93,94]. A mouse model for cutis laxa involving a 
ﬁ bulin-5 mutation exists [58,95]. Changes in other molecules found in elastic ﬁ bres 
may give rise to malfunctioning or abnormal structure. Marfan syndrome (MFS) 
is associated with mutations in the gene encoding ﬁ brillin-1, and is an autosomal 
dominant disorder characterised by pleiotropic manifestations involving primarily the 
ocular, skeletal, and cardiovascular systems [77,96]. Clinical features involved in the 
cardiovasculature include aortic aneurysms, diffuse elastic ﬁ bre calciﬁ cation, intimal 
hyperplasia, and elastolysis. Elastic ﬁ bres in the vessel wall can be fragmented and 
accumulated amorphous elastin is found [97]. This suggests a primary structural 
deﬁ ciency, but targeted mutation of the mouse ﬁ brillin-1 gene (homozygous mg∆)
has suggested that deﬁ ciency of ﬁ brillin-1 reduces tissue homeostasis. This results in 
aortic dilatation and dissection, leading to haemopericardium or haemothorax rather 
than malformation of the elastic ﬁ bre [98]. A homozygous mutation in the mouse 
ﬁ brillin-1 gene (mgR) results in underexpression of ﬁ brillin-1 and leads to MFS-like 
manifestations [99].
ELASTIN AS A BIOMATERIAL
Incorporation of elastin in biomaterials is especially signiﬁ cant when its elasticity or 
biological effects can be exploited. However, several problems may occur when using 
elastin as a biomaterial. One of them is calciﬁ cation, a poorly-understood phenomenon 
in biomaterial science, and often occurring in cardiovascular prosthetic implants (e.g. 
bioprosthetic heart valves and aortic homografts). Besides crosslinked cellular debris, 
elastin and collagen may serve as nucleation sites for mineralisation, independent 
of cellular components [100-102]. Calciﬁ cation may be genetically controlled by 
molecules that actively inhibit calciﬁ cation and may occur passively when these 
inhibitors are absent [103]. Calciﬁ cation can be prevented or reduced by aluminium 
chloride treatment [104], acyl azide crosslinking [105], ethanol/EDTA treatment [106], 
and presence of glycosaminoglycans [107].
Elastin can be used in biomaterials in different forms, including insoluble elastin in 
autografts, allografts, xenografts, decellularised extracellular matrix, and in puriﬁ ed 
elastin preparations. Insoluble elastin may also be hydrolysed to obtain soluble 
elastin preparations. Repeated elastin-like sequences can be produced by synthetic or 
recombinant means. Furthermore, recombinant tropoelastin or tropoelastin fragments 
can be used in biomaterials. Table 1 gives an overview of different forms of elastin 
and their molecular characteristics which we will now discuss with their (potential) 
applications.
18
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Table 1. Various forms of naturally occurring and (bio)synthetic elastin.
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BIOMATERIALS DERIVED FROM NATURAL ELASTIN
Elastin in autografts, allografts and xenografts
Evidently, autografts, allografts and xenografts contain elastic ﬁ bres. Well-known 
examples are split-skin autografts for burn wounds, autologous saphenous veins and 
umbilical vein allografts for coronary artery bypass graft surgery, and aortic heart valve 
xenografts. However, it is beyond the scope of this article to discuss characteristics and 
performances of these grafts.
Decellularised tissues containing elastin
We deﬁ ne decellularised tissues as tissue pieces that are puriﬁ ed in such a way as to 
remove cells but to maintain the three-dimensional architecture of the tissue. Cells 
have to be removed from these tissues, because cellular remnants irrevocably lead 
to an immunological response, e.g. we showed a rather severe tissue reaction with 
subcutaneous implanted rinsed elastic ligament preparation containing damaged cells 
[135]. The apparent advantage of decellularised constructs is that the structural design 
of the tissue is preserved in contrast to the preparation of scaffolds from puriﬁ ed 
components. On the other hand, this limits its application primarily to the tissue it is 
obtained from, for example decellularised bladder for bladder augmentation [110] and 
decellularised heart valves and vasculature for heart valve replacement and vascular 
grafts [102,136]. Some tissues, however, could also be used for other applications, e.g. 
decellularised bovine pericardium to enhance bone formation [137]. Other drawbacks 
of decellularised tissue are that it is difﬁ cult to obtain highly puriﬁ ed preparations from 
intact tissue (compared to pulverised material), and that decellularised tissue may 
result in ill-deﬁ ned preparations with large batch-to-batch variations. Decellularisation 
is performed with a wide variety of extraction methodologies, including detergents 
(Triton, SDS) and enzyme digestions (e.g. trypsin). Decellularisation by Triton 
or trypsin also changes the extracellular matrix composition [138]. It is difﬁ cult to 
compare results obtained from different laboratories, since each protocol will result 
in its own set of residual extracellular matrix components. In addition, it is unknown 
which molecule causes a speciﬁ c effect with these complex preparations.
Puriﬁ ed elastin preparations
Puriﬁ cation is important when studying the effect of mature extracellular elastin in 
ﬁ brous form (containing its natural crosslinks like (iso)desmosine) without introducing 
artefacts to the system by impurities. In applied research, like the use of elastin in 
biomaterials and tissue engineering, the puriﬁ ed intact ﬁ bres may be useful when 
preparing molecularly-deﬁ ned bioscaffolds from scratch thus avoiding unwanted 
immunological reactions to contaminations, and allowing studies to the body’s 
response to one single component: elastin [114]. Due to the intermolecular crosslinks 
in elastin, the protein is highly insoluble. In fact, elastin can only be dissolved after 
hydrolysing some peptide bonds. This insolubility is often used for isolation of elastin 
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from tissues. Historically, bovine and equine ligamentum nuchae have been used as a 
source for insoluble elastin, because a large percentage of their dry weight is elastin. 
Lansing et al. [111] isolated elastin from ligamentum nuchae based on treatment with 
0.1 M NaOH at 95°C for 45 min. Rasmussen et al. [139] used a puriﬁ cation procedure 
based on autoclaving at 120°C for 5 h. John and Thomas [112] obtained elastin from 
aorta and pulmonary tissues with a more gentle procedure using extraction steps with 
NaCl, guanidine-HCl, organic solvents, and digestions with collagenase and trypsin. 
Elastin has also been isolated by others from tissues like aorta [108], lung [140] and 
skin [141]. We have compared different puriﬁ cation protocols [142] and improved the
puriﬁ cation protocol of John and Thomas [114] in such a way that no contaminations 
were observed with a number of analytical techniques including SDS-PAGE, amino 
acid and sulfhydryl analysis (microﬁ brillar proteins like ﬁ brillin contain many Cys 
residues), and histological-based  techniques including bright ﬁ eld  microscopy 
(Verhoeff – Van Gieson and resorcin fuchsin – Van Gieson staining), ﬂ uorescence 
microscopy (immunostaining for type I and IV collagen and several ﬁ brillin epitopes), 
and electron microscopy. We found that the most discriminative method to evaluate the 
purity of elastin was transmission electron microscopy. Microﬁ brillar-like remnants are 
electron-dense structures in electron microscopy, and are readily distinguished from 
the electron translucent elastin. We found microﬁ brillar-like remnants with all three 
traditional methods tested, but not with our adapted method [142]. Later, we optimised 
the puriﬁ cation procedure, because we found a precarious equilibrium to exist between 
purity and intactness of the elastic ﬁ bres. We then proposed the term ‘elastin ﬁ bre’ for 
an intact elastic ﬁ bre with elastin as its sole component (Fig. 5) [114]. An advantage of 
puriﬁ ed elastin is that it can be moulded into different shapes. Puriﬁ ed elastin allows 
the construction of highly-deﬁ ned scaffolds, e.g. scaffolds can be composed consisting 
of elastin and collagen. Some collagen appeared to be essential to obtain coherent 
scaffolds. Properties of scaffolds can be controlled by varying different parameters, e.g. 
the ratio of collagen and elastin, extent/methodology of chemical crosslinking and the 
incorporation of other components, like glycosaminoglycans [143].
Hydrolysed elastin: soluble forms of elastin
Hydrolysed elastin (also known as solubilised elastin or elastin peptides) is also used 
in biomaterials. Most frequently used methods to prepare soluble elastin peptides are 
treatment with 0.25 M oxalic acid at 100°C [117] and 1 M KOH in 80% ethanol at 
37°C [118]. Proteolytic enzymes capable of degrading elastic ﬁ bres, including serine-
type elastases from polymorphonuclear leukocytes and several metallo-elastases of 
monocyte/ macrophage origin, also result in solubilised elastin [120,144]. Pepsin in 
0.5 M acetic acid at 37°C [145] and 0.5 M HCl at 80°C [119] are rarely employed. 
All these methods are based on hydrolysis of some peptide bonds of the insoluble 
elastin. Elastin peptides obtained after oxalic acid hydrolysis can be coacervated after 
suspension in 10 mM sodium acetate with 10 mM NaCl set to pH 5.5 with acetic 
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Figure 5. Transmission electron micrographs (A, C) and scanning electron micrographs (B, D) of intact equine 
ligamentum nuchae (A, B) and elastin ﬁ bres (C, D) puriﬁ ed hereof.  E= elastin; C= collagen ﬁ brils; arrows 
indicate microﬁ brils; Bar is 1 µm in TEM micrographs and 10 µm in SEM micrographs. Figure reproduced 
from [114] with permission.
acid, followed by heating and centrifugation at 37°C. Two fractions will be formed: 
α-elastin (a viscous coacervate) and β-elastin (in the supernatant) [38]. Using KOH, 
κ-elastin is formed which is a heterogeneous mixture of elastin peptides with a mean 
molecular mass of approximately 70 kDa, soluble in aqueous solutions [118]. The great 
advantage of these preparations is obviously their solubility which makes handling 
and analysis of the material more straightforward. In addition, elastin peptides 
inﬂ uence signalling, chemotaxis, proliferation and protease release via the elastin 
receptor [146]. Biomaterials containing solubilised elastin may thus exert biological 
effects (like increasing elastin synthesis) on a wide variety of cell types, and are 
especially beneﬁ cial when they can accomplish this effect over a longer period of time. 
A depot of these molecules in the biomaterial is thus recommendatory. Solid discs 
have been prepared from α-elastin by polymerising coacervated elastin with a diepoxy 
crosslinker. The elastic modulus could to some extent be modulated by the degree of 
crosslinking. In a preliminary experiment, vascular smooth muscle cells adhered to 
elastin discs, but showed decreased proliferation on the material [147]. We recently 
showed that crosslinked scaffolds composed of insoluble collagen and solubilised 
elastin not only induced angiogenesis, but also increased elastic ﬁ bre synthesis, as 
shown with antibodies against rat ﬁ brillin-1 and rat elastin. In addition, these scaffolds 
showed no calciﬁ cation in young Sprague Dawley rats (a sensitive calciﬁ cation model) 
in contrast to scaffolds containing insoluble elastin [148]. The cell biological effect 
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may be modulated by the amount of solubilised elastin in the scaffold and the extent of 
crosslinking. Materials based upon α-elastin or elastin ﬁ bres with type I and III collagen 
can be prepared [149,150], in combination with glycosaminoglycans  [151] or calcium 
phosphate [152]. Elastin preparations combined with ﬁ brin have also been prepared 
[153]. The potential of collagen-elastin and collagen-ﬁ brin materials were evaluated 
in in vivo models, e.g. as a tympanic membrane [154] and as a dural substitute [155]. 
Finally, solubilised elastin has been used to improve the biocompatibility of synthetic 
materials such as polyethylene glycol terephthalate (PET) [156].
BIOMATERIALS DERIVED FROM (BIO)SYNTHETIC ELASTIN
General
Using protein engineering, many different parameters of elastin-like molecules can 
be controlled; including amino acid sequence, peptide length, and -in the case of 
block copolymers- the length and number of the blocks. Another advantage is the 
opportunity to incorporate speciﬁ c sequences that have cell biological effects, like 
the Arg-Gly-Asp (RGD) sequence [157]. With this method, tailor-made proteins can 
be made, e.g. combining the properties of two proteins. Recombinant expression 
systems result in highly homogeneous protein preparations (composition, sequence 
and molecular mass) as opposed to molecules prepared by peptide synthesis [158]. On 
the other hand, with peptide synthesis it is easier to incorporate non-natural amino 
acids which may be useful in modiﬁ cation or crosslinking reactions. The thermally-
responsive behaviour of elastin-like polypeptides may also be exploited in biomaterials 
(soluble below transition temperature Tt, but aggregated above Tt), for example as 
injectable biomaterials.
It is important to study the in vivo reaction to (bio)synthetic proteins, since it is not 
known what biological effects they may exhibit. For every variation in the engineered 
protein, the in vivo biocompatibility should be tested independently. Until now, few 
biomaterials containing elastin-like polypeptides have been studied in vivo.
Tropoelastin
Tropoelastin can be produced by two methods; either by isolation from copper-deﬁ cient 
animals [115,116] or by molecular biological techniques [121]. The latter is preferred 
since isolation from copper-deﬁ cient animals is an animal-unfriendly method with low 
yield.
In 1990, the complete human tropoelastin molecule was expressed in a bacterial system 
[121]. Tropoelastin does not contain any crosslinks in contrast to puriﬁ ed elastin ﬁ bres. 
However, it was possible to crosslink tropoelastin using the enzyme lysyl oxidase in 
the absence of other macromolecules [159]. An advantage of recombinant elastin is 
that different tropoelastin isoforms can be prepared [5,122], including those which 
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rarely occur like the splice variant formed by inclusion of human exon 26A which 
is primarily expressed in certain diseases [13,14]. Weiss’ group started to use whole 
recombinant tropoelastin molecules to build elastic patches. Recombinant human 
tropoelastin was crosslinked into existing elastin by adding it to neonatal rat aorta 
smooth-muscle cell cultures. As much as 
12% of the supplemented recombinant 
protein  was incorporated into the insoluble 
elastin with formation of the elastin 
crosslinks desmosine and isodesmosine in 
a time-dependent fashion. The capacity of 
elastin to self-assemble was also used to 
make biomaterials like sponges, sheets and 
tubes from human tropoelastin (Fig. 6).
Tubes were made by coiling an elastin sheet. 
Biomaterials were subsequently crosslinked 
with bis(sulfosuccimidyl) suberate in 
PBS at 37°C to facilitate coacervation and 
crosslinking. Stress-strain curves showed 
elasticity up to 150% strain and Young’s moduli ranged from 220-280 kPa [124]. These 
recombinant elastin biomaterials would be even more promising and closer to nature 
if they could be fully crosslinked by the enzyme lysyl oxidase.
Tropoelastin fragments
Fragments of the human tropoelastin molecule expressed in E. coli can also self-
aggregate to form a coacervate [42]. Three hydrophobic domains ﬂ anking two 
crosslinking domains were sufﬁ cient to achieve self-assembly (Fig. 7) [21]. For 
example, human elastin peptides based on the sequences of exons 20-(21-23-24)2 of 
the elastin gene [hydrophobic (20 and 24) – crosslinking (21-23)],  spontaneously 
formed ﬁ brillar matrices after coacervation [39]. Coacervation of peptides based on 
the sequences of exons 20-(21-23-24) and exons 20-(21-23-24)2 caused aligning of 
Lys residues so that crosslinking with the oxidising agent pyrroloquinoline quinine 
(PQQ) in the presence of copper sulfate resulted in zero-length crosslinks, including 
desmosine and isodesmosine. A crosslinked sheet of this material had a lower elastic 
modulus than puriﬁ ed insoluble elastin from aorta (0.25 MPa vs. 0.81 MPa), but a 
similar resilience (~80%) [21]. Tropoelastin fragments based on exons 20-(21-23-24)2
may have potential to inhibit thrombosis in vascular grafts, and their application as 
a coating for synthetic materials has been explored. In vitro, platelet adhesion and 
activation were signiﬁ cantly reduced. In a rabbit model, a coating of these polypeptides 
on polyurethane catheters resulted in a marked increase in catheter patency and a 
signiﬁ cant decrease in ﬁ brin accretion and embolism [160].
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Figure 7. Postulated alignment of elastin peptides during coacervation juxtaposing side chains of lysine 
residues for the formation of covalent crosslinks. Hydrophobic domains (square planar structures) of two 
molecules interact with each other via hydrophobic side chains (spherical structures) and thus allow alignment 
of cross-linking domains (cylinders) with their pairs of lysine residues. Figure is reproduced from [39] with 
permission.
Elastin-like polypeptides
Urry and co-workers showed that physical properties of repetitive elastin-like 
polypeptides are highly dependent on the amino acid composition of the peptide repeat. 
One particular property of these polypeptides is the transition temperature Tt. The Tt
of polymers based on (Val-Pro-Gly-Xaa-Gly)n could be extensively manipulated by the 
amino acid at the Xaa position and resulted in a dependency on e.g. temperature, pH, 
and electrochemical potential. As an  example, a more hydrophobic amino acid (Trp) 
results in a lower Tt than a more hydrophilic amino acid (Glu) [161].
For the preparation of functional materials, high molecular mass polymers and 
crosslinkable systems are favourable. Urry et al. prepared various elastin-like materials 
by polymerisation of elastin pentapeptides, ﬁ rst by chemical synthesis, and later by 
recombinant expression systems. These include (Val-Pro-Gly-Val-Gly)n, (Gly-Val-Gly-
Val-Pro)251, and (Gly-Val-Gly-Ile-Pro)260, which were coacervated and subsequently 
crosslinked by γ-irradiation [125,162,163]. The elastin-like polymers could be produced 
in large quantities. Several bioelastic materials have been tested in animal models for 
soft-tissue restoration, e.g. as interpositional materials in intervertebral-disc restoration 
in a rabbit model [164]. Other potential applications are ﬁ lling material for urinary 
incontinence, urinary bladder reconstruction, and prevention of post-operative tissue 
adhesions [165].
In order to obtain a better deﬁ ned crosslinkable system, McMillan et al. expressed 
the synthetic elastin sequence (Val-Pro-Gly-Val-Gly)n where the bold Val residue was 
replaced with Lys every ﬁ fth repeat as a potential crosslinking site [127]. Huang et al.
[166] prepared ﬁ bres and non-woven fabrics from 39 repeats of this (Val-Pro-Gly-Val-
Gly)4(Val-Pro-Gly-Lys-Gly) sequence using electrospinning (also see section ‘Vascular 
constructs’). [167]. The coacervation temperature of this peptide is about 75°C. When 
functionalising this sequence with methacrylate to facilitate site-speciﬁ c solid-state 
photo-crosslinking, the coacervation temperature was reduced (up to 50°C), but no 
appreciable effect on ﬁ bre morphology was observed [168]. Lee et al. constructed 
(Gly-Val-Gly-Val-Pro)n where the bold Val residue was replaced with either Glu or Lys 
per 6 pentapeptides. The molecular mass of these polypeptides was 88 and 87 kDa, 
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respectively. Hydrogels and ﬁ bres (by solution spinning) were prepared from this block 
polymer by chemically crosslinking 50% Glu-substituted and 50% Lys-substituted 
polypeptide with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in the presence of 
N-hydroxybenzotriazole [125].
Tamburro’s group have prepared block polymers from glycine-rich elastin regions (Xaa-
Gly-Gly-Yaa-Gly)n via chemical synthesis in solution, where Xaa/Yaa is Val/Leu, Leu/
Val, Lys/Val and Orn/Orn. Only (Lys-Gly-Gly-Val-Gly)n, and (Orn-Gly-Gly-Orn-Gly)n,
both polydisperse polymers up to 14 kDa, were intermolecularly crosslinked either by 
glutaraldehyde and/or by the succinimidyl ester of glutaric acid to obtain biomaterials 
[169]. Although structural analysis was performed, mechanical and biocompatibility 
studies are lacking.
Another way to change material characteristics is to vary the composition of a complete 
protein block as was done in elastin-mimetic protein block copolymers containing 
identical hydrophobic endblock sequences separated by a central hydrophilic block (of 
varying composition). Mechanical properties of elastin-based protein ﬁ lms made from 
these protein block copolymers depended largely on the midblock amino acid sequence 
[128]. Hydrogels were made from elastin-mimetic proteins with a high molecular mass 
of up to 150 kDa [170]. 
Hybrids of elastin with other molecules
Elastin-ﬁ bronectin polypeptides: The CS5 domain of ﬁ bronectin is important in 
promoting the attachment and spreading of endothelial cells over that of ﬁ broblasts, 
vascular smooth muscle cells and blood platelets [171]. Artiﬁ cial proteins consisting 
of elastin-like peptides interspersed with the CS5 domain were produced in E. coli,
puriﬁ ed using its LCST behaviour and showed to be elastic and to promote human 
umbilical vascular endothelial cell (HUVEC) adhesion [130,172]. These elastin-
ﬁ bronectin polypeptides can be controlled by their amino acid sequence, length and 
spacing of the different blocks and degree of  crosslinking [130]. Furthermore, the 
placement of Lys residues (for crosslinking purposes) in the artiﬁ cial polypeptides is 
important in HUVEC spreading and their resistance to centrifugal detachment forces 
[129]. Initially, glutaraldehyde was used to crosslink elastin-CS5 materials [130]. 
Later, other crosslinkers including dissuccinimidyl suberate in DMF, hexamethylene 
diisocyanate in DMSO and bis(sulfosuccinimidyl) suberate were used, although tensile 
strength of materials crosslinked with the latter was less than of natural elastin (~0.2 
MPa vs. 0.3-0.6 MPa)  [173,174]. Such materials may be used as synthetic grafts. Under 
physiological shear stress, 70% of the cells stayed attached [172].
Silk-elastin polymers: Spider dragline silk (spidroin) consists largely of glycine and 
alanine repeats and displays ultimate tensile strength, in combination with high 
elasticity. Spider silks can be expressed in plants by retention in the endoplasmatic 
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reticulum [175]. Recently, spider silk-elastin fusion proteins of a 51.2 kDa spider silk 
and a 94.2 kDa elastin-like protein (separated by a c-myc tag for detection) were 
prepared by a similar approach and were cytocompatible for human chondrocytes 
[132].
Threads from the silk worm (ﬁ broin) are mainly composed of glycine, alanine and 
serine. The ﬁ broin molecule comprises a crystalline and amorphous region (ratio ~2:1). 
Recombinant ﬁ broin-like proteins can be synthesised, but have a low aqueous solubility 
which limits their biomedical application. Cappello et al. therefore synthesised polymers 
composed of ﬁ broin-like crystalline blocks (Gly-Ala-Gly-Ala-Gly-Ser) and elastin-like 
blocks (Gly-Val-Gly-Val-Pro) in E. coli. Silk-elastins provide an example of customising 
material properties of proteins up to ~1000 amino acid residues [131]. Depending 
on sequence and composition, silk-elastin polymers display LCST behaviour. Stimuli-
responsive silk-elastin polymers can be prepared since Tt decreases with increasing 
polymer length, polymer concentration and ionic strength. By replacing a Val by Glu, 
Tt also responds to pH (until pH 7.0) [176]. Block composition and polymer length are 
of major importance for mechanical properties, biodegradability (which is primarily 
by enzymatic hydrolysis) and physiological properties of these proteins. Possible 
applications are drug-delivery [177] and gene delivery systems [178,179]. Unlike most 
of the other hybrid materials, silk-elastin polymers have been studied in vivo. However, 
as Megeed et al. clearly point out the in vivo response needs to be investigated into 
more depth, especially since some antibodies can be raised against the silk-block in 
some silk-elastin polymers [180,181].
Fusion proteins: Another biological application of elastin-like polymers such as the 
polypentapeptide (Val-Pro-Gly-Xaa-Gly)n (Xaa is any amino acid except Pro) was drug 
delivery. Recombinant polypentapeptides expressed in E. coli could be puriﬁ ed based 
upon their phase transition [182], and when using the elastin-like polypeptide as a 
tag, other proteins could be puriﬁ ed based on this characteristic as well [183]. When 
drugs were conjugated to thermally-responsive polypeptides with a Tt of 41°C, delivery 
was possible to solid tumours based on local hyperthermia with enhanced endocytic 
uptake [184,185].
Synthetic polymers combined with elastin sequences: Furthermore, elastin-like 
sequences have been coupled to synthetic polymers. Ayres et al. prepared a block 
copolymer with a central poly ethylene glycol (PEG) chain and polymethacrylate
ﬂ anking blocks whose side chains were functional with Val-Pro-Gly-Val-Gly. These 
hybrid materials maintained an LCST behaviour as they displayed a similar coacervation 
behaviour as tropoelastin [133]. Amino acid residues in the main chain of a linear 
elastin polypeptide have also been functionalised with methacrylate in order to obtain 
a photocrosslinkable site [168]. Another example are photopolymerisable hydrogels
from PEG diacrylate derivatives that were mixed with Val-Ala-Pro-Gly-modiﬁ ed 
PEG monoacrylate derivatives to which smooth muscle cells could adhere, whereas 
platelets and ﬁ broblasts could not [134]. Synthetic elastin peptides can also be added 
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to scaffolds, hydrogels or surface coatings, e.g. elastin-laminin-like hybrid peptides 
to alginate dressings [186] and tropoelastin fragments coating for synthetic tubing 
[160].
APPLICATIONS OF ELASTIN AS A BIOMATERIAL
Elastin(-like) biomaterials have been suggested for a wide variety of applications, 
including skin substitutes [187], vascular grafts [188], heart valves [189], and elastic 
cartilage [190]. In this section, we will focus on skin, tubular constructs (for vascular 
grafts) and self-assembling materials.
Skin
Skin substitutes are usually applied to treat either burn wounds or chronic wounds. 
Elastic ﬁ bres are important components of the skin, but their production is usually 
limited in tissue engineered constructs. For instance in the skin substitute Apligraf, 
a type I collagen gel with cultured  human neonatal foreskin dermal ﬁ broblasts and 
keratinocytes,  little elastin was synthesised in vitro and elastin was not organised 
in ﬁ bres [191]. In addition, elastin expression in burn wounds grafted with sheets 
of cultured epithelial autografts may take 4–5 years [192]. Autologous skin grafting 
is still the gold standard for skin substitutes. Autografts, allografts, xenografts and 
deepidermised dermis of course still contain elastic ﬁ bres. The latter is made from fresh 
cadaver skin by removal of the epidermis and the cells from the dermis so that the 
extracellular matrix and basement membrane are maintained [193]. These materials 
have been extensively applied. However, only few researchers have explored the use 
of elastin(-like) containing materials as skin substitutes. These include a decellularised 
porcine membrane of approximately 70% collagen and 30% insoluble elastin and 
minor amounts of glycosaminoglycans [194], scaffolds of type I collagen coated with 
3% α-elastin [195], hybrid peptides of elastin covalently linked to alginate dressings 
[186] and injected α-elastin [196]. The decellularised collagen/elastin membrane 
was used in a two-step procedure in a rat excised wound model; in the ﬁ rst step the 
membrane was employed while in the second step cultured keratinocytes were applied. 
This resulted in a histologically satisfactory result, but due to wound contraction the 
membrane formed pleats within the layer of elastic ﬁ bres [194]. Later, this collagen/
elastin membrane was chemically crosslinked by EDC to reduce degradation in vivo
[197] and the inﬂ ammatory response was studied in both an in vitro culture system and 
the chorioallantoic membrane assay (CAM) of the chick embryo. The collagen/elastin 
membrane caused activation of macrophages and the formation of inﬂ ammatory tissue 
which pointed to a chronic process unwanted in a healing wound [198].
In a porcine excised wound model, a combination of collagen with 3% α-elastin as a 
dermal matrix substitute combined with meshed split skin grafts gave reduced wound 
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contraction, improved tissue regeneration and absence of myoﬁ broblasts compared 
to an epidermal transplantation only. Matrix remodelling and elastin regeneration 
occurred both in the upper and lower dermis [199]. In the same model, ﬁ broblasts 
seeded in the collagen/α-elastin matrix survived and proliferated, reducing migration/
proliferation of (unwanted) subcutaneous ﬁ broblasts into the wound and reducing 
degradation of the substitute [187]. In a clinical trial, split skin alone showed slightly 
better take than the graft with split skin, but no signiﬁ cant change in the number of 
regrafting procedures was found. Short term follow-up revealed that skin elasticity 
was considerably improved by the collagen/elastin dermal substitute as analysed by 
cutometer measurements [200]. The long-term objective evaluation (cutometer) with 
respect to elasticity was consistent, although the difference with controls decreased 
resulting in no statistical signiﬁ cancy after one year [201]. In the microscopical 
evaluation, promising differences were found for several parameters, including rete 
ridges, basement membrane maturation, and epidermal thickness [202].
A hybrid of elastin-laminin peptides promoted attachment and proliferation of normal 
human dermal ﬁ broblasts in culture. In a rabbit ear skin defect model, alginate dressings 
linked with elastin-laminin peptides reepithelialised faster than controls [186].
Recently, it was found that a proteolytic digest of elastin induced elastic ﬁ bre deposition 
in stimulated dermal ﬁ broblasts injected in the skin of nude mice as well as in cultured 
human skin explants [196].
Vascular constructs
There is a major need for small-diameter vascular grafts with long-term patency, 
especially for coronary artery bypass graft procedures. These grafts should preferably 
have ‘off-the-shelf’ availability with various diameters and lengths, easy storage and 
straightforward handling [136]. Brieﬂ y, biological requirements for tissue engineered 
grafts should include an endothelium which is conﬂ uent, adherent and quiescent, in 
order to resist thrombosis, and mechanical properties similar to the native vessel, like 
an elastin network for compliance and recoil  [203].
Different approaches exist to obtain tubular constructs. One is to use decellularised 
blood vessels in which the tubular organisation is maintained, another is to prepare 
tubular scaffolds from individual matrix components followed by seeding of cells, 
and a third is to make cells produce the extracellular matrix [204]. We will not 
discuss the latter. Decellularised blood vessels have been obtained from rat aorta 
[205] and porcine carotid arteries [8,108]. In vivo, decellularised rat aorta (mainly 
elastic lamina) showed inﬂ ammation-resistant properties and inhibited smooth muscle 
cell proliferation compared with collagen-containing matrices while endothelial cell 
migration was maintained [205]. In another study, decellularised porcine carotid arteries 
covering an expanded metal stent also showed less smooth muscle cell proliferation 
and lumen stenosis [8]. These materials may therefore prevent neointima formation 
and thus occlusion of the graft. The last material did not calcify in the investigated 
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time frame. However, calciﬁ cation was observed upon subcutaneous implantation of 
decellularised porcine arteries [108]. Calciﬁ cation needs to be thoroughly investigated 
in tissue-engineered grafts, since it may cause failure of the graft. With more extensive 
decellularisation (in combination with selective matrix removal), tubular constructs 
were obtained that were predominantly composed of elastin and could be repopulated 
with ﬁ broblasts in vitro. However, in vivo studies of this material have not been 
performed [206].
Figure 8. Experimental setup of an electrospinning system from soluble collagen and elastin (A). Elastin 
content in collagen/elastin solutions used for electrospinning inﬂ uences ﬁ bre diameter. With higher elastin 
content, ﬁ bres had a larger diameter as shown for (B) collagen:elastin 1:3, d=600 nm; (C) collagen:elastin 
1:2, d=330 nm; (D) collagen:elastin 2:1, d=220 nm. All ﬁ bres were spun at 22 kV. Bar is 2 µm in B, and 1 
µm in C, D. Figure is reproduced from Buttafoco et al. [213] with permission.
Another method to prepare tubular scaffolds is by pouring a diluted acetic acid 
suspension of puriﬁ ed type I collagen ﬁ brils and elastin ﬁ bres in a tubular mould, 
freezing at -18°C and lyophilising. In static culture as well as under pulsatile ﬂ ow, 
smooth muscle cells were able to adhere to and proliferate in these porous 3D collagen-
elastin tubes for up to 14 days while maintaining their contractile phenotype as 
evidenced from smooth muscle actin staining [207-209]. Tubes may also be prepared 
by winding of a sheet, as was performed with recombinant tropoelastin [124]. 
To prepare tubular constructs, protein spinning can also be used. Using wet spinning 
with air-drying of crosslinked (Gly-Val-Gly-Val-Pro)n, with the bold Val being Glu 
or Lys every sixth repeat, ﬁ bres of about 5 µm in diameter could be spun [125]. 
With electrospinning nm scale ﬁ bres can be prepared in contrast to traditional wet 
and dry protein spinning processes [210]. Fig. 8 shows the experimental setup of an 
electrospinning system. Electrospinning is usually performed with synthetic polymers. 
It is accomplished by inducing a large electric potential (15-30 kV) in a polymer 
solution or melt. By placing an oppositely charged target some distance from the 
charging solution, a static electric ﬁ eld is created. As the ﬁ eld strength grows, the
charge between the two overcomes the surface tension of the solution and a thin jet 
is ejected from the polymer solution reservoir. This jet is further thinned by whipping 
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in space and evaporation of the solvent. When the jet reaches the target, a dry ﬁ bre 
is collected. Consequently, tubular constructs can be made when using a rotating 
mandrel to collect the ﬁ bre [188]. 
Recently, electrospinning was also performed with soluble elastin. Huang et al. [166] 
used this method to spin an 81 kDa recombinant protein based upon 39 repeats of 
the elastomeric peptide sequence of elastin (Val-Pro-Gly-Val-Gly)4(Val-Pro-Gly-Lys-Gly) 
into ﬁ bres and nonwoven fabrics. Fibres had diameters from 0.2-3 µm and showed 
various different morphologies including beaded ﬁ bres, thin ﬁ laments, and broad 
ribbons. Morphology of structures was dependent on elastin concentration and ﬂ ow 
rate. Electrospinning of the same elastomeric peptide sequence functionalised with 
methacrylate was also possible [168]. In both cases, electrospinning was carried out 
under mild conditions, in distilled deionised water at ambient temperatures. A relatively 
low-viscosity solution of the elastomeric peptide was capable of yielding electrospun 
ﬁ bres of uniform diameter, which may be related to molecular self-assembly processes 
of the elastin [166,168]. The solution used to spin ﬁ bres from was also of importance, 
especially when using protein multiblock copolymers, and can result in differences in 
ﬁ bre morphology [128]. Huang et al. [210] also spun acid-soluble rat tail collagen in 10 
mM HCl (pH 2.0), but this was only possible in the presence of poly(ethylene) oxide to 
increase solution viscosity, and NaCl to increase solution conductivity. Bowlin’s group 
used electrospinning to construct tubular constructs of acid soluble calf skin type I 
collagen in a 1,1,1,3,3,3-hexaﬂ uoro-2-propanol solution [211]. In an initial step towards 
vascular tissue engineering, they spun tubular constructs of acid soluble calf skin type I 
collagen, human placenta type III collagen and soluble elastin from bovine ligamentum 
nuchae and succeeded to seed ﬁ broblasts, smooth muscle cells and human umbilical 
vein endothelial cells on glutaraldehyde-ﬁ xed scaffolds [188]. Although the method 
used is promising, the different cell types in the construct were not well characterised, 
no mechanical experiments were performed on the construct, and the use of organic 
solvents may signiﬁ cantly reduce biocompatibility. Furthermore, glutaraldehyde-ﬁ xed 
collagen scaffolds may be cytotoxic [212]. Buttafoco et al. used a more biological 
approach to electrospin tubular constructs composed of soluble collagen and elastin. 
Based on Huang’s method to electrospin collagen nanoﬁ bres and fabrics [210], they 
used calf skin soluble type I collagen and bovine ligament soluble elastin in 10 mM HCl 
with poly(ethylene) oxide and NaCl. Afterwards, crosslinking took place with EDC in 
the presence of N-hydroxysuccinimide (NHS). Poly(ethylene) oxide and NaCl could be 
fully leached out after crosslinking. The average ﬁ bre diameter was dependent on the 
collagen/elastin weight ratio; with more elastin, it was larger. Proliferation of smooth 
muscle cells was possible on these tubular scaffolds [213]. Electrospinning is a highly 
promising method for vascular reconstruction, but future research must establish its 
use in in vivo applications.
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Self-assembling materials
Processes involving self-assembly of polymers (including proteins) are currently the 
subject of much attention, particularly in the areas of nanotechnology and biomaterials 
[214]. Molecular self-assembly is per deﬁ nition the spontaneous organisation of 
molecules under thermodynamical equilibrium conditions into structurally well-deﬁ ned 
and rather stable arrangements through a number of non-covalent interactions [215]. 
Elastin is a biological example of a protein polymer that can self-organise. Upon 
heating, tropoelastin, solubilised elastin and (bio)synthetic elastin coacervate, caused 
by hydrophobic interactions between the hydrophobic domains in the molecule.
Figure 9. Elastin vesicles obtained by quench freezing solubilised elastin in diluted acetic acid followed 
by lyophilisation. (A) Scanning electron micrograph (SEM) shows that globular structures are formed. (B) 
Transmission electron micrograph (TEM) establishes vesicle nature of the globules in A. (C) Fluorescent-
labelled macromolecules could be differentially incorporated in the vesicle wall and vesicle lumen as is shown 
for 10,000 Da dextran-conjugates labelled with Alexa Fluor488 (vesicle wall) and Alexa Fluor594 vesicle 
lumen). (D) Labelled macromolecules were released over time by digestion with elastase. Bar is 5 µm in A, 1 
µm in B, 2 µm in C and 20 µm in D. Figure adapted from [221], original colour ﬁ gure on page 153.
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Self-assembly into ﬁ brous structures is well-known, and was observed with 
tropoelastin [124], tropoelastin fragments [39], and synthetic elastin block polymers 
[128,166,168].
Self-assembly is especially useful to prepare nano-scale materials. For polymers, self-
assembled structures included nanotubes, nanoﬁ bres, nanocoatings and nanoporous 
ﬁ lms [216]. The self-assembling behaviour of elastin was used to obtain various 
elastin biomaterials, e.g. hydrogels [217], sheets [124], nanoparticles [218], sponge-
like isotropic networks [21] and nanoporous materials [219]. They may be valuable 
for cellular orientation, small-diameter blood vessels, and drug-delivery or growth 
factor delivery devices. Another application of elastin in biomaterials may be elastin 
biovesicles, as a potential drug delivery system. Vesicle structures have found ample 
applications as targetable drug carriers in cosmetics and pharmaceutics and other 
applications, but usually these are made of lipids or synthetic polymers. Vesicles from 
biological proteins may be the ultimate biocompatible and biodegradable product. 
Usually, protein vesicles from synthesised proteins are based on the amphiphilicity 
of the molecules [220]. However, we recently showed the preparation of vesicles (250 
nm – 10 µm in diameter) from solubilised elastin (Fig. 9A, B) by a novel approach 
combining freezing and lyophilisation procedures where amphilicity is not necessary 
[221]. Vesicle formation was critically dependent on elastin concentration, solvent, 
freezing mode and pressure conditions during lyophilisation. Fluorescent-labelled 
(macro)molecules could be differentially incorporated in the vesicle wall and/or vesicle 
lumen (Fig. 9C) and were released by elastase digestion (Fig. 9D). Elastin vesicles are 
a highly promising release system, since they are highly adaptable.
OUTLOOK
Elastin-based materials are promising in the ﬁ eld of biomaterials and tissue engineering. 
They exhibit interesting biological, biomechanical, biochemical and biophysical 
properties, and may comprise novel approaches for improving tissue regeneration.
Before this can actually happen, certain aspects of elastin-based materials should be 
studied in order to attain a more predictable outcome in vivo, opposed to the trial-
and-error research as is often carried out at the moment. It would be advantageous to 
better incorporate results from basic research into applications for tissue engineering. 
For example, the effect of elastin peptide-containing biomaterials on a speciﬁ c cell 
type may be predicted from the activation of signalling pathways activated by elastin 
peptides.
Another recommendation is to extend cytocompatibility and biocompatibility studies 
of elastin-based materials, especially of elastin-like block polymers. Polypeptides with 
new elastin sequences have been expressed without studying their biocompatibility. 
The choice of the experimental animal model is also of major importance. Currently, 
different materials are studied at different implantation sites in different animal 
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models, making it impossible to compare results. It will thus be worthwhile to propose 
and standardise speciﬁ c animal models and explicit operation protocols for speciﬁ c 
applications, like small-diameter blood vessels. In addition, comparative studies of 
different elastin-based materials in in vivo applications will be valuable. This would 
lead to a more systematic approach of biomaterials in general and elastin-based 
biomaterials in particular.
Elastin-based materials should be well-deﬁ ned in order to pinpoint a speciﬁ c effect. 
Tailor-made materials are likely to have the best potential in various applications. 
Variables that are important to control include the chemical composition and the 
architecture. Puriﬁ ed elastin preparations and synthetic elastins may therefore have 
great potential in soft tissue regeneration. Self-assembling elastin-based materials are an 
emerging and promising topic within the elastin biomaterials ﬁ eld. The preparation of 
highly-deﬁ ned polypeptides with a propensity to self-aggregate, resulting in biomaterials 
with deﬁ ned mechanical properties, and likely also a speciﬁ c biological activity, will 
increase the use of elastin in biomaterials. Self-assembly may also result in microtubes 
and nanotubes with promising applications in tissue engineering and beyond.
Tissue engineering of skin and blood vessels using elastin-based biomaterials are now 
getting into reach. In this respect, the Cinderella nature of elastin as a component in 
biomaterials may soon be over.
AIM AND OUTLINE OF THIS THESIS
Elastin preparations display remarkable properties, such as elasticity, long-term stability, 
self-assembly, and many cell biological effects, and this makes them valuable as 
biomaterials for tissue engineering. The aim of this thesis is to prepare highly-puriﬁ ed 
elastin ﬁ bres as well as solubilised products hereof for use in the ﬁ eld of tissue engineering. 
The puriﬁ cation of elastin, the ‘makability’ of the biomaterials and the in vitro and 
in vivo evaluation are emphasised. An overview of the preparation and application of 
elastin-based biomaterials is given in Chapter 1. The puriﬁ cation of insoluble elastin 
from equine ligamentum nuchae is described in Chapter 2 and 3. In Chapter 4, the 
development of scaffolds from elastin ﬁ bres, type I collagen ﬁ brils, and chondroitin sulfate 
is presented. Scaffolds were designed to mimic the extracellular matrix composition. 
The preparation of scaffolds containing type I collagen ﬁ brils and solubilised elastin is 
described in Chapter 6. The tissue response to scaffolds composed of type I collagen with 
elastin ﬁ bres and type I collagen with solubilised elastin are described in respectively 
Chapter 5 and 6. Special attention is given to calciﬁ cation, vascularisation and elastic 
ﬁ bre formation. Chapter 7 deals with the preparation of vesicles from solubilised elastin 
as well as from other molecules. The ability to incorporate ﬂ uorescent macromolecules 
in the wall and/or lumen of these elastin vesicles is also discussed. Finally, a summary 
of the studies and future directions are given in Chapter 8.
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ABSTRACT
Elastin is an insoluble, highly crosslinked protein providing elasticity to organs like lung, 
aorta and ligaments. Despite its remarkable mechanical properties, elastin has found 
little use as a biomaterial. Puriﬁ cation of elastin from elastic ﬁ bres presents a major 
challenge, among others for the intimate interwovenness of elastin and microﬁ brils. 
In this study, elastin was puriﬁ ed from equine ligamentum nuchae using ﬁ ve different 
procedures. One procedure was based on treatment with 0.1 M NaOH, another on 
autoclaving and treatment with cyanogen bromide. Three other procedures were based 
on combinations of extraction steps and enzyme digestions. Purity of preparations was 
assessed by SDS-PAGE, amino acid analysis, and bright ﬁ eld, immunoﬂ uorescence and 
transmission electron microscopy. Only the procedure involving extractions/enzymes 
combined with an early application of 2-mercaptoethanol and cyanogen bromide 
gave a highly puriﬁ ed elastin preparation. Electron microscopic analysis showed that 
this preparation was devoid of microﬁ brillar components. This procedure is therefore 
the method of choice for preparation of insoluble elastin as a biomaterial for tissue 
engineering.
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INTRODUCTION
Elastin is an important connective tissue protein that provides elasticity to organs, 
such as lung, aorta and ligaments. It is synthesised as a ~72 kDa soluble precursor 
(tropoelastin) that undergoes posttranslational modiﬁ cations resulting in the formation 
of speciﬁ c interchain crosslinks like (iso)desmosine and (dehydro)lysinonorleucine 
[1,2]. All but about 5 of the 34 Lys residues of tropoelastin participate in crosslinks, 
and this results in an insoluble polymer in which lysine-derived crosslinks occur 
approximately every 65-70 residues [3]. The elastic ﬁ bre is basically composed of 
two entities: amorphous elastin and microﬁ brils. During formation of the elastic 
ﬁ bre, the microﬁ brillar components act as a scaffold on which elastin is deposited. 
These components exist, among others, out of ﬁ brillin, lysyl oxidase and microﬁ bril-
associated glycoproteins (MAGPs) [1,4]. Despite its remarkable mechanical properties, 
elastin has found little use as a biomaterial [5-7]. A key issue in the use of proteins 
as a biomaterial is purity. Contamination with (globular) proteins irrevocably leads 
to immunological responses and precludes application as a biomaterial. Puriﬁ cation 
has always been a problem in the use of elastin [8,9] and  elastin preparations have a 
strong tendency to calcify [10,11]. Contaminations within the preparation, like calcium-
binding microﬁ brillar components, may very well be of importance in this respect.
Here, we compare ﬁ ve puriﬁ cation procedures for elastin from equine ligamentum 
nuchae, using various methods to analyse the purity of the end product, including 
transmission electron microscopy which to our knowledge has never been used before 
for this aim.
MATERIALS & METHODS
Materials
Equine ligamentum nuchae was used as a source for insoluble elastin. Commercial 
bovine elastin products were used as a standard (E60, E61 and E70, Elastin Products 
Company, Owensville, MO, USA). Elastin E61 was puriﬁ ed using a method similar to 
procedure 1 (Fig. 1). Unless stated otherwise, this preparation was used in comparative 
studies. Collagenase I from Clostridium histolyticum (C-0130) and trypsin (T-8253) 
were purchased from Sigma (St Louis, MO, USA). Dithiobis(2-nitrobenzoic acid) 
(DTNB) was from Pierce (Rockford, IL, USA).
Isolation of elastin
Elastin was isolated from equine ligamentum nuchae using ﬁ ve different procedures (Fig.
1). In all cases ligamentum nuchae was freed from adhering non-elastinous material, cut 
into pieces of about 1 cm3 (working on ice), and minced to a ﬁ ne powder under liquid 
nitrogen conditions. All following steps were performed at 22°C, unless stated otherwise.
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Figure 1. Outline of the ﬁ ve procedures used to isolate elastin from equine ligamentum nuchae.
Procedure 1 adapted from Lansing et al. [12]: This procedure makes use of three 24 h 
extractions with 10 vol. (10 ml/g) 1 M NaCl at 4°C. After each extraction step insoluble 
material was recovered by centrifugation at 13000g at 4°C for 20 min. After the last 
extraction step, the pellet was washed with water and defatted with 30 vol. acetone 
(3x 1 h). The material was dried in a desiccator, subsequently suspended in 30 vol. 0.1 
M NaOH, and heated at 95°C for 45 min. The suspension was cooled, washed with 
water, and lyophilised.
Procedure 2 adapted from Rasmussen et al. [13]: In this procedure the minced tissue 
was extracted with 10 vol. 5 M guanidine-HCl containing 1% (w/v) 2-mercaptoethanol 
(pH 7) for 24 h. The mixture was then diluted to the 4-fold volume with water and 
centrifuged at 13000g for 20 min. The pellet was suspended in 20 vol. water and 
autoclaved for 5 h at 120°C. The mixture was ﬁ ltered while still hot, washed with 
boiling water (3x 20 vol.) and dried in a desiccator. The dried product was suspended 
in 40 vol. 97% formic acid to which 1% (w/v) cyanogen bromide was added, and 
incubated for 24 h. The mixture was then diluted to the 4-fold volume with water, 
ﬁ ltered, washed with water until pH 6 was reached, and lyophilised.
Procedure 3a adapted from John and Thomas [14]: This procedure consists of 
different extraction steps and digestions with enzymes. The tissue was extracted three 
times overnight with 10 vol. 1 M NaCl containing 0.02% (w/v) NaN3 at 4°C. After 
each extraction step, insoluble material was recovered by centrifugation at 13000g at 
4°C for 20 min. After the last extraction step the material was washed with water and 
resuspended in 10 vol. ethanol for 90 min and then ﬁ ltered through a paper funnel. 
This procedure was repeated with 10 vol. chloroform/methanol (2:1) for 90 min, 10 
vol. acetone for 30 min, and 10 vol. ether for 30 min. The insoluble material was 
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dried in a desiccator. The dried powder was extracted three times with 10 vol. 5 M 
guanidine-HCl containing 0.02% (w/v) NaN3 (pH 7) for 24 h. After the last extraction 
step the material was washed with water and incubated for 48 h at 37°C with 1000 U 
collagenase/g substrate in 10 vol. 0.2 M Tris-HCl (pH 7.4) containing 0.05 M CaCl2 and 
0.02% NaN3; after 24 h another 250 U collagenase/g were added. The enzyme was 
inactivated by the addition of EDTA (ﬁ nal concentration 25 mM) and the preparation 
was washed with water. Then the pellet was resuspended in 10 vol. 0.1 M NH4HCO3
(pH 8.2) containing 0.02% (w/v) NaN3 and 10,000 U trypsin/g for 4 h at 37°C. The 
reaction was stopped by phenylmethylsulphonylﬂ uoride (PMSF, ﬁ nal concentration 
1.86 mM). The pellet was washed with water, followed by three overnight extractions 
with 10 vol. 1 M NaCl containing 0.02% (w/v) NaN3, and washed again with water. 
The end product was lyophilised.
Procedure 3b modiﬁ ed from procedure 3a: This procedure resembles procedure 
3a, but contains three modiﬁ cations. First, aiming at removing more non-elastinous 
material, an extra 500 U collagenase/g substrate was added after 24 h, instead of 250 
U/g. Second, after washing out the trypsin and PMSF, the pellet was incubated in 5 
vol. 97% formic acid, and cyanogen bromide added to a ﬁ nal concentration of 1% 
for 24 h. The mixture was then diluted to the 4-fold volume with water, ﬁ ltered and 
washed with water until pH 6 was reached. After this step, an overnight treatment 
with 1 M 2-mercaptoethanol in 0.5 M Tris-HCl (pH 6.8) containing 0.02% (w/v) NaN3
was performed. The preparation was washed, and the NaCl extractions were carried 
out as described above.
Procedure 3c modiﬁ ed from procedure 3b: This puriﬁ cation contains the same steps 
as procedure 3b, but in a different order. After three extractions with 1 M NaCl and the 
various organic solvents extractions, the cyanogen bromide step was carried out in 30 
vol. formic acid. After washing, the pellet was extracted three times  for 24 h with 5 M 
guanidine-HCl and 1 M 2-mercaptoethanol in 0.5 M Tris-HCl containing 0.02% (w/v) 
NaN3 (pH 6.8). After washing with water, the collagenase and trypsin digestions were 
carried out. No enzyme inhibitors were used. The ﬁ nal step consisted of the three 
extractions with 1 M NaCl and washings with water. The ﬁ nal elastin preparation was 
stored at –80°C.
Determination of elastin purity
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE): All elastin 
preparations were incubated for 10 min at 95°C under reducing conditions (5% (v/
v) 2-mercaptoethanol) and analysed on a 10% (w/v) gel. Contaminants and elastin 
degradation products will penetrate the gel and are visualised by silver staining using 
a 0.1% (w/v) AgNO3 solution [15].
48
ch
ap
te
r 
2
pu
ri
ﬁ 
ca
ti
on
 o
f 
in
so
lu
bl
e 
el
as
ti
n
Amino acid analysis: Elastin samples were hydrolysed under vacuum with 6 M HCl 
for 22 h at 110°C, dried under vacuum and dissolved in 10 mM HCl. Hydrolysed 
samples were ﬁ rst deproteinised by addition of an 18.8 % (w/v) 5-sulphosalicylic acid 
solution (Fluka Chemie AG, Buchs, Switzerland), and contained norleucine (Sigma) 
as an internal standard. Separation of the components was obtained by column 
ion exchange chromatography on a Biochrom 20 amino acid analyzer (Amersham 
Pharmacia Biotech, Uppsala, Sweden) using lithium buffers with increasing pH.
Sulfhydryl quantiﬁ cation: Sulfhydryl content was measured using DTNB as a reagent 
at pH 8. This reagent reacts with sulfhydryl groups in solution, and yields a yellow 
colour that is measured spectrophotometrically at 412 nm. The sulfhydryl content of 
the samples was calculated by comparison of a standard curve with L-cysteine [16].
Light microscopy: Puriﬁ ed elastin powders were embedded in 1.5% (w/v) agarose, 
ﬁ xed in 4% formaldehyde in phosphate buffered saline (PBS pH 7,2), and embedded 
in parafﬁ n. The starting material (ligamentum nuchae) was ﬁ xed in formaldehyde, and 
embedded. Sections of 5 µm were mounted onto organosilane-coated slides, dewaxed 
in xylol and hydrated through a graded series of ethanol. Sections were stained for 
elastin, collagen, and nuclei according to resorcin fuchsin - Van Gieson [17] and 
Verhoeff - Van Gieson [18].
Immunoﬂ uorescence analysis (IFA): Elastin preparations were suspended in water 
and frozen in liquid nitrogen. Ligamentum nuchae was frozen directly in liquid 
nitrogen. Cryosections of 5 µm were mounted onto organosilane coated glass slides. 
After blocking with 1% (w/v) bovine serum albumin (BSA) in PBS (pH 7.2), sections 
were incubated overnight with rabbit anti-bovine type I collagen (1:50, Chemicon, 
Temecula, CA, USA), goat anti-bovine type IV collagen (1:50, Southern Biotechnology 
Associates, Birmingham, AC, USA), mouse anti-bovine ﬁ brillin IgG (1:50, Chemicon), 
mouse anti-bovine ﬁ brillin 1 IgG (1:50, Neomarkers, Fremont, CA, USA), or mouse 
anti-bovine elastin clone BA-4 IgG (1:500, Sigma) and washed with PBS. Subsequently, 
sections were incubated for 90 min with Alexa 488-labeled secondary antibodies 
(Molecular Probes, Eugene, OR, USA) diluted 1:100 in PBS containing 1% (w/v) BSA. 
Sections were washed and mounted in mowiol.
Transmission electron microscopy (TEM): Elastin preparations were embedded in 
1.5% (w/v) agarose, ﬁ xed in 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) 
for 12 h at 4°C, and postﬁ xed with 1% (w/v) osmium tetroxide in 0.1 M phosphate 
buffer (pH 7.4). After a rinsing period of 3 h the samples were dehydrated in an 
ascending series of ethanols and embedded in Epon 812. Toluidine-blue stained semi-
thin sections (1 µm) were cut on a Reichert Ultracut E microtome to select appropriate 
areas. Ultrathin sections (60 nm) were picked up on formvar-coated grids, stained with 
uranyl acetate and lead citrate, and examined in a Philips 301 electron microscope.
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RESULTS
All procedures were applied at least in duplicate and gave a similar yield (21, 19, 23, 
20, and 20% on base of dry weight per dry tissue weight for procedures 1, 2, 3a, 3b, 
and 3c, respectively).
SDS-PAGE
SDS-PAGE of the elastin preparations puriﬁ ed by the different procedures indicated 
no major contaminations with soluble proteins, except for the starting material, 
and the commercial elastin (Fig. 2). Using BSA as a reference, it was estimated that 
the contamination was less than 0.02%. Contaminations in the commercial elastin 
consisted mainly of high molecular mass impurities (>70 kDa).
Figure 2. SDS-PAGE of ligamentum nuchae (100 µg), elastin preparations puriﬁ ed by different procedures 
(500 µg), commercial elastin (500 µg), and BSA (100 ng). Amounts represent dry weights put on gel. Note 
that only soluble contaminants and/or elastin breakdown products will enter the gel, but not insoluble elastin, 
which represents the vast majority of the preparations.
Amino acid analysis
Amino acid analysis showed that all puriﬁ cation procedures removed Met, which does 
not occur in elastin (Table 1). Hydroxylysine (Hyl), which is characteristic for collagen, 
and absent in elastin, was removed with procedures 2 and 3, but not by procedure 1. 
The commercial elastin preparation also contained some Hyl. Hydroxyproline (Hyp), 
which is present in both elastin and collagen, could still be detected. Furthermore, a 
high percentage of Gly, Ala, Val and Pro was present, typical for elastin. Desmosine 
(Des) and isodesmosine (Ide) contents were comparable to literature values [8,9,14].
Sulfhydryl quantiﬁ cation
Microﬁ brils, an intrinsic component of elastic ﬁ bres, consist mainly of ﬁ brillin. This protein 
contains approximately 14% Cys residues, of which two-third form S-S bridges and 
one-third have free sulfhydryl groups [19]. Tropoelastin contains only two Cys residues 
at the C-terminus of the protein, which form an intramolecular disulﬁ de bond [20].
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Table 1. Amino acid composition of equine ligamentum nuchae (starting material), elastin puriﬁ ed by ﬁ ve 
different methods, and commercial elastin.
* The amino acid composition of human elastin was theoretically calculated from the cDNA of tropoelastin. 
Posttranslational modiﬁ cations are therefore not taken into account and consequently the values for Lys, 
Pro, Cys, Des, and Ide are not correct [21].
Values are mean (n = 4 ± SD), expressed per 1000 amino acid residues and not corrected for losses during 
hydrolysis.
Analysis of the sulfhydryl content therefore gives information on the purity of the 
elastin preparation. Elastin prepared by procedure 3b contained a substantial amount 
of sulfhydryl groups (2.51 mg Cys equivalents per g elastin preparation), while starting 
material, and elastins prepared by procedure 1 and the commercial elastin preparation 
only had a moderate content of sulfhydryl groups (0.30, 0.25, and 0.12 mg/g, 
respectively). The preparations obtained by procedures 2, 3a and 3c contained minor 
amounts (0.04, 0.05, and 0.07 mg/g, respectively). Procedures 2, 3b and 3c contain a 
2-mercaptoethanol step in the puriﬁ cation, which will lead to reduction of disulﬁ de 
bonds (including the one found in elastin). Sulfhydryl groups in elastin prepared by 
autoclaving (procedure 2) may be oxidised thereafter. Residual 2-mercaptoethanol will 
react with DTNB in procedures 3b and 3c, and may add to the sulfhydryl content. 
Even after additional washings of the elastin preparation puriﬁ ed by procedure 3b, the 
content of sulfhydryl groups did not substantially decrease, in contrast to procedure 3c. 
Procedure 3c would therefore become the procedure of choice regarding this topic.
Bright ﬁ eld microscopy
Major components of ligamentum nuchae are elastin and collagen as was indicated 
by resorcin fuchsin–Van Gieson and Verhoeff-Van Gieson staining procedures. Puriﬁ ed 
elastin preparations stained well for elastin, and showed no collagen, or nuclei. It was 
not possible to distinguish between more and less pure elastin preparations using these 
two staining techniques.
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Figure 3. Immunostaining of ligamentum nuchae and elastin preparations for various components. (A-E) 
Ligamentum nuchae stained for type I collagen (A, B), type IV collagen (C), ﬁ brillin (D), and elastin (E); (F) 
elastin preparation puriﬁ ed by procedure 3c stained for elastin; (G-H) commercial preparation E60 stained for 
type I collagen (G), and ﬁ brillin (H). Bar indicates 50 µm.
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Immunoﬂ uorescence microscopy
Immunoﬂ uorescence microscopy was applied to detect molecules by speciﬁ c antibodies. 
Next to elastin, type I collagen, type IV collagen (in blood vessels), and ﬁ brillin (in 
microﬁ brils) are abundantly present in ligamentum nuchae (Fig. 3A-E). Type I collagen 
was found surrounding the elastic ﬁ bres. Type IV collagen was found in between the 
bundles of elastic ﬁ bres generally conﬁ ned to blood vessels. Fibrillin was detected on 
both the inside and outside of the elastic ﬁ bre, closely associated to the ﬁ bre. After 
puriﬁ cation the intensity of elastin staining was increased (Fig. 3E, F), probably 
because of unmasking of elastin epitopes by removal of associated substances. In 
commercial preparation E60, type I collagen and ﬁ brillin could still be detected (Fig.
3F, G). In all other elastin preparations immunostaining for the various components 
was absent. However, since epitopes may be destructed during puriﬁ cation, absence of 
staining does not prove the absence of a speciﬁ c component in the preparation.
Transmission electron microscopy
TEM was used to identify impurities in the elastin preparations in detail (e.g. cell 
debris, collagen ﬁ brils and microﬁ brils). Contaminations are visible as electron-dense 
material on the electron-translucent elastin. Representative results are shown in Fig.
4. Elastin preparations isolated by procedures 3b and 3c were pure. Elastin puriﬁ ed 
by procedures 1, 2, and 3a still contained non-elastinous material. According to the 
size and location of these contaminations, they probably represent (part of) the 
microﬁ brillar components of the elastic ﬁ bre.
DISCUSSION
In this study, elastin was puriﬁ ed from equine ligamentum nuchae using ﬁ ve different 
procedures, of which three consisted of consecutive extraction steps and enzyme 
digestions. One takes advantage of the fact that elastin is insoluble under many 
circumstances, like heating in 0.1 M NaOH at 95°C, or autoclaving for 5 h. Elastin 
may be affected by these procedures because of the high temperatures used. Three 
extraction procedures (3a, 3b, 3c) do not exceed ambient temperature levels, and 
are therefore preferred to gain a puriﬁ ed elastin preparation. These procedures use 
different extraction steps and enzyme digestions to remove contaminations. NaCl and 
guanidine-HCl will bring many proteins into solution, organic solvents will extract fats, 
collagenase and trypsin digestions will break down collagen and other proteins. Two 
procedures (3b, 3c) also use CNBr in formic acid, which will cleave proteins at Met 
residues (which are absent in elastin, but ubiquitous in for instance collagen), and 2-
mercaptoethanol, which will lead to reduction of disulﬁ de bridges (rare in elastin, but 
abundantly present in for example ﬁ brillin).
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Figure 4. Transmission electron micrographs of ligamentum nuchae (A, B), and elastin preparations puriﬁ ed 
by procedure 1 (C, D), procedure 2 (E, F), or procedure 3c (G, H). E=elastin; C=collagen ﬁ brils; MF= 
microﬁ brils, arrows=microﬁ brillar resembling structures. Bar indicates 0.5 µm.
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Table 2 gives a summary of the results of the purity assessment of the different elastin 
preparations and the commercial elastin. Soskel and Sandburg [8] analysed six methods 
for extracting elastin from hamster lungs. They used several criteria for elastin purity 
based on amino acid analysis, viz. low His (< 5 per 1000 amino acid residues), low 
Hyp (< 15 per 1000 amino acid residues), high Ala (> 200 per 1000 amino acid 
residues), no Met and Hyl, high Val (> 75 per 1000 amino acid residues), and an Ile : 
Leu ratio of 0.6. It is now known that this last criterion should be 0.36 instead of 0.6 
[21]. Elastin puriﬁ ed by all but one of the procedures described, meet these criteria. 
Procedure 1 results in a preparation that still contains Hyl, as does the commercial 
elastin which also has an Ile/Leu ratio of 0.47 in stead of 0.36. Since amino acid 
analysis is a rather insensitive method for the detection of impurities, we turned to 
other methods. SDS-PAGE, sulfhydryl analysis, light microscopy, and TEM were also 
used to assess purity. Using these methods, only procedure 3c was found satisfactory, 
especially with respect to remnants of microﬁ brils.
Elastin and elastic ﬁ bres have often been implied as the major site of calciﬁ cation in 
aorta and heart valves, for both natural elastic ﬁ bres and biomaterials [11,22-24]. Elastic 
ﬁ bres do not only contain elastin, so calciﬁ cation can be due to other components 
within the ﬁ bre. Calciﬁ cation often occurs at the outside of the elastic ﬁ bre, where 
microﬁ brils are present [10,25]. There are some clues that components other than 
elastin are involved in the process of calciﬁ cation. An increase of the calcium content 
is paralleled by an increase in the number of acidic amino acid residues (Glu and 
Asp) in elastic ﬁ bres [26]. The percentage of these residues is about 1% in elastin, but 
is 10% in ﬁ brillin, the major microﬁ brillar component [21]. Some other microﬁ bril-
associated proteins also have a large amount of acidic amino acid residues [27]. A 
similar association of calciﬁ cation with an increase in the number of polar amino acid 
residues, abundantly present in microﬁ brils, has been suggested [26]. Fibrillin may 
be a candidate protein in the elastic ﬁ bre that causes calciﬁ cation. It contains 47 EGF-
like domains, of which 43 have a calcium-binding consensus sequence [28,29], and it 
actually binds calcium [30,31].
Our TEM results prove that elastin puriﬁ ed by traditional methods still contains non-
elastinous material of microﬁ brillar nature. Elastin preparations have been used that 
were ill-deﬁ ned and may have contained impurities. By using isolation procedures 
based on autoclaving, for instance, microﬁ brillar components are not completely 
removed. If impurities are of importance in the process of calciﬁ cation, removal of 
them should lead to better elastin-based biomaterials. Using procedure 3c, a highly 
pure elastin preparation was isolated.
Future experiments will be devoted to study whether calciﬁ cation of insoluble elastin 
can be prevented by application of our highly puriﬁ ed preparations. If these studies 
are promising, elastin may become an important molecule, especially in biomaterials 
aimed at replacing organs in which elasticity is crucial, e.g. small diameter blood 
vessels.
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Table 2. Overview of purity of various elastin preparations according to six criteria.
SDS PAGE is + if no bands are seen on the gel. Amino acid analysis is + if His and Hyl are not detectable. 
Sulfhydryl content is - if > 0.5 mg Cys equivalents/g elastin; ± if 0.1 < value < 0.5; + if < 0.1. Bright 
ﬁ eld microscopy is + if no collagen can be detected. Immunoﬂ uorescence microscopy is + if elastin can be 
readily detected. TEM is + if no microﬁ brillar structures are present. VVG= Verhoeff – Van Gieson staining; 
RFVG= resorcin fuchsin – Van Gieson staining; IFA= immune ﬂ uorescence assay. * N.D. = not done.
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ABSTRACT
Puriﬁ cation protocols for elastin generally result in greatly damaged elastin ﬁ bres and 
this likely inﬂ uences the biological response. We here describe a novel protocol for the 
isolation of elastin where the ﬁ bres stay intact, and introduce the term ‘elastin ﬁ bre’ for 
intact elastic ﬁ bres with elastin as their sole component. As opposed to elastic ﬁ bres, 
elastin ﬁ bres do not contain any microﬁ brils or associated molecules. Elastin ﬁ bres 
were isolated from equine elastic ligaments according to various protocols and analysed 
by SDS-PAGE, amino acid quantiﬁ cation, immunoﬂ uorescence assay, transmission/
scanning electron microscopy, and cellular reactivity in vivo. The optimal protocol 
comprised several extraction steps and trypsin digestion. Elastin ﬁ bres were free of 
contaminants and had a smooth, regular appearance. The cellular response towards 
puriﬁ ed, intact elastin ﬁ bres was different in comparison to puriﬁ ed, but affected, ﬁ bres 
and to contaminated ﬁ bres. Intact ﬁ bres consisting of only elastin may be important 
for both fundamental and applied research, e.g. tissue engineering, which need well-
deﬁ ned preparations to study the cellular biological effect of individual components.
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INTRODUCTION
Elastic ﬁ bres are widely distributed over the body, especially in organs where elasticity 
is a major issue, like lung and blood vessels [1]. Elastic ﬁ bres are composed of elastin 
and microﬁ brils. The latter is an intrinsic component of elastic ﬁ bres and is present 
on both the inside and the outside of elastic ﬁ bres. Microﬁ brils consist of and are 
associated with a variety of molecules including ﬁ brillins, microﬁ bril-associated 
(glyco)proteins, latent TGFβ-binding proteins, ﬁ bulins, emilins, proteoglycans and 
lysyl oxidase [2]. Elastic ﬁ bres are crucial in tissue homeostasis, but are not readily 
replaced in case of damage [3,4]. This seriously hampers tissue regeneration, e.g. in 
case of skin injury, and could be due to difﬁ culties in recapitulating the complex spatio 
temporal expression patterns of proteins like tropoelastin, lysyl oxidase and ﬁ brillins 
[5-7].
Evidence exists that the biological behaviour of cells towards proteins organised in 
ﬁ brillar form differs from that towards single proteins, e.g. in case of collagen where 
ﬁ brillar and monomeric collagen give different responses [8]. This possibly also holds 
for elastin [9,10]. Elastin in ﬁ brous form is not identical to its monomer, due to the 
formation of speciﬁ c crosslinks like (iso)desmosines. Cell biological studies of the 
effect of elastin in its native conformation, i.e. as a ﬁ bre, have been hampered by a 
lack of efﬁ cient isolation methodology. Current methods, such as treatment with 0.1 M 
NaOH at 95°C or autoclaving, are not able to adequately remove extracellular matrix 
components, such as collagen and microﬁ brillar components, and result in partial 
degradation of the elastic ﬁ bre [11,12]. It is therefore impossible to study the cellular 
effect of elastin ﬁ bres per se.
We have previously presented a puriﬁ cation protocol for insoluble elastin [13]. Although 
this protocol resulted in a highly puriﬁ ed elastin preparation, additional experiments 
showed that this method was not adequate to obtain intact ﬁ bres. Therefore, we 
adapted several steps in this puriﬁ cation procedure to develop a novel method to 
obtain both highly puriﬁ ed and intact ﬁ brillar elastin. We introduce the term ‘elastin 
ﬁ bre’ to indicate an elastic ﬁ bre in which the only component is elastin and show that 
the biological response to elastin preparations depends on the integrity and purity of 
the ﬁ bre.
MATERIALS & METHODS
Elastin puriﬁ cation
Equine ligamentum nuchae was used as a source for insoluble elastin. Elastic ligament 
was pulverised under liquid nitrogen conditions using a Fritsch Pulverisette 19 with a 
1 mm sieve (Idar-Oberstein, Germany). Three puriﬁ cation procedures were compared 
(Fig. 1).
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Procedure A: Procedure A is a traditional method based on treatment with 0.1 M 
NaOH at 95°C for 45 min [11]. This procedure makes use of three 24 h extractions 
with 10 vol. (10 ml/g wet weight tissue) 1 M NaCl at 4 °C. After each extraction step 
insoluble material was recovered by centrifugation at 13000g at 4 °C for 20 min. After 
the last extraction step, the pellet was washed with demineralised water, and defatted 
with 30 vol. acetone (3x 1 h). The material was dried in a desiccator, subsequently 
suspended in 30 vol. 0.1 M NaOH, and heated at 95°C for 45 min. The suspension was 
cooled, washed with demineralised water, and stored at -80°C.
Figure 1. Outline of the procedures used to isolate elastin from equine ligamentum nuchae.
Procedure B: Procedure B is adapted from Daamen et al. [13] and John and Thomas 
[14] and results in a highly puriﬁ ed elastin preparation in which the ﬁ bres, however, are 
greatly affected. The procedure consists of different extraction steps and digestions with 
enzymes. Pulverised ligament was extracted 3 times overnight with 10 vol. of 1 M NaCl 
containing 0.02% (w/v) NaN3 at 4 °C.  After each extraction step, insoluble material was 
recovered by centrifugation at 13000g at 4°C for 20 min, washed with demineralised 
water and resuspended in 10 vol. ethanol for 90 min. The mixture was then ﬁ ltered 
through a paper funnel and resuspended in 10 vol. chloroform/methanol (2:1) for 90 
min. The mixture was ﬁ ltered again through a paper funnel and resuspended in 10 vol. 
acetone for 30 min, and the same procedure was repeated with 10 vol. of ether. The 
insoluble material was dried in a desiccator. The dried powder was incubated in 15 vol. 
97% formic acid, and cyanogen bromide was added to a ﬁ nal concentration of 1%, 
and left to react for 24 h under non-oxidising conditions. The mixture was then diluted 
with 45 vol. demineralised water, ﬁ ltered and washed with demineralised water until 
a pH of 6 was reached. After washing, the pellet was extracted three times (24 h each) 
with 0.5 M Tris HCl, containing 5 M guanidium chloride, 1 M 2-mercaptoethanol, and 
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0.02% (w/v) NaN3 (pH 6.8). After the last extraction step the material was washed 
with demineralised water and incubated for 48 h at 37°C with 1000 U collagenase per 
gram of substrate in 10 vol. 0.2 M Tris HCl (pH 7.4) containing 0.05 M CaCl2 and 0.02% 
NaN3; after 24 h another 500 U collagenase/g was added. The preparation was washed 
with demineralised water and between each washing step recovered by centrifugation 
at 13000g for 20 min. After the last wash the pellet was resuspended in 10 vol. 0.1 M
NH4HCO3 (pH 8.2) containing 0.02% (w/v) NaN3, and 10,000 U trypsin for 4 h at 
37°C. The pellet was washed with demineralised water, followed by three overnight 
extractions with 10 vol. 1 M NaCl containing 0.02% (w/v) NaN3, and washed again 
with demineralised water. The end product was stored at -80 °C. Collagenase (C-0130) 
and trypsin (T-4665) were from Sigma (St Louis, MO, USA).
Procedure C: In the optimised procedure (procedure C), procedure B was adapted. 
A number of parameters was varied (see Results & Discussion section) including the 
nature of the chaotropic agent, the presence of CNBr, the nature of the reducing agent, 
the presence of trypsin, and the presence, concentration and duration of collagenase 
digestion. In the ﬁ nal procedure, 5 M guanidine-HCl was replaced by 4 M urea and the 
collagenase digestion was omitted.
Analysis of elastin ﬁ bre purity
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE): Elastin 
preparations were incubated at 95°C for 10 min under reducing conditions (5% (v/v) 
2-mercaptoethanol) and analysed on a 10% (w/v) polyacrylamide gel. This method 
is particularly useful for analysing purity since contaminants and elastin degradation 
products, but not ﬁ brillar elastin, will penetrate the gel. Proteins were visualised by 
silver staining using a 0.1% (w/v) AgNO3 solution.
Amino acid analysis: Elastin samples were hydrolysed under vacuum with 6 M HCl 
for 22 h at 110 °C, dried under vacuum over NaOH pellets and dissolved in 10 mM 
HCl. Hydrolysed samples were ﬁ rst deproteinised by addition of an 18.8 % (w/v) 
5-sulphosalicylic acid solution (Fluka Chemie, Buchs, Switzerland), containing 
norleucine (Sigma) as an internal standard. Separation of amino acids was obtained 
by ion exchange column chromatography on a Biochrom 20 amino acid analyser 
(Amersham Pharmacia Biotech) using lithium buffers with increasing pH.
Immunohistochemistry: Immunoﬂ uorescence microscopy was used to study the 
presence of elastin, type I collagen and ﬁ brillin in the elastin preparations. Elastin 
preparations were suspended in demineralised water and frozen in liquid nitrogen. 
Ligamentum nuchae was frozen directly in liquid nitrogen. Cryosections of frozen 
preparations were mounted onto glass slides. After blocking with 1% (w/v) bovine 
serum albumin (BSA) in PBS, sections were incubated with mouse anti-bovine elastin 
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IgG (1:1000, Sigma), rabbit anti-bovine type I collagen IgG (1:100, Chemicon, Temecula, 
CA, USA) and mouse anti-bovine ﬁ brillin IgG (1:50, Chemicon) for 90 min, washed 
with PBS, followed by a 1 h incubation with Alexa-labelled secondary antibodies (1:100, 
Molecular Probes, Eugene, OR, USA). All antibodies were diluted in PBS containing 
1% (w/v) BSA. Sections were washed and mounted in mowiol.
Transmission electron microscopy (TEM): Elastin preparations were embedded in 
1.5% (w/v) agarose, ﬁ xed in 2% (v/v) glutaraldehyde in 0.1 M phosphate buffer (pH 
7.4), postﬁ xed with 1% (w/v) osmium tetroxide, dehydrated in an ascending series 
of ethanols and embedded in Epon 812. Ultrathin sections (60 nm) were picked up on 
formvar-coated grids, post stained with lead citrate and uranyl acetate, and examined 
in a JEOL 1010 electron microscope (Tokyo, Japan).
Analysis of elastin ﬁ bre integrity
Scanning electron microscopy (SEM): SEM was used to study the intactness of the 
elastin ﬁ bres. Lyophilised elastin preparations were mounted on stubs and sputtered 
with an ultrathin layer of gold in a Polaron E5100 SEM coating system. Specimens were 
studied with a JEOL JSM-6310 SEM apparatus operating at 15 kV.
Subcutaneous implantation
NIH guidelines for the care and use of laboratory animals (NIH publication 85-23 
Rev. 1985) were observed. The study was approved by the Ethical Committee of the 
University of Nijmegen. Sprague-Dawley rats (male, 21 days old) were purchased from 
Harlan (Zeist, The Netherlands). The animals were fed pelleted diet (RMH-B 10 mm) 
and water ad libitum. Scaffolds composed of 50% puriﬁ ed collagen ﬁ brils [15] and 
50% elastin ﬁ bres (isolated according to procedure A, B and C) were washed in 70% 
(v/v) ethanol (4 x 30 min) and in sterile phosphate buffered saline (pH 7.2) (8 x 30 
min) at 22°C. Rats were anaesthetised with isoﬂ urane. After disinfection, subcutaneous 
pockets were made to the right and left of two midline incisions on the back. Punches 
(ø 6 mm, thickness 6 mm) of the scaffolds were implanted in the pockets at a distance 
of about 1 cm from the incisions (4 implants/rat). For each scaffold two rats received 
two punches of the same scaffold. Implants with surrounding tissue were harvested 
after 3 days, ﬁ xed in 4% (v/v) formaldehyde in phosphate buffer (pH 7.2) for 24 h 
at 4°C, and embedded in parafﬁ n. Sections of 5 µm were mounted onto glass slides, 
dewaxed in xylol, hydrated through a graded series of ethanol and haematoxylin-eosin 
stained [16].
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Figure 2. Transmission (A, C, E, G) and scanning electron micrographs (B, D, F, H) of equine ligamentum 
nuchae (A, B), elastin puriﬁ ed according to procedure A (C, D), procedure B (E, F), and procedure C (G, H). 
Inset in E shows SiO2 attached to an elastin ﬁ bre. Note the disruption of ﬁ bres using procedures A and B, and 
the smooth, regular appearance of ﬁ bres using procedure C. E= elastin; C= collagen ﬁ brils; arrows indicate 
microﬁ brillar remnants; arrows heads indicate holes in the ﬁ bres. Bar is 1 µm in TEM micrographs and 10 
µm in SEM micrographs.
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RESULTS & DISCUSSION
The general strategy to isolate elastin is to remove/degrade all other biomolecules. 
Initially the tissue is rinsed with NaCl-containing solutions to remove salt-soluble 
proteins, and with organic solvents to remove lipid-containing molecules. Traditional 
methods (as exempliﬁ ed by method A) then solubilise remaining proteins by partial 
hydrolysis using harsh methods like NaOH treatment at high temperature. Elastin is largely 
resistant to these treatments. Alternative methods (as exempliﬁ ed by method B) rely on 
further washings using chaotropic salts (guanidine-HCl), and cleavage of proteins by 
using CNBr treatment (cleaves at the site of methionine residues present in virtually all 
proteins, but not in elastin) and/or proteases (e.g. collagenase and trypsin). The methods 
used so far, however, result in either contaminated and/or disrupted elastin ﬁ bres. In this 
study we developed a novel isolation protocol, based on method B, which resulted in 
puriﬁ ed and intact elastin ﬁ bres. A number of different analytical techniques including 
SDS-PAGE, amino acid analysis, immunoﬂ uorescence microscopy, and transmission 
and scanning electron microscopy were used to study purity and intactness. The 
advantages and disadvantages of each of these techniques have been discussed [13].
In ligamentum nuchae (the source of elastin ﬁ bres), elastic ﬁ bres are surrounded 
by collagen ﬁ brils and other (extra)cellular components, and contain microﬁ brils at 
the periphery and within the ﬁ bres. The elastic ﬁ bres are present as bundles and 
are connected by collagen (Fig. 2A, B). EM showed that elastic ﬁ bres puriﬁ ed using 
conventional procedures, like procedure A, still contained microﬁ brillar remnants and 
that they were partially damaged (Fig. 2C, D). SDS-PAGE of elastin puriﬁ ed by method 
A gave a smear of high molecular mass impurities on a silver-stained gel (elastin ﬁ bres 
are too large to enter the gel), whereas method B resulted in an empty lane (results not 
shown). Method B resulted in highly puriﬁ ed elastin, but the intactness of the ﬁ bres 
was severely comprised as indicated by EM analysis (Fig. 2E, F). We therefore adapted 
this method to obtain puriﬁ ed as well as intact elastin ﬁ brils.
A number of parameters was varied. Omission of the CNBr step resulted in damaged as 
well as impure ﬁ bres. Replacement of 2-mercaptoethanol with dithiothreitol (DTT) did 
result in pure elastin, but the ﬁ bres were damaged. Omission of both the collagenase 
and trypsin enzyme digestions led to intact, but impure ﬁ bres. Omission of only trypsin 
resulted in pure, but damaged, ﬁ brils. SEM analysis of elastic ﬁ bres after various 
extraction steps indeed indicated that the collagenase treatment led to destruction 
of the ﬁ bres (Fig. 3, compare 3D with 3E). The collagenase preparation used may 
contain other proteases (according to the manufacturer’s data sheet), possibly elastase. 
Reduction of the amount of collagenase and/or time of digestion, however, still resulted 
in damaged ﬁ bres. We therefore omitted the collagenase treatment. To evaluate if 
collagen was still removed, immunoﬂ uorescence and TEM were applied. No collagen 
ﬁ brils and no immunoreactivity with anti-collagen antibodies were detected (Fig. 2G
and Fig. 4). Elastin puriﬁ ed with method C did not show immunoreactivity with 
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anti-ﬁ brillin antibodies either (results not shown). Immunostaining for elastin, 
however, was highly positive. Collagen ﬁ brils were largely removed by chaotropic salt/
mercaptoethanol/CNBr treatments. Trypsin was necessary for the removal of remnants 
of microﬁ brillar components, and although, in principal, trypsin is capable to digest 
elastin (it cleaves near Lys and Arg residues which are present in elastin), results 
showed that with a 4 h digestion, the elastin ﬁ bres remained intact (Fig. 2H). Using 
TEM, it was noticed that an electron-dense precipitate was present (see insert Fig. 2E).
This could be attributed to the guanidine-HCl step. Guanidine-HCl sometimes contains 
an anti-caking agent (SiO2) that sticks to elastin ﬁ bres and can not be removed anymore. 
Omission of guanidine-HCl, however, did not result in a pure elastin preparation and 
therefore it was replaced by urea, another chaotropic agent, which gave satisfactory 
results. Taken together, the omission of collagenase and the replacement of guanidine-
HCl by urea (procedure C) resulted in highly puriﬁ ed, intact elastin ﬁ bres (Fig. 2G, H).
SDS-PAGE, immunoﬂ uorescence and transmission electron microscopy gave similar 
results for method B and C, indicating that method C results in highly puriﬁ ed elastin.
Figure 3. Scanning electron micrographs of partly puriﬁ ed elastin after each of method B’s puriﬁ cation 
steps (see Fig. 1 for sequential steps). (A) after NaCl extraction, (B) after organic solvents steps, (C) after 
CNBr in formic acid step, (D) after guanidium chloride/ 2-mercaptoethanol extractions, (E) after collagenase 
digestion, (F) after trypsin digestions, e.g. elastin in Fig. 3C was isolated with the NaCl extraction, organic 
solvents steps and guanidium chloride/ 2-mercaptoethanol extractions. Insert in E shows an enlargement of 
affected ﬁ bres. Note that elastin ﬁ bres get damaged after the collagenase digestion. Bar is 10 µm.
However, amino acid analysis for method B and C gave slightly different ﬁ ndings 
(Table 1). For elastin puriﬁ ed according to method C, frequently occurring amino acid 
residues like Gly, Pro and Val, resemble the theoretical amino acid composition of 
bovine more closely than method B (equine cDNA was not available). Because method 
C also resulted in intact elastin ﬁ bres, this may indicate that these elastin molecules are 
less prone to proteolysis compared to method B elastin. This may be crucial for correct 
cell adhesion, for instance mediated by integrin αvβ3 which binds to the C-terminal 
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Figure 4. Immunostaining for type I collagen (A, B) and elastin (C, D) in ligamentum nuchae (A, C) and 
elastin puriﬁ ed according to method C (B, D). Bar is 20 µm.
Table 1. Amino acid composition of elastin puriﬁ ed by methods B and C.
* The amino acid composition of bovine elastin was theoretically calculated from the cDNA of tropoelastin. 
Posttranslational modiﬁ cations and alternative splicings are therefore not taken into account [24,25]. 
Values are mean (n = 3 ± SD), expressed per 1000 amino acid residues and not corrected for losses during 
hydrolysis. Des= desmosine; Ide= isodesmosine. Amino acid composition of elastin puriﬁ ed according to 
method B are from method 3c [13].
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end of elastin [17]. Fig. 5 shows that elastin was present homogeneously in the elastin 
ﬁ bres puriﬁ ed according to method C. Yields for the different puriﬁ cation procedures 
A, B, and C were similar and were on basis of dry weight 21, 20 and 22% of the original 
ligament, respectively.
Figure 5. Scanning electron micrographs of cross-sectioned elastin ﬁ bres puriﬁ ed according to procedure C. 
Elastin is distributed throughout the whole ﬁ bre, and no holes are present. Bar is 10 µm in A and 5 µm in B.
The cellular response toward elastin preparations made by procedure A, B, or C was 
clearly different (Fig. 6). Upon implantation of impure, partially affected elastin 
(procedure A), many cells (including macrophages, ﬁ broblasts and neutrophiles) 
inﬁ ltrated the scaffold. Implantation of pure, but severely affected elastin (procedure 
B) gave rise to the inﬂ ux of large amounts of neutrophiles. However, pure and intact 
ﬁ bres (procedure C) resulted in only a mild cellular response with few cells inﬁ ltrating 
the scaffold. Differences in the purity of insoluble elastin preparations thus gave a 
distinct cellular response upon implantation. 
Moreover, these results indicated that the intactness of elastin ﬁ bres is of major 
inﬂ uence to the cellular response. It has been demonstrated that elastin degradation is 
accompanied by an inﬂ ammatory response e.g. in animal models of elastase-induced 
emphysema [18] and elastase-induced abdominal aortic aneurysms [19,20]. Therefore, 
degraded elastin ﬁ bres (as obtained by method B) likely induce an inﬂ ammatory 
response. Also, partly puriﬁ ed elastin (as in method A) contains (degradation 
products of) microﬁ brillar components that may attract neutrophiles. Similarly, an 
impure preparation of collagen-elastin (a mildly cleansed membrane of porcine origin 
composed of mainly collagen (70%) and elastin) resulted in inﬂ ammation, activation 
of macrophages and angiogenesis [21].
The availability of isolated elastin in its native, ﬁ brillar conformation may be important 
for both fundamental and applied research. For cell biological studies to elastin it is 
now possible to study the effect of mature extracellular elastin in ﬁ brous form, without 
introducing artefacts to the system caused by affected ﬁ bres and/or impurities. It is 
also possible to test whether conﬂ icting data, e.g. to the speciﬁ city of matrix
metalloproteinases [22], are due to impurities still present within or associated 
with the elastic ﬁ bre. In applied research, like the use of elastin in biomaterials and
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Figure 6. Light microscopical overview of the cellular response to scaffolds 3 days after subcutaneous 
implantation in Sprague Dawley rats. Scaffolds composed of elastin and collagen 1:1 were used. (A-C) elastin 
prepared according to procedure A, B, and C, respectively. Note that few cells were found upon implantation of 
pure intact elastin ﬁ bres (procedure C), whereas many cells were present when using other elastin preparations. 
Sections were HE stained. Bar is 10 µm.
tissue engineering, the puriﬁ ed intact ﬁ bres may be useful when preparing deﬁ ned 
bioscaffolds from scratch [23], thus avoiding unwanted immunological reactions to 
contaminations, and allowing studies to the body’s response to one single component: 
elastin.
In summary, we have developed a puriﬁ cation method which results in highly puriﬁ ed, 
intact ﬁ bres of elastin. We called these ﬁ bres ‘elastin ﬁ bres’ opposed to elastic ﬁ bres.
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ABSTRACT
Extracellular matrix components are valuable building blocks for the preparation of 
biomaterials involved in tissue engineering, especially if their biological, chemical 
and physical characteristics can be controlled. In this study, isolated type I collagen 
ﬁ brils, elastin ﬁ bres and chondroitin sulfate (CS) were used for the preparation of 
molecularly-deﬁ ned collagen-elastin-glycosaminoglycan scaffolds. A total of twelve 
different scaffolds were prepared with four different ratios of collagen and elastin (1:9, 
1:1, 9:1 and 1:0), with and without chemical crosslinking, and with and without CS. 
Collagen was essential to fabricate coherent, porous scaffolds. Electron microscopy 
showed that collagen and elastin physically interacted with each other and that elastin 
ﬁ bres were enveloped by collagen. By carbodiimide-crosslinking, amine groups were 
coupled to carboxylic groups and CS could be incorporated. More CS could be bound 
to collagen scaffolds (10%) than to collagen-elastin scaffolds (2.4-8.5% depending on 
the ratio). The attachment of CS increased the water-binding capacity to up to 65%. 
Scaffolds with a higher collagen content had a higher tensile strength whereas addition 
of elastin increased elasticity. Scaffolds were biocompatible as was established using 
human myoblast and ﬁ broblast culture systems. It is concluded that molecularly-
deﬁ ned composite scaffolds can be composed from individual, puriﬁ ed, extracellular 
matrix components. Data are important in the design and application of tailor-made 
biomaterials for tissue engineering.
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INTRODUCTION
Tissue engineering is a ﬁ eld of research, which aims at regenerating tissues and organs. 
Tissues are basically made up of cells and extracellular matrix. Cells taken out of their 
context will lose their shape and function. A major goal of tissue engineering is the 
preparation of a suitable scaffold for cells to proliferate, migrate and differentiate. The 
scaffold should assist cells to form the desired tissue. To reproducibly prepare bioscaffolds 
and to study the biological effect of a single component, molecularly-deﬁ ned scaffolds 
have to be prepared. In tissues and organs, major extracellular matrix components are 
collagens, elastin, and glycosaminoglycans. Each tissue/organ has its own unique set 
and content of these biomolecules. Type I collagen is an extracellular matrix protein 
that is widely used as scaffold material [1]. It provides adhesive properties and tensile 
strength. Elastin provides elasticity to tissues/organs and is crucial for e.g. blood 
vessels in order to cope with variations in blood pressure [2]. Glycosaminoglycans 
(GAGs) are negatively charged polysaccharides with biocharacteristics like hydration 
of the extracellular matrix [3,4] and binding of effector molecules (e.g. growth factors 
and cytokines) [5-8]. In contrast to collagen, elastin is rarely used in bioscaffolds and 
when applied only poorly-deﬁ ned elastin preparations have been used. Aprahamian 
et al. [9] made a matrix of elastin with ﬁ brin in the presence of type I collagen. 
Rabaud et al. [10] prepared a gel from a collagenous preparation and insoluble elastin. 
Others used elastin present in isolated blood vessels [11, 12] or heart valves [13]. Also, 
elastin hydrolysates have been added to biomaterials. For example, Singla and Lee 
[14] prepared glutaraldehyde-crosslinked matrices from soluble α-elastin and collagen 
to study the calciﬁ cation rate in a rat model. To our knowledge, well-deﬁ ned highly-
puriﬁ ed insoluble elastin ﬁ bres have never been used to prepare deﬁ ned scaffolds for 
tissue engineering.
Here, we report the preparation of deﬁ ned collagen-elastin-GAG scaffolds. Twelve 
different scaffolds were prepared using four different ratios of collagen and elastin 
(1:0; 9:1; 1:1; 1:9), with and without chemical crosslinking, and with and without 
chondroitin sulfate. All scaffolds were characterised biochemically, biomechanically 
and immunohistologically, and their effect on cell proliferation and differentiation was 
studied in vitro.
MATERIALS & METHODS
Materials
Mouse anti-chicken chondroitin sulfate monoclonal antibody (clone CS-56, C-8035), 
and FITC-labelled goat anti-mouse IgM (F-9259) were from Sigma (St Louis, MO, USA). 
Chondroitin sulfate A (C-9819) was also from Sigma, and was basically a mixture of 60% 
chondroitin 4-sulfate and 40% chondroitin 6-sulfate. No other GAGs could be detected 
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using agarose gel electrophoresis with silver staining; also no protein contaminations 
could be detected as analysed by SDS-PAGE applying 1 mg of material and Coomassie 
Brilliant Blue staining. Rabbit anti-bovine type I collagen antibody was from Chemicon 
(Temecula, CA, USA). Alexa 594-labeled goat anti-rabbit IgG was from Molecular 
Probes (Eugene, OR, USA). Chondroitinase ABC was from Seikagaku (Tokyo, Japan).
Isolation of collagen and elastin
Insoluble type I collagen was isolated from bovine achilles tendon (deep ﬂ exor) 
using neutral salt and dilute acid extractions as described [15]. Purity of collagen 
was analysed using SDS-PAGE and amino acid analysis. The collagen preparation was 
essentially free of other proteins.
Elastin ﬁ bres were isolated from equine ligamentum nuchae essentially as described, 
but with omission of the collagenase digestion [16]. Purity of elastin was assessed using 
SDS-PAGE, amino acid analysis, and transmission electron microscopy. No impurities 
could be detected by any of these methods. Microﬁ brillar components (present in 
unpuriﬁ ed elastic ﬁ bres) were absent.
Preparation of collagen-elastin-GAG scaffolds
In total, twelve different scaffolds were prepared with different ratios of collagen and 
elastin, with and without 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide (EDC) 
crosslinking and with and without chondroitin sulfate.
Non-EDC-crosslinked type I collagen scaffolds were prepared as described [15]. Brieﬂ y, 
a 2% (w/v) collagen suspension was prepared in 0.5 M acetic acid (pH 2.5) and shaken 
at 4°C for 16 h. This suspension was then diluted to 1% (w/v) with ice-cold distilled 
water, homogenised, and deaerated under vacuum to remove entrapped air bubbles. 
The collagen suspension was poured into a mould, frozen at -80°C and lyophilised, 
resulting in porous collagen scaffolds. Non-EDC-crosslinked composite scaffolds of 
type I collagen and elastin were prepared similarly using suspensions of type I collagen 
and elastin in a 9:1, 1:1, or 1:9 ratio. 
To increase the strength of the scaffolds, chemical crosslinking of collagen and collagen-
elastin scaffolds was performed using EDC and N-hydroxysuccinimide (NHS) [17]. 
Scaffolds were incubated for 0.5 h in 20 ml 50 mM 2-morpholinoethane sulfonic acid 
(MES) (pH 5.5) in the presence of 40% (v/v) ethanol. Subsequently, the scaffolds were 
crosslinked by immersion in 20 ml 50 mM MES (pH 5.5) containing 33 mM EDC and 
6 mM NHS. After reaction for 4 h at 22 °C, the scaffolds were washed twice in 0.1 M 
Na2HPO4 (pH 9.1) for 1 h. Finally, the scaffolds were washed with 1 M NaCl and 2 M 
NaCl for 2 h and 1 day (with 6 changes of washing solution), respectively, followed by 
washings with distilled water. EDC-crosslinking of the scaffolds was also performed 
in the presence of 2.75% (w/v) CS which results in the covalent attachment of CS to 
the scaffold.
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Characterisation of the scaffolds
Amine group content: The amine group content of scaffolds was determined 
spectrophotometrically after reaction with 2,4,6-trinitrobenzene sulfonic acid [18]. The 
presence of CS did not interfere with this assay.
CS content: The CS content of scaffolds was determined by hexosamine analysis using 
p-dimethylamino-benzaldehyde [15,19]. Scaffolds were hydrolysed with 6 M HCl for 
6 h at 105°C. Samples were dried under vacuum and dissolved in distilled water for 
hexosamine analysis. CS was used as a standard.
Water-binding capacity: Scaffold samples of about 5 mg dry weight were incubated 
in 3 ml PBS (pH 7.2) at 20°C. After 1 h, the wet weight was determined and the 
water-binding capacity calculated using the equation: water-binding capacity = [(wet 
weight-dry weight)·100%]/(dry weight).
Scanning electron microscopy (SEM): Scaffolds were critical point dried using CO2
with a Polaron E3000 critical point drying apparatus, mounted on stubs and sputtered 
with an ultrathin layer of gold in a Polaron E5100 SEM coating system. Specimens were 
studied with a JEOL JSM-6310 SEM apparatus operating at 15 kV.
Transmission electron microscopy (TEM): Scaffolds were ﬁ xed in 2% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for 12 h at 4°C, and postﬁ xed with 
1% (w/v) osmium tetroxide in 0.1 M phosphate buffer (pH 7.4). After a rinsing period 
of 3 h, the samples were dehydrated in an ascending series of ethanols and embedded 
in Epon 812. Ultrathin sections (60 nm) were post stained with lead citrate and uranyl 
acetate, picked up on formvar-coated grids and examined in a JEOL 1010 electron 
microscope.
Light microscopy: For conventional histochemical analysis, scaffolds were ﬁ xed in 4% 
(v/v) formaldehyde in phosphate buffer (pH 7.2) and embedded in parafﬁ n. Sections 
of 5 µm were mounted onto organosilane-coated slides, dewaxed in xylol and hydrated 
through a descending series of ethanols. Sections were stained for elastin and collagen 
according to Verhoeff -Van Gieson [20].
Immunoﬂ uorescence microscopy: Immunoﬂ uorescence microscopy was used to study 
the distribution of CS in the scaffolds. Scaffolds were hydrated in 0.1 M phosphate 
buffer (pH 7.2) and frozen in liquid nitrogen. Cryosections of 5 µm were mounted onto 
organosilane-coated glass slides. After blocking with 1% (w/v) bovine serum albumin 
(BSA) in PBS (pH 7.2), sections were incubated with mouse anti-chicken chondroitin 
sulfate monoclonal antibody (1:50) and rabbit anti-bovine type I collagen antibody 
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(1:500) for 90 min, washed with PBS, followed by a 1 h incubation with FITC-labelled 
goat anti-mouse IgM (1:100) and Alexa 594-labeled goat anti-rabbit IgG (1:100). 
Antibodies were diluted in PBS containing 1% (w/v) BSA. The sections were washed 
and mounted in mowiol. Elastin was detected on the basis of its autoﬂ uorescence 
using UV optics.
To study if scaffold-bound CS was available for biological interactions, its degradation 
by chondroitinase ABC was studied. Cryosections of 5 µm were incubated for 30 min 
in 25 mM Tris-HCl (pH 8.0) + 1 mM magnesium acetate, followed by an incubation 
with 1 U/ml chondroitinase ABC in the same buffer for 16 h at 37°C. Subsequently, 
sections were immunostained for CS as described above.
Mechanical properties: Stress-strain analysis of scaffolds was performed by uniaxial 
measurements using a Zwick Z020 mechanical tester. Scaffolds were hydrated for 24 h 
in PBS (pH 7.2) and drawn at a speed of 5 mm/min. The elastic modulus was calculated 
from the inclination of the stress-strain graph; the tensile strength was monitored after 
rupture of the scaffolds.
Effects of scaffolds on cells in vitro
The in vitro cytotoxicity of scaffolds was evaluated on the basis of cell morphology, 
viability, and proliferation. Human myoblasts [21] and human HFL1 lung ﬁ broblasts 
(ATCC cell line CCL153) were used. All scaffolds were washed with 70% (v/v) ethanol 
and sterile PBS (pH 7.2).
Proliferation of cells indirectly in contact with scaffolds: To analyse possible release 
of toxic products by the scaffolds, 4.0·104/well ﬁ broblasts were grown in proliferation 
medium (10% (v/v) foetal bovine serum, 4 mM glutamine, penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in Dulbecco’s modiﬁ ed Eagle medium (DMEM)) on culture 
plastic (Falcon, Becton Dickinson Labware, New Jersey, USA). After 24 h, scaffolds 
(Ø 8 mm) were added onto the cell inserts (Falcon). Cells were allowed to grow for 
another 48 h. Trypsinised cells were counted using trypan blue in a Bürker counting-
chamber. Trypan-blue positive cells indicate non-viable cells. Therefore, only Trypan-
blue negative cells were counted. The cell proliferation inhibition index (CPIIindirect) was 
calculated according to: CPIIindirect = 100% - [(number of cells in cultures with scaffold / 
number of cells in culture without scaffold) x 100%] [15]. Cells with no added scaffold 
will have a CPIIindirect of 0%.
Proliferation of cells directly in contact with scaffolds: Fibroblast proliferation was 
assessed by measuring the mitochondrial dehydrogenase activity using the tetrazolium 
salt 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate 
(WST-1) (Boehringer Mannheim, Germany), according to the manufacturer’s protocol. 
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Ø 6 mm scaffolds were placed in 96-wells plates. Cells were seeded on the scaffolds 
(104 cells in 200 µl per well) and cultured for 3 days at 37°C/ 5% CO2 in proliferation 
medium (10% (v/v) foetal bovine serum, 4 mM glutamine, penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in DMEM). After the addition of 20 µl WST-1 per well and 
subsequent incubation for 3 h at 37°C/ 5% CO2, the absorption was measured at 490 
nm. The mitochondrial dehydrogenase activity of day 3 cultures was divided by the 
activity of day 1 cultures. The enzyme activity ratio was expressed as a percentage 
of the ratio of cells grown on culture plastic. The cell proliferation inhibition index 
(CPIIdirect) was calculated according to: CPIIdirect = 100% - [(enzyme activity of cells in 
cultures with scaffold / enzyme activity of cells in culture without scaffold) x 100%]. 
Cells grown on culture plastic (no scaffold added) will have a CPIIdirect of 0%.
Cell morphology: Cell morphology was assessed using SEM. Ø 16 mm scaffolds were 
placed in 24-well culture dishes and cells were seeded on top. Human ﬁ broblasts were 
seeded on the airside of the scaffolds with a density of about 105 cells per cm2 in 
proliferation medium (10% (v/v) foetal bovine serum, 4 mM glutamine, penicillin (100 
U/ml) and streptomycin (100 µg/ml) in DMEM). Cells were cultured at 37°C and 5% 
CO2 for 3 days after which the proliferation medium was changed for differentiation 
medium which contained 2% (v/v) horse serum, 4 mM glutamine, penicillin (100 
U/ml) and streptomycin (100 µg/ml) in DMEM. Human myoblasts were cultured on 
the scaffolds using similar conditions, but different media. The proliferation medium 
contained 4% (v/v) Ultroser G (Sopar-Biochem, Brussels, Belgium), 10% (v/v) rat 
brain extract, 4 mM glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) in 
DMEM. The differentiation medium contained 0.4% (v/v) Ultroser G, 10% (v/v) rat 
brain extract, 4 mM glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) 
in DMEM. After culturing for 14 days, scaffolds were ﬁ xed by immersion in 2% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for 1 h at 4°C, and prepared for 
SEM.
RESULTS
Biochemical and biophysical properties of the scaffolds
Table 1 gives an overview of the composition and properties of the twelve scaffolds 
used in this study. The amine group content of the pure collagen scaffold was 281 
nmol/mg scaffold. The composite collagen-elastin scaffolds contained less NH2
groups, since elastin contained less amine groups than type I collagen (elastin had 27 
± 2 nmol NH2 groups/mg elastin). We were not able to construct a stable scaffold 
made of only elastin, even not after crosslinking. Collagen-elastin crosslinking using 
EDC/NHS results in the formation of crosslinks between carboxylic and amine groups, 
and thus in a reduction of the number of amine groups. Crosslinking efﬁ ciency was 
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highest for collagen scaffolds (about 100 nmol amine groups/mg scaffold were utilised 
upon crosslinking), and smallest for collagen-elastin 1:9 scaffolds (about 30 nmol 
amine groups/mg scaffold were utilised in the crosslinking process). Under the same 
conditions, collagen could be crosslinked to a higher extent than collagen-elastin 
scaffolds, because more amine groups are present. Collagen-elastin crosslinking using 
EDC/NHS in the presence of CS results, besides the formation of crosslinks between 
these proteins, in the covalent attachment of CS through its carboxylic groups. Coupling 
of CS to scaffolds generally had no effect on crosslinking efﬁ ciency. Since collagen 
contains more amine groups than elastin, the CS content incorporated into the scaffold 
is dependent on the collagen-elastin ratio. The content of CS was 10.0% (w/w) for 
the collagen scaffold, and decreased concomitantly with the collagen content of the 
collagen-elastin scaffolds.
Table 1. Biochemical and biomechanical characteristics of collagen-elastin-chondroitin sulfate scaffolds.
* 1 g of COL-CS scaffold contains 900 mg collagen and 100 mg CS.
** 1 g of COL-EL-CS 9:1 scaffold contains 823 mg collagen, 92 mg elastin and 85 mg CS.
*** 1 g of COL-EL-CS 1:1 scaffold contains 471 mg collagen, 471 mg elastin and 58 mg CS.
**** 1 g of COL-EL-CS 1:9 scaffold contains 98 mg collagen, 878 mg elastin and 24 mg CS.
COL= collagen; EL= elastin; CS= chondroitin sulfate. N.D.= Not done; scaffolds were to weak to measure 
tensile strength and E-modulus. Results are mean ± SD of 3 independent experiments.
The coupling of CS to the scaffolds increased the water-binding capacity. This effect 
was most prominent for the collagen scaffold. In the collagen-elastin scaffolds, less CS 
was present, and thus the increase in water-binding capacity was less. EDC-crosslinking 
without CS did not inﬂ uence the water-binding capacity of the scaffolds.
Regarding the mechanical characteristics of the non-crosslinked scaffolds, the 
tensile strength of the pure collagen scaffold was the highest (about 100 kPa), and 
introduction of elastin to the scaffold lowered the tensile strength as well as the E-
modulus. Crosslinking of the scaffolds increased the tensile strength and increased 
the E-modulus. Attachment of CS to a scaffold did not result in a signiﬁ cant change 
of tensile strength. When manually pulling at a hydrated non-crosslinked scaffold that 
was glued to a petri dish, it became clear that scaffolds containing a larger content of 
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elastin could be extended further, and recoiled faster upon release of the force. The 
collagen and collagen-elastin 9:1 scaffolds could be extended to 125%, the collagen-
elastin 1:1 scaffold to 140% and the collagen-elastin 1:9 scaffold to almost 150% (see 
movie at http://www.ncmls.kun.nl/biochemistry/matrix/movies/scaffolds.avi).
Figure 1. Verhoeff-Van Gieson staining of a collagen scaffold (A), a 9:1 collagen-elastin scaffold (B), a 1:1 
collagen-elastin scaffold (C), and a 1:9 collagen-elastin scaffold (D). Collagen has a grey colour, elastin is 
black. Arrows indicate elastin ﬁ bres. Bar is 100 µm.
Morphological properties of the scaffolds and distribution of single 
components
All scaffolds showed a porous structure with pores ranging from 20-100 µm. Elastin 
ﬁ bres were much thicker than collagen ﬁ brils and therefore scaffolds containing more 
elastin had larger pores, since the dry weight/cm3 was constant for all scaffolds. EDC-
crosslinking and coupling of CS to the scaffolds did not alter the porosity. Collagen 
and elastin were randomly distributed in the scaffolds, although elastin tended to be 
present in small clusters consisting of up to twenty elastin ﬁ bres, especially when 
a scaffold contained a high amount of elastin (Fig. 1). SEM (Fig. 2) clearly showed 
thick elastin ﬁ bres and thin collagen ﬁ brils. Collagen was also present as lattice-like 
lamellae, mostly orientated parallel or perpendicular to the surface, but the more 
elastin was present, the less lamellae were found. SEM indicated that elastin ﬁ bres 
and collagen ﬁ brils physically interact with one another, which was conﬁ rmed by TEM 
(Fig.3).
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Figure 2. Scanning electron micrographs of the air side of a collagen scaffold (A), a 9:1 collagen-elastin 
scaffold (B), a 1:1 collagen-elastin scaffold (C), and a 1:9 collagen-elastin scaffold (D). Collagen is present as 
ﬁ brils and sheets. Note interactions between (thick) elastin ﬁ bres (large arrows) and collagen ﬁ brils (small 
arrows). Bar is 10 µm.
Figure 3. Transmission electron micrograph of a collagen-elastin 1:1 scaffold at several magniﬁ cations. A, B 
and C show connections between separate thick elastin ﬁ bres by thin collagen ﬁ brils. D, E and F demonstrate 
the ensheathment of single elastin ﬁ bres by a layer of collagen ﬁ brils that are often frayed at sites of contact 
with elastin. Bar is 1 µm.
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Collagen connected separate elastin ﬁ bres, and elastin ﬁ bres were ensheathed by a 
layer of collagen ﬁ brils. In many occasions, the native collagen ﬁ bril was frayed into 
protoﬁ brils at places where it contacted elastin.
Immunoﬂ uorescence indicated that CS colocalised primarily with collagen and could 
be removed from the scaffolds by speciﬁ c digestion using the enzyme chondroitinase 
ABC (Fig. 4). This suggests that the CS bound to the scaffolds preserves its 
natural conformation and remains biologically available (i.e. capable to display its 
biocharacteristics).
Figure 4. Localisation of scaffold components by immunoﬂ uorescence staining for type I collagen (A, E, I, 
M), CS (C, G, K, O before chondroitinase ABC digestion; D, H, L, P after chondroitinase  ABC digestion), and 
by UV optics for elastin (B, F, J, N) of a collagen-CS scaffold (A-D), a 9:1 collagen-elastin-CS scaffold (E-H), 
a 1:1 collagen-elastin-CS scaffold (I-L), and a 1:9 collagen-elastin-CS scaffold (M-P). Bar is 50 µm. Colour 
ﬁ gure on page 152.
Biocompatibility of scaffolds in vitro
Proliferation of cells indirectly or directly in contact with scaffolds
To analyse possible release of toxic products by the scaffolds, ﬁ broblasts were grown 
indirectly in contact with scaffolds. The values of the indirect cell proliferation inhibition 
index (CPIIindirect) did not show negative effects on the proliferation of ﬁ broblasts 
for all scaffolds. The direct cell proliferation inhibition index (CPIIdirect) also did not 
show effects on the proliferation of ﬁ broblasts for collagen, collagen-elastin 9:1 and 
1:1 scaffolds, but a small decrease was found for ﬁ broblast proliferation on collagen-
elastin 1:9 scaffolds (Table 2).
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Table 2. Results of in vitro cell proliferation of human ﬁ broblasts grown indirectly and directly in contact 
with scaffolds.
*  CPII = cell proliferation inhibition index; CPIIindirect of cells grown on culture plastic was set to 0%.
**CPIIdirect was calculated from mitochondrial dehydrogenase activity using WST-1. The enzyme activity of 
  cells grown on culture plastic was set to 0%. Values are mean ± SD of 3 independent experiments.
Figure 5. SEM images of human muscle cells grown on a collagen scaffold (A), a 9:1 collagen–elastin scaffold 
(B), a 1:1 collagen–elastin scaffold (C), and a 1:9 collagen–elastin scaffold (D). Myoblasts were cultured for 
14 days. Myotubes were formed on all scaffolds, except collagen:elastin 1:9 scaffolds. Bar is 10 µm.
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Cell morphology
The cell morphology of ﬁ broblasts and myoblasts was studied on the scaffolds after 
14 days of culturing. Fibroblasts formed normal spindle-shaped cells on all scaffolds 
(data not shown). Myoblasts adhered, aligned, and fused to form multinucleated 
myotubes of several hundreds of µm in length on all scaffolds, except on the collagen-
elastin 1:9 scaffolds (Fig. 5). On the latter, cells did not have an elongated form, but a 
rounder form with small sprout-like structures. This could be caused by a diminished 
proliferation of myoblasts on the collagen-elastin 1:9 scaffolds, because myoblasts 
only start to differentiate when cells contact one another. Another possibility is that 
myoblasts do not fully differentiate on an elastin surface. Cells generally followed 
the direction of the collagen ﬁ brils or elastin ﬁ bres of the scaffolds beneath them. No 
differences of morphology were found between cells cultured on non-EDC-crosslinked 
and crosslinked scaffolds, or on scaffolds with and without CS.
DISCUSSION
For a rational design of scaffolds for tissue engineering, it is essential to study the 
effect of individual components. To do so, scaffolds have to be designed starting with 
highly puriﬁ ed molecules and the contribution of each component in the scaffold has 
to be controlled. This is also crucial when scaffolds are to be constructed which mimic 
nature’s extracellular matrices, and which vary considerably from tissue to tissue. 
For instance, when making a scaffold for an artery construct, a much larger content 
of elastin is necessary than when preparing a scaffold for artiﬁ cial skin. In skin, the 
ratio collagen:elastin is about 9:1, whereas in an artery this ratio is 1:1 averaging all 
artery layers, and 1:9 when considering the lamina elastica only [22]. In ligaments, 
the ratio collagen-elastin is also about 1:9 [22], and in lung about 1:1 [23]. Likewise, 
the amount (and type) of glycosaminoglycans, another major scaffold component, 
varies from matrix to matrix. In cartilage for example, chondroitin sulfate is the main 
glycosaminoglycan making up 20% of the dry weight. In skin, dermatan sulfate is 
most abundant (about 1% of the dry weight), whereas in the vitrous body of the eye 
it is hyaluronate [24]. Given the large heterogeneity in the body’s scaffolds, it was the 
purpose of this study to demonstrate that tailor-made, molecularly-deﬁ ned scaffolds 
can be produced from the main components of the extracellular matrix. 
We prepared twelve scaffolds with different ratios of highly puriﬁ ed collagen, elastin 
and CS, and compared them to each other. With more collagen, the tensile strength 
of the scaffold was generally higher, whereas increase of elastin increased elasticity. 
Collagen-elastin 1:1 scaffolds could be extended to about 140% of the original length; 
collagen-elastin 1:9 scaffolds to almost 150%. Under normal physiological conditions, 
circumferential stress-strain extensions of blood vessels are about 20% of the original 
diameter [25]. This extension, caused by differences in blood pressure, can easily be 
reached with these scaffolds, which also provides the elasticity necessary for coping 
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with changes in blood pressure. Elastin reduced, but CS increased the water-binding 
capacity. SEM and TEM data indicated that elastin ﬁ bres and collagen ﬁ brils interacted 
with each other. Collagen formed a small layer of ﬁ brils around the elastin ﬁ bres, thus 
incorporating elastin in the scaffolds. Collagen may act as a glue that holds the elastin 
ﬁ bres together. This may explain the inability to construct a stable scaffold of elastin 
only. Collagen-elastin 1:9 scaffolds are difﬁ cult to handle, indicating that a certain 
amount of collagen is necessary to prepare a coherent scaffold. The inability to prepare 
scaffolds composed of only elastin could be due to the low number of amine groups 
in elastin. The introduction of amine groups (e.g. by a diamine compound) may be a 
solution for this. In case the amines are too distant from the carboxylic groups in order 
to be crosslinked, bridging may be accomplished by e.g. aminocaproic acid. Next to 
the biochemical composition of the scaffolds, the mechanical properties of the scaffold 
can be controlled, e.g. by the composition (choice of ECM components and their ratio), 
the type and extent of chemical crosslinking, and the pore size of the scaffold. The 
pore sizes can be varied by changing the freezing rate in the manufacturing process. 
Fast freezing will result in small ice crystals and smaller pores after lyophilisation. The 
shape of the scaffold can easily be controlled by the mould that is chosen. The water-
binding capacity of the scaffolds can be inﬂ uenced by the attachment of GAGs, as 
shown with CS. Glycosaminoglycans can also be used as slow-release vehicles for e.g. 
growth factors [26]. Using speciﬁ c growth factors, a scaffold may be able to selectively 
interact with surrounding cells to improve tissue regeneration in vivo.
In conclusion, a variety of biological scaffolds have been prepared with deﬁ ned 
biochemical, biomechanical, and morphological characteristics. The methodology 
applied may be instrumental to produce organ-speciﬁ c scaffolds for tissue 
engineering.
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ABSTRACT
Collagen-elastin scaffolds may be valuable biomaterials for tissue engineering because 
they combine tensile strength with elasticity. In this study, the tissue response to 
and the calciﬁ cation of these scaffolds were evaluated. In particular, the hypothesis 
was tested that calciﬁ cation, a common phenomenon in biomaterials, may be due 
to microﬁ brils within the elastic ﬁ bre, and that these microﬁ brils might generate a 
tissue response. Four scaffolds were subcutaneously implanted, viz. collagen, collagen 
+ pure elastin, collagen + microﬁ bril-containing elastin, and collagen + pulverised 
elastic ligament (the source for elastin). Explants were evaluated at day 3, 7 and 21. 
In young Sprague Dawley rats, collagen + ligament calciﬁ ed substantially, whereas 
collagen + elastin (with and without microﬁ brils) calciﬁ ed less, and collagen did not. 
Calciﬁ cation started at elastic ﬁ bres. In both Sprague Dawley and Wistar adult rats, 
however, none of the scaffolds calciﬁ ed. Mononuclear cell inﬁ ltration was prominent 
in young and adult Sprague Dawley rats. In adult Wistar rats, this inﬁ ltration was 
associated with the presence of microﬁ brils.
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INTRODUCTION
Tissue engineering involves the development of innovative biomaterials to replace 
or repair damaged and defective tissue. Type I collagen and elastin are structural 
extracellular matrix proteins that are abundantly present in human tissues and form 
natural scaffolds in the body. Collagen provides tensile strength and is widely used 
as a biomaterial, e.g. in skin substitutes, vascular grafts, scaffolds for cartilage repair, 
and bone implants [1-3]. Elastin provides elasticity to tissues. This, together with its 
stability due to speciﬁ c interchain crosslinks, makes elastin a desirable protein for tissue 
engineering [4]. Recently, it has been demonstrated that elastin is capable to regulate 
proliferation, migration and differentiation of vascular smooth muscle cells, and that 
it reduces the vascular proliferative response to arterial injury in vivo [5]. This makes 
the application of elastin in tissue engineering even more signiﬁ cant. However, unlike 
type I collagen, elastin has found little use as a biomaterial [6-8]. One reason is that 
elastin preparations have a strong tendency to calcify upon implantation [9]. Another 
is that puriﬁ cation of elastin is complex [10]. Calciﬁ cation may be due to microﬁ brillar 
components within the elastic ﬁ bre that are difﬁ cult to remove. A major component 
in this respect is ﬁ brillin, which binds calcium due to its many calcium-binding EGF 
domains [11]. In dystrophic calcinosis cutis, mineralisation of the elastic ﬁ bre has 
been shown to start at microﬁ brils present within and surrounding the elastic ﬁ bre 
[12]. In general, calciﬁ cation is a major, not well-understood problem in biomaterial 
application. Especially cardiovascular prosthetic implants such as bioprosthetic heart 
valves, aortic homografts and trileaﬂ et polymeric valve prostheses are prone to calcify. 
Crosslinked cellular debris, collagen and elastin have been suggested as the onsets for 
calciﬁ cation [13-15].
We previously described the preparation and biochemical, biomechanical, 
immunohistochemical and in vitro evaluation of collagen-elastin-glycosaminoglycan 
scaffolds [16]. In this study, we investigated whether puriﬁ cation of elastin, i.e. removal 
of microﬁ brils, can (partially) prevent calciﬁ cation and may inﬂ uence the tissue 
response such as cellular events and matrix remodelling. For this reason, we prepared 
four different scaffolds using puriﬁ ed collagen, puriﬁ ed elastin, partly puriﬁ ed elastin 
(i.e. with microﬁ brils) and elastic ligament (the source for elastin), and implanted 
these subcutaneously in rats. Different rat models were used to monitor variations 
between rat strain and age on the outcome of the experiment.
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MATERIALS & METHODS
Materials
Four different biomaterials were prepared: 1) puriﬁ ed type I collagen, 2) puriﬁ ed 
insoluble elastin, 3) partly puriﬁ ed insoluble elastin, still containing microﬁ brils 
and some collagen, and 4) pulverised ligamentum nuchae, the source for elastin. 
Insoluble type I collagen was puriﬁ ed from bovine achilles tendon using diluted 
acetic acid, NaCl, urea, and acetone extractions as described [17]. Insoluble elastin 
was isolated from equine ligamentum nuchae using extractions with NaCl, organic 
solvents, CNBr in formic acid, urea with diluted 2-mercaptoethanol, and digestion with 
trypsin, essentially as described, but with omission of the collagenase digestion [10]. 
Microﬁ bril-containing insoluble elastin was prepared using only one NaCl extraction, 
organic solvents extractions and CNBr in formic acid treatment. Pulverised equine 
ligamentum nuchae was prepared using a Fritsch Pulverisette 19 with a 1 mm sieve 
(Idar-Oberstein, Germany).
Mouse anti-bovine elastin IgG (clone BA-4) was purchased from Sigma Chemical Co. (St 
Louis, MO, USA). Rabbit anti-bovine type I collagen, rabbit anti-rat type I collagen, and 
rabbit anti-rat type III collagen IgGs were from Chemicon (Temecula, CA, USA). Goat 
anti-human type IV collagen IgG was from Southern Biotechnology Inc. (Birmingham, 
AL, USA). Alexa 488-labelled goat anti-mouse IgG, goat anti-rabbit IgG, and donkey 
anti-goat IgG were from Molecular Probes Europe (Leiden, The Netherlands).
Preparation of scaffolds
Four different scaffolds were prepared composed of puriﬁ ed collagen (COL), puriﬁ ed 
collagen + puriﬁ ed elastin in a 1:1 ratio (COL-EL), puriﬁ ed collagen + microﬁ bril-
containing elastin in a 1:1 ratio (COL-mfEL), and puriﬁ ed collagen + pulverised elastic 
ligament in a 1:1 ratio (COL-Ligament). Collagen was incorporated into all scaffolds, 
because we were unable to prepare coherent scaffolds of elastin only. Scaffolds were 
prepared by lyophilising an acidic 1% suspension of the various preparations. All 
scaffolds were chemically crosslinked for 4 h with 33 mM 1-ethyl-3-(3-dimethyl 
aminopropyl)carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) in 50 mM 2-
morpholinoethane sulfonic acid (MES) (pH 5.5) in the presence of 40% (v/v) ethanol. 
After reaction, the scaffolds were washed in 0.1 M Na2HPO4 (pH 9.1), 1 M NaCl, 2 M 
NaCl, and demineralised water [16,17].
Characterisation of elastin-containing preparations and scaffolds
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE): Puriﬁ ed 
elastin, microﬁ bril-containing elastin, and pulverised ligamentum nuchae preparations 
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were incubated at 95°C for 10 min under reducing conditions (5% (v/v) 2-mercaptoethanol) 
and analysed on a 10% (w/v) gel. Non-elastin components will penetrate the gel and are 
visualised by a Coomassie Brilliant Blue solution (0.1% (w/v)) [18].
Transmission electron microscopy (TEM): TEM was used to analyse the presence/
absence of microﬁ brils and other (extra)cellular components. Puriﬁ ed elastin, 
microﬁ bril-containing elastin, and pulverised ligamentum nuchae preparations were 
embedded in 1.5% (w/v) agarose, ﬁ xed in 2% (v/v) glutaraldehyde in 0.1 M phosphate 
buffer (pH 7.4) for 12 h at 4 °C, and post ﬁ xed with 1% (w/v) osmium tetroxide in 0.1 
M phosphate buffer (pH 7.4) for 1 h. After a rinsing period of 3 h with 0.1 M phosphate 
buffer (pH 7.4), the samples were dehydrated in an ascending series of ethanols and 
embedded in Epon 812. Ultrathin sections (60 nm) were picked up on formvar-coated 
grids, post stained with lead citrate and uranyl acetate, and examined in a JEOL 1010 
electron microscope. 
Scanning electron microscopy (SEM): SEM was used to analyse the morphology of 
the scaffolds. Scaffolds were mounted on stubs and sputtered with an ultrathin layer 
of gold in a Polaron E5100 SEM coating system. Specimens were studied with a JEOL 
JSM-6310 SEM apparatus with an accelerating voltage of 15 kV.
Amine group content: The amine group content of scaffolds was determined 
spectrophotometrically after reaction with 2,4,6-trinitrobenzene sulfonic acid [19].
Implantation of scaffolds
NIH guidelines for the care and use of laboratory animals (NIH publication 85-23 
Rev. 1985) were observed. The study was approved by the Ethical Committee of the 
University of Nijmegen. Sprague-Dawley rats (male, 21 days old and 3 months old) and 
Wistar rats (male, 3 months old) were purchased from Harlan (Zeist, The Netherlands). 
Young rats were housed per 3, and adult rats per 2. The animals were fed pelleted diet 
(RMH-B 10 mm) and water ad libitum.
Scaffolds were washed in 70% (v/v) ethanol (4 x 30 min) and sterile phosphate 
buffered saline (PBS) (pH 7.2) (8 x 30 min) at 22°C. Rats were anaesthetised with 
halothane. After disinfection, subcutaneous pockets were made to the right and left of 
two midline incisions on the back. Punches (ø 6 mm) of the scaffolds were implanted 
in the pockets at a distance of about 1 cm from the incisions (4 implants/rat). For each 
implantation time, two rats received two punches of the same scaffold on one side of 
the midline incision. Implants with surrounding tissue were harvested from Sprague 
Dawley rats at 3, 7 and 21 days after implantation, from Wistar rats at 21 days only.
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Processing of explants
Immediately after explantation, scaffolds were divided in two halves. One 
half was processed for conventional light microscopy, the other half for 
immunohistochemistry.
Conventional histology: Scaffolds and surrounding tissue were ﬁ xed in 4% (v/v) 
formaldehyde in phosphate buffer (pH 7.2) immediately after explantation for at least 
24 h at 4 °C, and embedded in parafﬁ n. Consecutive sections of 5 µm were mounted 
onto glass slides, dewaxed in xylol and hydrated through a graded series of ethanol. 
Sections were routinely haematoxylin-eosin stained. Elastin and collagen were stained 
according to Elastin Van Gieson (EVG), and calcium deposits were visualised by 
Von Kossa staining [20]. Sections of the explants were semi-quantitatively scored 
independently by at least two experienced investigators.
Immunohistochemistry: Immunoﬂ uorescence microscopy was used to study the 
biodegradation of scaffold collagen and elastin, and the formation of new collagens 
by the host. Scaffolds were frozen in liquid nitrogen. Cryosections were mounted 
onto glass slides. After blocking with 1% (w/v) bovine serum albumin (BSA) in PBS, 
sections were incubated with mouse anti-bovine elastin (1:1000), rabbit anti-bovine 
type I collagen, rabbit anti-rat type I collagen, rabbit anti-rat type III collagen (all 
1:100), or goat anti-human type IV collagen (1:50) for 90 min, washed with PBS, 
followed by a 1 h incubation with Alexa 488-labelled secondary antibodies (1:100). All 
antibodies were diluted in PBS containing 1% (w/v) BSA. Sections were washed and 
mounted in mowiol. The antibody to bovine elastin also reacts with equine elastin; the 
antibody to human type IV collagen cross-reacts with rat type IV collagen; the antibody 
to bovine type I collagen does not substantially cross-react with rat type I collagen or 
vice versa.
RESULTS
Characteristics of elastin preparations
Elastin preparations were studied using SDS-PAGE and TEM (Fig. 1). SDS-PAGE of the 
elastin preparations indicated no contamination with other proteins in puriﬁ ed elastin, 
whereas microﬁ bril-containing elastin and pulverised elastic ligament contained a 
large number of additional proteins. TEM indicated that the puriﬁ ed elastin ﬁ bres were 
free of microﬁ brils and no other structural elements could be detected. In microﬁ bril-
containing elastin, microﬁ brils could be easily observed as well as some residual 
collagen ﬁ brils, but without any other contaminations. Pulverised elastic ligament 
contained all tissue elements, including damaged cells.
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Characteristics of scaffolds
The 3D morphology of the scaffolds was analysed with SEM (Fig. 2). Collagen was 
present as ﬁ ne ﬁ brillar and sheet-like structures, whereas elastin was observed as thick 
ﬁ bres. Pulverised ligament showed bundles of elastic ﬁ bres, since the collagenous 
meshwork between individual elastic ﬁ bres was not removed. The amine group content 
was measured to investigate the extent of EDC/NHS crosslinking. In all scaffolds, 35-
40% of amine groups were used in crosslinking. Collagen possesses a larger amount 
of amine groups than elastin, which explains the absolute values for the different 
preparations (Table 1).
Figure 1. (A) SDS-PAGE gel of highly puriﬁ ed elastin (EL; 0.5 mg), microﬁ bril-containing elastin (mfEL; 
0.5 mg) and pulverised ligament (0.1 mg). Only soluble contaminants and/or elastin breakdown products 
will enter the gel; insoluble elastin, which represents the vast majority of the preparations, does not. (B-D) 
Transmission electron micrographs of highly-puriﬁ ed elastin (B), partly-puriﬁ ed microﬁ bril-containing elastin 
(C), and pulverised elastic ligament (D). C= collagen; E= elastin; N= nucleus of ﬁ broblast; arrows indicate 
microﬁ brils. Bar is 0.5 µm.
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Figure 2. Scanning electron micrographs of the crosslinked scaffolds. (A) COL, (B) COL-EL, (C), COL-mfEL, 
and (D) COL-Ligament. Collagen is present as thin ﬁ brils and sheets, elastin as thick ﬁ bres. Arrows indicate 
elastic ﬁ bres. Bar is 10 µm.
Table 1. Amine group content of various scaffolds.
.
COL= scaffold composed of collagen only; COL-EL= scaffold composed of equal amounts of collagen 
and highly puriﬁ ed elastin; COL-mfEL= scaffold composed of equal amounts of collagen and microﬁ bril-
containing elastin; COL-Ligament= scaffold composed of equal amounts of collagen and pulverised 
ligamentum nuchae. Results are mean ± SD of three individual experiments.
95
Calciﬁ cation of scaffolds
All animals remained in good condition and no infectious problems occurred. 
Macroscopically, a thin capsule was observed around the scaffolds at explantation. In 
Table 2 an overview of calciﬁ cation behaviour and cellular response is given.
Young Sprague Dawley rats
COL did not calcify in young Sprague Dawley rats except one out of 4 at day 21 as 
was assessed by Von Kossa staining. At day 3, some calciﬁ cation could be observed 
in COL-Ligament where it was present within the elastic ﬁ bres. Calciﬁ cation did not 
seem to be dependent on local cell inﬁ ltration, since calciﬁ cation developed in cell-
free as well as cell-dense areas. All other scaffolds showed no calciﬁ cation at this time 
point. At day 7, all of the composite scaffolds (COL-EL, COL-mfEL, COL-Ligament) 
showed calciﬁ cation to some extent. COL-Ligament showed intensive calciﬁ cation at 
elastic ﬁ bres only. At day 21, calciﬁ cation of COL-EL, COL-mfEL, and COL-Ligament 
had increased (Fig. 3). COL-EL and COL-mfEL calciﬁ ed to about the same extent. In 
COL-Ligament, calciﬁ cation had extended to collagen.
Adult Sprague Dawley rats
Adult Wistar rats
All scaffolds implanted in adult rats did not show any calciﬁ cation up to day 21.
Figure 3. Light microscopical evaluation of the calciﬁ cation of scaffolds, 21 days after implantation 
in young Sprague Dawley rats. (A) COL, (B) COL-EL, (C), COL-mfEL, and (D) COL-Ligament. Calcium 
deposits have an intense black colour due to Von Kossa staining. Arrows indicate elastic ﬁ bres. Bar is 50 µm.
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Table 2. General overview of calciﬁ cation and cellular events after subcutaneous implantation of the scaffolds 
in rats.
* Absolute numbers of phagocytic cells were higher than of PMNs or non-phagocytic cells, e.g.+ for 
phagocytic cells refers to more cells than + for PMNs or non-phagocytic cells. ** Blood vessels were 
assessed by immunostaining for rat type IV collagen, present in vascular basement membranes. *** 1 out of 
4 implanted collagen scaffolds showed moderate calciﬁ cation at this time point.
PMNs= polymorphic nuclear cells, i.e. granulocytes;  phagocytic cells include monocyte-derived macrophages 
and monocytes; non-phagocytic cells include lymphocytes, plasma cells and mast cells. Events were scored 
ranging from sporadic (sp) to severe (++). -: not present.
Tissue response to scaffolds
Fig. 4 and Fig. 5 show some representative examples of the tissue response to scaffolds 
in young and adult Sprague Dawley rats and adult Wistar rats at different time points 
(see Table 2).
Young Sprague Dawley rats
At day 3, several macrophages and some polymorphic nuclear granulocytes (PMNs) 
were present, mostly at the periphery of the scaffolds. More PMNs were present near 
elastic ﬁ bres than near collagen, especially in COL-Ligament and COL-mfEL. At day 
7, a ﬁ brous capsule was observed around the scaffolds. Some capillaries were located 
in the capsule and at the periphery of the scaffolds. At this time, PMNs were only 
sporadically present, while early events of mononuclear cell inﬁ ltrations were found. 
Mononuclear cells include phagocytic cells like active monocyte-derived macrophages, 
monocytes as well as non-phagocytic cells such as lymphocytes, plasma cells and 
mast cells. Foreign body giant cells (fused macrophages with multiple nuclei) were 
encountered in variable amount. At day 21, capillaries were present in between the 
ﬁ bres of the scaffolds. Phagocytic cells dominated the scaffolds, while the amount of 
non-phagocytic cells increased at the periphery, especially near COL-Ligament and 
COL-mfEL (Fig. 4).
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Figure 4. Light microscopical overview of the cellular response to scaffolds at day 21 in young Sprague 
Dawley rats. (A) COL, (B) COL-EL, (C), COL-mfEL, and (D) COL-Ligament. Note the increased amount of 
mononuclear cell inﬁ ltration, especially in COL-Ligament scaffolds. Sections were HE stained. C= capsule; 
G= giant cell; arrows indicate elastic ﬁ bres. Bar is 50 µm.
Adult Sprague Dawley rats
At day 3, all implants were encapsulated with a ﬁ brous capsule. Some PMNs had 
inﬁ ltrated mainly COL-mfEL and COL-Ligament (Fig. 5A, B), while some phagocytic 
cells inﬁ ltrated COL and COL-EL. At day 7, PMNs were only sporadically found. Increased 
ﬁ brous encapsulation was commonly present with capillaries both intracapsularly and 
at the periphery of the scaffolds. Phagocytic cells accumulated both at the periphery 
and to less extent in the scaffold. Most of these cells were present in COL-Ligament, 
less in COL-mfEL and COL-EL, and only at the periphery of COL. (Fig. 5C, D). At day 
21, capillaries were found throughout COL-Ligament, COL-mfEL and COL-EL and these 
scaffolds were almost completely inﬁ ltrated with phagocytic cells, but to less extent 
in COL.
Adult Wistar rats
Scaffolds from adult Wistar rats were only explanted at day 21 (Fig. 5E, F). At this 
time, a ﬁ brous capsule was formed around all scaffolds. In general, the tissue response 
of adult Wistar rats to implanted scaffolds was distinctly milder compared to Sprague 
Dawley rats. Few cells had inﬁ ltrated the scaffolds. COL and COL-EL showed few 
mononuclear and giant cells at the periphery. In COL-mfEL and COL-Ligament, these 
cells had inﬁ ltrated deeper into the scaffolds.
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Figure 5. Light microscopical evaluation of the cellular response to scaffolds implanted in adult Sprague 
Dawley rats (A-D) and adult Wistar rats (E-F). (A) COL-EL and (B) COL-mfEL 3 days after implantation. 
Note that more PMN’s (neutrophiles) are present in COL-mfEL than in COL-EL. (C) COL-EL and (D) COL 7 
days after implantation. In COL, an increase of mononuclear cells, especially non-phagocytic cells, was found 
at the periphery of the scaffold. (E) COL-EL and (F) COL-mfEL 21 days after implantation. In COL-mfEL, 
locally an increase of mononuclear cells was found. Sections were HE stained. C= capsule; G= giant cell; 
arrow heads indicate neutrophiles; arrows indicate elastic ﬁ bres. Bar is 50 µm.
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Vascularisation of the scaffolds
Young Sprague Dawley rats
Few small blood vessels, visualised by immunostaining for type IV collagen present 
in endothelial basement membranes, were found at day 7 at the periphery of the 
scaffolds. At day 21, some blood vessels were found at the periphery of COL, while 
other scaffolds showed more vascularisation at that time, both at the periphery and 
within the scaffolds.
Adult Sprague Dawley rats
Vascularisation increased over time. In general, COL-EL, COL-mfEL and COL-Ligament 
contained more blood vessels than COL. At day 7, vascularisation of COL-EL, COL-mfEL 
and COL-Ligament was mainly in the capsule and at the periphery of the scaffolds; at 
day 21 it was also within the scaffold (Fig 6A, B).
Adult Wistar rats
Few blood vessels were only found at the periphery of COL-mfEL and COL-Ligament.
Figure 6. Immunostaining of COL-EL scaffolds for type IV and type III collagen as indicators of vascularisation 
and matrix production after subcutaneous implantation in adult Sprague Dawley rats. (A) COL-EL after 7 and 
(B) after 21 days immunostained for type IV collagen. At day 7, type IV collagen staining is mainly present at 
the periphery, at day 21 in the whole scaffold. (C) COL-EL after 7 days and (D) after 21 days immunostained 
for type III collagen. At day 7, type III collagen staining is mainly present at the scaffold periphery, at day 21 
it is found throughout the scaffold. C= capsule; S= scaffold. Bar is 50 µm.
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Scaffold degradation and matrix synthesis
Table 3 gives an overview of the immunoﬂ uorescence staining for scaffold components 
and for newly formed extracellular matrix molecules at different time points.
Table 3. Overview of immunostaining results of explants for scaffold and rat extracellular matrix 
components.
Events were scored ranging from sporadic (sp) to abundant (++). -: not present.
Scaffold degradation
Young Sprague Dawley rats
Conventional histology showed small amounts of degraded collagen which were locally 
visible from day 7 on at the periphery. At day 21, degraded collagen was also found 
deeper within the scaffolds, but especially centrally a large amount of intact scaffold 
collagen remained present. Immunostaining for bovine type I collagen supported 
these ﬁ ndings. At day 21, the presence of thin and fragmented collagen structures 
were most profound at the scaffold periphery. Locally, fragmented elastin in COL-EL, 
COL-mfEL and COL-Ligament was found from day 7 on. At day 21, the total amount 
of elastic ﬁ bres was decreased and more fragmented elastic ﬁ bres were observed, 
suggesting resorption and degradation of the ﬁ bres. Both calciﬁ ed elastin/elastic ﬁ bres 
and non-calciﬁ ed elastin/elastic ﬁ bres were found within macrophages and giant cells. 
Immunoﬂ uorescence results showed that staining for elastin gave the best signal for 
COL-EL, most likely due to unmasking of the epitope during puriﬁ cation. Calciﬁ ed 
elastin could also be visualised with the antibody. Fragments of elastin (smaller than 
elastic ﬁ bres) were found in all elastin-containing scaffolds at day 21.
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Adult Sprague Dawley rats
Degraded collagen was visible at the periphery at day 7. Fragmented elastin (both EL 
and mfEL) was visible locally from day 7 on. Especially in COL-Ligament scaffolds, 
severely fragmented elastic ﬁ bres were present at day 21, suggesting fastest degradation 
of these scaffolds.
Adult Wistar rats
At day 21, a large amount of scaffold collagen and elastin was still present in adult 
Wistar rats, implying the lowest degradation rate of scaffolds in all rat models used. 
Only locally, degraded collagen ﬁ brils and elastic ﬁ bres were observed at the periphery 
for all scaffolds.
Matrix synthesis
Young Sprague Dawley rats
Newly formed rat type I collagen was generally found in the ﬁ brous capsule surrounding 
the implant and aligning with the collagen ﬁ brils in the scaffold. At day 21, young 
Sprague Dawley rats showed more staining for type I collagen in elastin-containing 
scaffolds than in collagen scaffolds.
From day 7 on, type III collagen could be clearly observed in the ﬁ brous capsule and at 
the periphery of the scaffolds. At day 21, type III collagen was present throughout the 
scaffolds, aligning with the collagenous and elastinous scaffold components. Staining 
for type III collagen in COL was less intense than in the other scaffolds.
Adult Sprague Dawley rats
In adult Sprague Dawley rats, staining for rat type I and III collagen was similar to 
staining in young Sprague Dawley rats. Whereas at day 7 type III collagen was mainly 
present in the capsule and the outer part of the scaffolds, at day 21 it was found 
throughout the scaffold (Fig. 6C, D).
Adult Wistar rats
At day 21, minor amounts of new matrix collagens were observed in scaffolds implanted 
in adult Wistar rats. Type I collagen was sporadically found in all scaffolds, more type 
III collagen was found in COL-mfEL and COL-Ligament scaffolds than in COL and 
COL-EL.
DISCUSSION
Tissue response to new biomaterials has to be evaluated before their use in tissue 
engineering for clinical purpose. Here, we studied the tissue response and calciﬁ cation 
of subcutaneous implanted porous biomaterials composed of either collagen only 
(COL), collagen + highly-puriﬁ ed insoluble elastin in a 1:1 ratio (COL-EL), collagen 
+ microﬁ bril-containing (i.e. partly puriﬁ ed) elastin in a 1:1 ratio (COL-mfEL), and 
collagen + pulverised ligament in a 1:1 ratio (COL-Ligament). Young and adult Sprague 
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Dawley rats and adult Wistar rats were used as animal models.
The juvenile rat is widely accepted as a sensitive model to evaluate calciﬁ cation 
[9,13,21,22]. In our experiment, calciﬁ cation only occurred when elastin-containing 
scaffolds were implanted in young Sprague Dawley rats (3 weeks old at implantation), 
but no calciﬁ cation was found when scaffolds were implanted in adult Sprague Dawley 
or Wistar rats (3 months old). Calciﬁ cation of implanted biomaterials depends on 
many variables. One of them is the animal’s age. Nimni et al. already found that after 
two weeks skin collagen subcutaneously implanted in young Long Evans rats (one 
month old) calciﬁ ed much more than in older ones (8 months old) [23]. Another 
parameter for calciﬁ cation may be the purity of the material. In our experiment, 
collagen scaffolds did not give rise to calciﬁ cation in young rats (only 1 out of 12 
showed calciﬁ cation). Using a puriﬁ ed acellular intestinal collagen layer, Abraham 
et al. did not ﬁ nd calciﬁ cation either [24]. With less-deﬁ ned collagen preparations, 
calcium deposits are formed indicating that contaminants may trigger calciﬁ cation 
[14,23,25]. This partially applies to elastin as well. Calciﬁ cation started within the 
elastic ﬁ bre [15]. Calciﬁ cation was seen from day 3 for COL-Ligament scaffolds, and 
from day 7 for COL-mfEL and COL-EL scaffolds. Although absence of microﬁ brils from 
the elastic ﬁ bre did not result in a decrease of calciﬁ cation, calciﬁ cation was more 
severe if an impure preparation (i.e. pulverised ligament) was used. Our hypothesis 
that calciﬁ cation may be partly due to the presence of microﬁ brils within the elastic 
ﬁ bre could be rejected in this study. Another calciﬁ cation variable might be imputed 
to the intactness of the elastic ﬁ bre. Bailey et al. recently found that fragmented and 
damaged aortic elastic ﬁ bres are associated with more severe calciﬁ cation than intact 
ones [26]. Our puriﬁ ed elastic ﬁ bres are still intact, though. Calciﬁ cation may be 
genetically controlled by molecules that actively inhibit calciﬁ cation and may occur 
passively when these inhibitors are absent [27]. Other possible solutions to prevent 
calciﬁ cation are aluminium chloride treatment [9], ethanol/EDTA treatment [28], and 
attachment of glycosaminoglycans [29,30].
This study underlines that young Sprague Dawley rats are a sensitive model to study 
calciﬁ cation. Apart from that, an accompanying strong tissue response was characteristic 
for these rats. Major cellular inﬁ ltrations were found in COL-EL, COL-mfEL and 
COL-Ligament scaffolds at day 21. Van Wachem et al. observed huge inﬁ ltration of 
lymphocytes, including numerous plasma cells, after subcutaneous implantation of 
porcine heart valve cusps and walls into young Sprague Dawley rats [31]. However, 
in our scaffolds, we found substantially less mononuclear cells in both young and 
adult Sprague Dawley rats. Adult Wistar rats showed an even milder tissue response 
to the implanted scaffolds. Elastin without microﬁ brils resulted in less inﬁ ltration of 
mononuclear cells compared to microﬁ bril-containing elastin. For tissue engineering 
purposes, ﬁ bres of highly puriﬁ ed elastin are thus preferred to microﬁ bril-containing 
elastic ﬁ bres.
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Scaffolds showed to be biodegradable by all hosts, as expected, but none of the scaffolds 
was fully resorbed at day 21. Degradation was associated with phagocytic cells, and 
calciﬁ ed elastic ﬁ bres were found in macrophages and to a certain extent in giant 
cells. More degradation was found in Sprague Dawley rats, which was underlined by 
the higher numbers of phagocytic cells in these scaffolds. Minor collagen degradation 
of crosslinked collagen scaffolds took place in Wistar rats, which was comparable 
with results described by Pieper et al. [32]. In this rat strain, elastin was only locally 
degraded. Collagen-elastin scaffolds may thus function as a temporary elastic matrix 
here [16].
Type I and type III collagens were made by all hosts. Generally, with a more extensive 
tissue response, new matrix formation and vascularisation occurred both earlier 
in time and to a larger extent. This means that in both young and adult Sprague 
Dawley rats more new matrix components were produced than in Wistar rats. In most 
cases, the presence of elastin in the scaffold was associated with a higher degree of 
vascularisation.
Elastin-containing scaffolds did not calcify in adult rats. In young rats, however, 
calciﬁ cation of scaffolds containing elastin or elastic ﬁ bres was observed and removal of 
microﬁ brils from the elastic ﬁ bre did not prevent or reduce this. Absence of microﬁ brils 
reduced the tissue response in adult Wistar rats. Tissue response to and calciﬁ cation of 
scaffolds differed with age, strain and purity of the materials and therefore the choice 
of animal model is of key importance when evaluating biomaterials for their capacity 
to function as a temporary matrix for tissue engineering and matrix remodelling.
REFERENCES
 1. Kim BS, Baez CE, Atala A. Biomaterials for tissue engineering. World J Urol 2000;18:2-9.
 2. Van Susante JLC, Pieper J, Buma P, Van Kuppevelt TH, Van Beuningen H, Van Der Kraan PM, 
Veerkamp JH, Van Den Berg WB, Veth RPH. Linkage of chondroitin-sulfate to type I collagen scaffolds 
stimulates the bioactivity of seeded chondrocytes in vitro. Biomaterials 2001;22:2359-2369.
 3. Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharm 2001;221:1-22.
 4. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic ﬁ bres. J Cell Sci 2002;115:2817-2828.
 5. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating MT, Li DY. A 
critical role for elastin signaling in vascular morphogenesis and disease. Development 2003;130:411-
423.
 6. Samouillan V, Dandurand-Lods J, Lamure A, Maurel E, Lacabanne C, Gerosa G, Venturini A, 
Casarotto D, Gherardini L, Spina M. Thermal analysis characterization of aortic tissues for cardiac 
valve bioprostheses. J Biomed Mater Res 1999;46:531-538.
 7. Lamme EN, De Vries JC, Van Veen H, Gabbiani G, Westerhof W, Middelkoop E. Extracellular matrix 
characterization during healing of full-thickness wounds treated with a collagen/elastin dermal 
substitute shows improved skin regeneration in pigs. J Histochem Cytochem 1996;44:1311-1322.
 8. Rabaud M, Elie JY, Lefebvre F, Ducassou D, Mettetal P, Le Guillou M, Collet D, Perissat J, Fradin 
D, Fontan F. A new biodegradable elastin-ﬁ brin material; its use in urological, digestive and 
cardiovascular surgery. J Biomater Appl 1992;7:20-46.
 9. Vyavahare N, Ogle M, Schoen FJ, Levy RJ. Elastin calciﬁ cation and its prevention with aluminum 
chloride pretreatment. Am J Pathol 1999;155:973-982.
 10. Daamen WF, Hafmans T, Veerkamp JH, Van Kuppevelt TH. Comparison of ﬁ ve procedures for the 
puriﬁ cation of insoluble elastin. Biomaterials 2001;22:1997-2005.
 11. Handford PA. Fibrillin-1, a calcium binding protein of extracellular matrix. Biochim Biophys Acta 
2000;1498:84-90.
 12. Fartasch M, Haneke E, Hornstein OP. Mineralization of collagen and elastic ﬁ bers in superﬁ cial 
dystrophic cutaneous calciﬁ cation: an ultrastructural study. Dermatologica 1990;181:187-192.
104
ch
ap
te
r 
5
ti
ss
ue
 r
es
po
ns
e 
to
 d
eﬁ
 n
ed
 c
ol
la
ge
n-
el
as
ti
n 
sc
af
fo
ld
s
 13. Paule WJ, Bernick S, Strates B, Nimni ME. Calciﬁ cation of implanted vascular tissues associated with 
elastin in an experimental animal model. J Biomed Mater Res 1992;26:1169-1177.
 14. Nimni ME, Myers D, Ertl D, Han B. Factors which affect the calciﬁ cation of tissue-derived 
bioprostheses. J Biomed Mater Res 1997;35:531-537.
 15. Schoen FJ, Levy RJ. Tissue heart valves: current challenges and future research perspectives. J 
Biomed Mater Res 1999;47:439-465.
 16. Daamen WF, Van Moerkerk HThB, Hafmans T, Buttafoco L, Poot AA, Veerkamp JH, Van Kuppevelt 
TH. Preparation and evaluation of molecularly-deﬁ ned collagen–elastin-glycosaminoglycan scaffolds 
for tissue engineering. Biomaterials 2003;24:4001-4009.
 17. Pieper JS, Oosterhof A, Dijkstra PJ, Veerkamp JH, Van Kuppevelt TH. Preparation and characterization 
of porous crosslinked collagenous matrices containing bioavailable chondroitin sulphate. Biomaterials 
1999;20:847-858.
 18. Daamen WF, Hafmans T, Veerkamp JH, Van Kuppevelt TH. Comparison of ﬁ ve procedures for the 
puriﬁ cation of insoluble elastin. Biomaterials 2001;22:1997-2005.
 19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature 1970;227:680-689.
 20. Olde Damink LH, Dijkstra PJ, Van Luyn MJ, Van Wachem PB, Nieuwenhuis P, Feijen J. Cross-linking 
of dermal sheep collagen using a water-soluble carbodiimide. Biomaterials 1996;17:765-773.
 21. Bancroft JD, Stevens A. Theory and practice of histological techniques. Edinburgh (UK). Churchill 
Livingstone, 1990.
 22. Vyavahare N, Ogle M, Schoen FJ, Levy RJ. Elastin calciﬁ cation and its prevention with aluminum 
chloride pretreatment. Am J Pathol 1999;155:973-982.
 23. Paule WJ, Bernick S, Strates B, Nimni ME. Calciﬁ cation of implanted vascular tissues associated with 
elastin in an experimental animal model. J Biomed Mater Res 1992;26:1169-1177.
 24. Van Luyn MJ, Van Wachem PB, Dijkstra PJ, Olde Damink LH, Feijen J. Calciﬁ cation of subcutaneously 
implanted collagens in relation to cytotoxicity, cellular interactions and crosslinking. J Mat Sci 
1995;6:288-296.
 25. Chanda J, Kuribayashi R, Abe T. Heparin coupling in inhibition of calciﬁ cation of vascular 
bioprostheses. Biomaterials 1999;20:1753-1757.
 26. Nimni ME, Bernick S, Cheung DT, Ertl DC, Nishimoto SK, Paule WJ, Salka C, Strates BS. Biochemical 
differences between dystrophic calciﬁ cation of cross-linked collagen implants and mineralization 
during bone induction. Calcif Tissue Int 1988;42:313-320.
 27. Abraham GA, Murray J, Billiar K, Sullivan SJ. Evaluation of the porcine intestinal collagen layer as a 
biomaterial. J Biomed Mater Res 2000;51:442-452.
 28. Nimni ME, Myers D, Ertl D, Han B. Factors which affect the calciﬁ cation of tissue-derived 
bioprostheses. J Biomed Mater Res 1997;35:531-537.
 29. Nimni ME, Bernick S, Cheung DT, Ertl DC, Nishimoto SK, Paule WJ, Salka C, Strates BS. Biochemical 
differences between dystrophic calciﬁ cation of cross-linked collagen implants and mineralization 
during bone induction. Calcif Tissue Int 1988;42:313-320.
 30. Van Wachem PB, Van Luyn MJ, Olde Damink LH, Dijkstra PJ, Feijen J, Nieuwenhuis P. 
Biocompatibility and tissue regenerating capacity of crosslinked dermal sheep collagen. J Biomed 
Mater Res 1994;28:353-363.
 31. Schoen FJ, Levy RJ. Tissue heart valves: current challenges and future research perspectives. J 
Biomed Mater Res 1999;47:439-465.
 32. Bailey MT, Pillarisetti S, Xiao H, Vyavahare NR. Role of elastin in pathologic calciﬁ cation of xenograft 
heart valves. J Biomed Mater Res 2003;66A:93-102.
 33. Schinke T, McKee MD, Karsenty G. Extracellular matrix calciﬁ cation: where is the action? Nat Genet 
1999;21:150-151.
 34. Vyavahare N, Ogle M, Schoen FJ, Levy RJ. Elastin calciﬁ cation and its prevention with aluminum 
chloride pretreatment. Am J Pathol 1999;155:973-982.
 35. Singla A, Lee CH. Inhibition of CEM calciﬁ cation by the sequential pretreatment with ethanol and 
EDTA. J Biomed Mater Res 2003;64A:706-713.
 36. Andre-Frei V, Chevallay B, Orly I, Boudeulle M, Huc A, Herbage D. Acellular mineral deposition in 
collagen-based biomaterials incubated in cell culture media. Calcif Tissue Int 2000;66:204-211.
 37. Simionescu DT, Lovekamp JJ, Vyavahare NR. Glycosaminoglycan-degrading enzymes in porcine 
aortic heart valves: implications for bioprosthetic heart valve degeneration. J Heart Valve Dis 
2003;12:217-225.
 38. Van Wachem PB, Brouwer LA, Zeeman R, Dijkstra PJ, Feijen J, Hendriks M, Cahalan PT, Van Luyn 
MJ. In vivo behavior of epoxy-crosslinked porcine heart valve cusps and walls. J Biomed Mater Res 
2000;53:18-27.
 39. Pieper JS, Van Wachem PB, Van Luyn MJ, Brouwer LA, Hafmans T, Veerkamp JH, Van Kuppevelt TH. 
Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats. 
Biomaterials 2000;21:1689-1699.
Chapter6
A biomaterial composed of collagen and solubilised elastin 
enhances angiogenesis and elastic ﬁ bre formation 
without calciﬁ cation
     Willeke Daamen, 
     Suzan Nillesen,
     Ronnie Wismans,
     Dieter Reinhardt,
     Theo Hafmans, 
     Jacques Veerkamp, 
     Toin van Kuppevelt. 
106
ch
ap
te
r 
6
so
lu
bi
lis
ed
 e
la
st
in
 e
nh
an
ce
s 
an
gi
og
en
es
is
 a
nd
 e
la
st
ic
 ﬁ
 b
re
 f
or
m
at
io
n
ABSTRACT
Elastin is the prime protein in elastic tissues that contributes to elasticity of e.g. lung, 
aorta, and skin. Upon injury, elastic ﬁ bres are not readily replaced which hampers 
tissue regeneration. Incorporation of solubilised elastin (hydrolysed insoluble elastin 
ﬁ bres or elastin peptides) in biomaterials may improve regeneration, since solubilised 
elastin is able to promote proliferation as well as elastin synthesis.
Porous biomaterials composed of highly puriﬁ ed collagen and solubilised elastin were 
prepared by freezing and lyophilisation. Solubilised elastin formed spherical structures 
that were incorporated in the collagenous part of the scaffolds and that persisted 
after chemical crosslinking of the scaffolds. Crosslinked collagen-solubilised elastin 
scaffolds were subcutaneously implanted in young Sprague Dawley rats where they 
formed a depot for solubilised elastin. The scaffolds showed no calciﬁ cation in this 
sensitive calciﬁ cation model, in contrast to scaffolds containing elastin ﬁ bres. Scaffolds 
also induced angiogenesis, as was revealed by type IV collagen staining, and promoted 
elastic ﬁ bre synthesis, as was shown with antibodies against rat elastin and ﬁ brillin-1.
It is concluded that scaffolds produced from collagen and solubilised elastin present 
a non-calcifying biomaterial with a capacity for soft tissue regeneration, especially in 
relation to elastic ﬁ bre synthesis.
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INTRODUCTION
Elastin is the major insoluble protein present in elastic tissue contributing to the 
elasticity of lung, aorta, ligaments and skin. Elastic ﬁ bres are not readily replaced upon 
injury, probably due to difﬁ culties in recapitulating normal developmental expression 
patterns of tropoelastin and associated molecules [1,2]. This seriously hampers tissue 
regeneration.
Solubilised elastin (obtained by hydrolysing insoluble elastin) may markedly improve 
tissue regeneration, since it exhibits multiple biological effects. These include enhanced 
cell migration [3], cell proliferation [4] and elastin synthesis [5,6]. Solubilised elastin 
interacts with the elastin-laminin receptor which is composed of three subunits; two 
transmembrane subunits of 61 and 55 kDa and one extracellular subunit of 67 kDa, the 
latter binding tropoelastin and other elastin-like molecules. The receptor is present on 
a large number of cells, including ﬁ broblasts, vascular smooth muscle cells, endothelial 
cells, chondrocytes, monocytes, lymphocytes and polymorphonuclear leukocytes and 
its signal transduction pathway is mediated through a pertussis toxin sensitive G-
protein [7-10]. In addition to the elastin-laminin receptor, other receptors may play a 
role as well, e.g. integrins [11]. Biomaterials containing solubilised elastin may thus 
exert biological effects on a wide variety of cell types.
We have previously prepared biomaterials composed of highly puriﬁ ed type I collagen 
and elastin ﬁ bres and studied their tissue reaction [12,13]. In young Sprague Dawley 
rats (but not in adult rats), implantation of these scaffolds resulted in calciﬁ cation 
of elastin ﬁ bres. Although initiation of tissue calciﬁ cation does not require a cellular 
response [14], the in vivo milieu can accelerate the process [15], e.g. through the 
extracellular release of enzymes by macrophages and giant cells involved in elastin 
degradation [16-18].
In this study, we prepared porous scaffolds containing solubilised elastin. Solubilised 
elastin may improve synthesis of elastin through interaction with the elastin-laminin 
receptor [5]. Furthermore, if enzymes involved in elastin degradation indeed play a role 
in increasing calciﬁ cation, application of solubilised elastin may reduce the presence 
of macrophages and giant cells and thus reduce calciﬁ cation. In addition, solubilised 
elastin is less hydrophobic and additionally charged compared to insoluble elastin. 
Negative charges from C-terminal carboxylic groups may prevent positively charged 
calcium ions from precipitating in the same way as negatively charged sulfate groups 
have been shown to suppress calcium-binding to e.g. polyurethane [19]. In this study, 
we prepared and characterised collagen-solubilised elastin scaffolds and studied their 
in vivo behaviour with respect to calciﬁ cation, angiogenesis and elastin synthesis.
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MATERIALS & METHODS
Materials
Mouse anti-bovine elastin IgG clone BA-4 was purchased from Sigma Chemical Co. (St 
Louis, MO, USA); goat anti-rat alpha-elastin from Elastin Products Co. (Owensville, 
MO, USA); rabbit anti-bovine type I collagen, rabbit anti-rat type I collagen, and rabbit 
anti-rat type III collagen IgGs from Chemicon (Temecula, CA, USA); goat anti-human 
type IV collagen IgG from Southern Biotechnology Inc. (Birmingham, AL, USA). Rabbit 
anti-human ﬁ brillin-1 (pAb-rF6H) and rabbit anti-human ﬁ brillin-2 (anti-rFBN2-
1) antisera were prepared as described [20,21]. Alexa488- and Alexa594-labelled 
secondary antibodies were from Molecular Probes Europe (Leiden, The Netherlands), 
rabbit anti-goat peroxidase and 3,3-diaminobenzidine tetrahydrochloride (DAB) were 
from DAKO (Glostrup, Denmark).
Isolation of scaffold components
Insoluble type I collagen was puriﬁ ed from bovine achilles tendon. Brieﬂ y, tendons 
were cleaned from non-collagenous tissue, pulverised under liquid nitrogen conditions 
using a Pulverisette 19 with a 0.5 mm sieve (Fritsch, Idar-Oberstein, Germany) and 
extensively rinsed with consecutively 0.1 M NaCl in 50 mM Tris-HCl pH 7.2, 1.0 M 
NaCl in 50 mM Tris-HCl pH 7.2, 4 M urea in 0.5 M acetic acid, 0.5 M acetic acid, 
acetone and demineralised water [22].
Insoluble elastin ﬁ bres (ELﬁ bre) were isolated from equine ligamentum nuchae. Non-
elastinous tissue was removed and ligaments were pulverised under liquid nitrogen 
conditions through a 1.0 mm sieve. The pulverised ligament was then washed/treated 
with 1 M NaCl in 10 mM phosphate buffer pH 7.4 (PB), various organic solvents, 
formic acid with CNBr, 4 M urea + 1 M 2-mercaptoethanol in 0.1 M PB, trypsin and 1 
M NaCl in 10 mM PB [23].
Solubilised elastin (ELsol) was prepared from insoluble elastin ﬁ bres by oxalic acid 
hydrolysis [24]. Brieﬂ y, 10 g elastin was hydrolysed for 1 h with 75 ml 0.25 M oxalic 
acid at 95°C. Then, the preparation was quickly cooled on ice, centrifuged and the 
supernatant collected. The pellet was hydrolysed again for 1 h with oxalic acid, followed 
by cooling and centrifuging. This procedure was repeated until all insoluble material 
was solubilised (generally after a total of 14 steps). Supernatants were pooled, dialysed 
against 10 mM PB and subsequently dialysed against MilliQ water using Amicon Ultra-
15 10 kDa MWCO ﬁ lter tubes (Millipore, Billerica, MA, USA).
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Characterisation of solubilised elastin preparation
The amount of solubilised elastin in the elastin pool was determined by Lowry [25], size 
of elastin using 1D gel electrophoresis (4% polyacrylamide gel with silver staining) [26] 
and gel permeation chromatography [27] (column material: Sephacryl S-500, reference 
samples: ferritin (0.88 MDa), dextran blue (2 MDa), and Helix pomatia heamocyanin 
(9 MDa), size-charge distribution using 2D gel electrophoresis [28], amine group 
content after reaction with 2,4,6-trinitrobenzene sulphonic acid [29], and amino acid 
composition using a Biochrom 20 amino acid analyser (Amersham Pharmacia Biotech, 
Uppsala, Sweden) [30].
Preparation of scaffolds
Various scaffolds were prepared composed of collagen only (COL), collagen + insoluble 
elastin ﬁ bres in a 1:1 ratio (COL-ELﬁ bre), or collagen with solubilised elastin in 97:3, 9:1 
and 1:1 ratios (COL-ELsol).
Brieﬂ y, a 2% (w/v) protein suspension (collagen without or with elastin ﬁ bres) was 
shaken overnight in 0.5 M acetic acid at 4°C. If appropiate, ELsol was added and the 
suspension diluted to 1% (w/v) with cold MilliQ water and homogenised on ice using 
a Potter-Elvehjem homogeniser. Air-bubbles were removed by centrifuging at 250 g for 
10 min at 4°C. The suspension was then slowly poured into a plastic mould, frozen 
in a bath of ethanol and solid CO2 (-80°C) and lyophilised in a Zirbus lyophiliser 
(Bad Grund, Germany). For scaffolds composed of collagen + ELsol in a 1:1 ratio, a 
suspension with a ﬁ nal concentration of 1.6% was used as well.
Scaffolds were applied as such (non-crosslinked), or crosslinked. For crosslinking, 200 
mg scaffold was incubated for 4 h at 22°C with 20 ml 33 mM 1-ethyl-3-(3-dimethyl 
aminopropyl)carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) in 50 mM 
2-morpholinoethane sulphonic acid (MES) pH 5.0 containing 40% ethanol. EDC/NHS-
crosslinked scaffolds were then washed with 0.1 M Na2HPO4 (twice for 1 h), 1 M NaCl 
(twice for 2 h), 2 M NaCl (once overnight, 5 times 30 min) and MilliQ water (6 times 
30 min). The scaffolds were then frozen in ethanol/CO2 again and lyophilised [12,31]. 
For in vivo experiments, EDC/NHS-crosslinked COL and COL-ELﬁ bre 1:1 scaffolds 
from a 1.0% suspension were used along with COL-ELsol 1:1 scaffolds from a 1.6% 
suspension.
Characterisation of scaffolds
The amine group content was measured to evaluate the degree of crosslinking [29]. 
The amount of Elsol bound to collagen was established by estimating the protein content 
in the solution after crosslinking. Proteins in this solution were precipitated with 10% 
TCA on ice for 2 h and centrifuged. The pellet was then dissolved in 10 mM NaOH 
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and the protein amount assayed according to Lowry [25]. The same procedure was 
applied to evaluate the in vitro release of ELsol from the scaffolds. Both non-crosslinked 
and EDC/NHS-crosslinked collagen scaffolds did not give any release of protein from 
the scaffolds after 24 h or 7 days in PBS, and therefore the protein release from COL-
ELsol scaffolds could be attributed to ELsol only. Water-binding capacity of scaffolds 
was determined as previously described [12]. Scanning electron microscopy (SEM) was 
used to analyse the morphology of the scaffolds [12], transmission electron microscopy 
(TEM) to determine the ultrastructure of the scaffolds [23] and immunoﬂ uorescence 
microscopy to study the distribution of ELsol in the scaffolds using mouse anti-bovine 
elastin (1:1000) as a primary antibody [13].
In vivo evaluation of scaffolds
The study was approved by the Ethical Committee of the Radboud University Nijmegen 
Medical Centre. Sprague Dawley rats (male, 3 weeks old) were purchased from Harlan 
(Zeist, The Netherlands) and housed per 2. The animals were fed pelleted diet and
water ad libitum. Scaffolds were washed in 70% (v/v) ethanol (4 x 30 min) and sterile 
PBS (8 x 30 min). Rats were anaesthetised with isoﬂ urane. Subcutaneous pockets were 
made to the right and left of two midline incisions on the back. Punches (ø 6 mm) 
of the scaffolds were implanted in the pockets at a distance of about 1 cm from the 
incisions (4 implants/rat). For each implantation time, 2 COL, 2 COL-ELﬁ bre and 4 COL-
ELsol scaffolds were implanted. COL and COL-ELﬁ bre results could be compared with 
previous experiments [13,32]. Implants with surrounding tissue were harvested at 3, 7 
and 21 days after implantation. Immediately after explantation, scaffolds were divided 
in two halves. One half was processed for conventional light microscopy, the other half 
for immunohistochemistry.
For conventional light microscopy, explants were ﬁ xed in 4% (v/v) formaldehyde in 
PB for at least 24 h at 4°C, and embedded in parafﬁ n. 5 µm sections were either 
haematoxylin-eosin (HE), Elastin Van Gieson (EVG; visualisation of elastin and 
collagen) or Von Kossa-stained (VK; visualisation of calcium deposits) [33]. Histological 
evaluation was performed independently by at least two persons.
Immunohistochemistry (both immunoﬂ uorescence and peroxidase-antiperoxidase) 
was used to study the biodegradation of scaffold components and the formation 
of extracellular matrix by the host. Scaffolds were frozen in liquid nitrogen, 5 µm 
cryosections were mounted on superfrost slides and air-dried. Immunoﬂ uorescence 
assay was performed as described [13]. Primary antibodies used were mouse anti-
bovine elastin (1:1000), rabbit anti-bovine type I collagen, goat anti-rat elastin, rabbit 
anti-rat type I collagen, rabbit anti-rat type III collagen (all 1:100), rabbit anti-human 
ﬁ brillin-1 and rabbit anti-human ﬁ brillin-2 (both 1:500). Antibodies were visualised 
with Alexa488 or Alexa594-conjugated secondary antibodies diluted in PBS containing 
5% normal rat serum. The antibody to bovine elastin also reacted with equine elastin, 
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the antibodies against human ﬁ brillin also reacted with rat ﬁ brillin, and the antibody to 
bovine type I collagen did not substantially cross-react with rat type I collagen or vice
versa. For immunohistochemistry with the peroxidase-antiperoxidase (PAP) method, 
cryosections were ﬁ xed with 4% paraformaldehyde in PBS for 20 min. Endogenous 
peroxidase was inhibited with 0.3% H2O2 for 10 min. After blocking for 30 min with 
2% BSA in PBS containing 0.1% Tween (PBST), sections were incubated with goat anti-
human type IV collagen (1:50) for 1 h, washed, and incubated for 1 h with rabbit anti-
goat IgG peroxidase (1:100), and washed. Antibodies were diluted in PBST containing 
5% normal rabbit serum, washings were with PBST. Sections were washed with 50 
mM Tris-HCl (pH 7.6) and incubated for 10 min with diaminobenzidine (DAB; 0.5 
mg/ml) and ammonium nickel-sulfate (7.5 mg/ml) in Tris-HCl. Finally, the reaction 
substrate was added (0.2 µl 30% H2O2/ml). Sections were washed, counterstained with 
haematoxylin, dehydrated and embedded. The antibody to human type IV collagen 
cross reacted with rat type IV collagen.
RESULTS
Analysis of solubilised elastin preparation
The solubilised elastin preparation was analysed by SDS-PAGE which revealed that the 
molecular mass range of the solubilised elastin was between 70 and >>880 kDa. Gel 
permeation chromatography gave a mean molecular mass of the solubilised elastin 
of about 1100 kDa. 2D gel electrophoresis showed that the elastin peptides had an 
isoelectric point of around 6. The amine group content of the solubilised elastin was 
292 ± 5 nmol amine groups / mg protein. Amino acid composition of solubilised 
elastin was similar to elastin ﬁ bres for all amino acid residues, including desmosine 
and isodesmosine (both 0.5 ± 0.0 per 1000 amino acid residues).
Analysis of scaffolds containing solubilised elastin
Porous scaffolds were prepared using various ratios of collagen with ELsol. After 4 h of 
crosslinking, less than 5% of ELsol could be retrieved from the remaining crosslinking 
solution. Hence, the crosslinking efﬁ ciency of ELsol to the scaffolds was at least 95%. 
In Table 1, the biochemical characteristics of the scaffolds are summarised. EDC/NHS-
crosslinking coupled ELsol ﬁ rmly to the scaffolds, since the in vitro release was only 2% 
after 7 days in case of EDC/NHS-crosslinked collagen + ELsol scaffolds, whereas this 
was about 60% after only 24 h when crosslinking was omitted. Both collagen and ELsol
possessed about 300 nmol amine groups per mg. Therefore scaffolds made from these 
components had the same amount of amine groups for all ratios prior to crosslinking. 
After EDC/NHS-crosslinking, approximately 60% of the amine groups remained for all 
scaffolds, indicating that 40% of the amine groups was used in the crosslinking reaction.
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Table 1. Biochemical characteristics of scaffolds prepared from collagen, collagen + elastin ﬁ bres and collagen 
+ solubilised elastin.
* No scaffolds could be prepared of ELsol alone.
** COL-ELsol 1:1 (1.6) scaffold was prepared from a 1.6% suspension of collagen and ELsol.
ND= not determined; COL= collagen; ELﬁ bre= insoluble elastin ﬁ bres; ELsol= solubilised elastin. Results 
are mean ± SD of 3 individual experiments.
ELsol did not contribute to the water-binding activity of scaffolds. At a higher percentage 
of ELsol, the water-binding capacity of COL-ELsol scaffolds was decreased.
On the scanning EM level (Fig. 1), non-crosslinked COL-ELsol scaffolds showed spherical 
structures attached to collagenous ﬁ brils/sheets. Spheres of different sizes (ranging 
from about 200 nm to 10 µm) were found throughout the scaffolds. After crosslinking, 
these spheres deformed to some extend. COL and COL-ELﬁ bre scaffolds did not show 
this spherical organization. Immunoﬂ uorescence staining using an antibody against 
bovine elastin demonstrated that the spheres in COL-ELsol scaffolds were composed of 
ELsol. The same was found based on the autoﬂ uorescence of elastin (Fig. 2A, B). In 
semi-thin epon sections, COL-ELsol show both closed and open elastin spheres (Fig. 2C, 
D). TEM showed that ELsol spheres in EDC/NHS-crosslinked COL-ELsol scaffolds had a 
wide size distribution and were mostly incorporated into the collagen network (Fig.
2E, F). The latter ﬁ gure also shows a sphere with a less-dense outer core. Crosslinking 
does not occur instantaneously which may cause this effect.
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Figure 1. Morphology of scaffolds as analysed by scanning electron microscopy.  (A, B) non-crosslinked 
(NX) COL-ELsol; (C, D) EDC/NHS-crosslinked (X) COL-ELsol; (E) COL and (F) COL-ELﬁ bre scaffolds. A and C 
represent cross-sectional views, whereas B, D, E and F are enlarged top views. Arrowheads indicate insoluble 
elastin ﬁ bres in COL-ELﬁ bre, whereas arrows indicate spherical structures that are only present in the COL-ELsol.
Spherical structures in EDC/NHS-crosslinked COL-ELsol are somewhat deformed compared to non-crosslinked 
COL-ELsol(inserts in B and D). Bar is 100 µm in A and C, and 10 µm in other images.
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Figure 2. Light microscopical and transmission electron microscopical evaluation of spherical structures in 
COL-ELsol scaffolds. (A) Immunoﬂ uorescence staining for elastin and (B) autoﬂ uorescence visualisation using 
UV optics in EDC/NHS-crosslinked scaffolds show that spherical structures are composed of ELsol. (C, D) 
Toluidine blue-stained semi-thin epon sections show that ELsol spheres are either closed (black arrowheads) 
or open (black arrows) in non-crosslinked scaffolds. (E-F) TEM images display that ELsol spheres (white 
arrowheads) are incorporated in the collagenous structures (white arrows) of EDC/NHS-crosslinked scaffolds. 
Bar is 50 µm in A, B, 20 µm in C, D and 0.25 µm in E, F.
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Tissue response to implanted scaffolds
All animals remained in good condition and no infections were observed. Macroscopically, 
a thin capsule was seen around the scaffolds at explantation. In Table 2 an overview of 
calciﬁ cation behaviour and cellular response is given for the three different scaffolds.
Table 2. General overview of calciﬁ cation and cellular events after subcutaneous implantation of the EDC/
NHS-crosslinked scaffolds in young Sprague Dawley rats.
* Absolute numbers of phagocytic cells were higher than of PMNs or non-phagocytic cells, e.g. + for 
phagocytic cells refers to more cells than + for PMNs or non-phagocytic cells.
** Blood vessels were assessed by immunostaining for rat type IV collagen, present in vascular basement 
membranes.
PMNs= polymorphic nuclear cells, i.e. granulocytes; phagocytic cells include monocyte-derived macrophages 
and giant cells; non-phagocytic cells include lymphocytes, plasma cells and mast cells. Events were scored 
ranging from sporadic (sp) to severe (++). -: not present.
Calciﬁ cation of scaffolds
In young Sprague Dawley rats, COL-ELsol did not calcify at all in the time span 
investigated in contrast to COL-ELﬁ bre (Fig. 3). In COL-ELﬁ bre, part of the elastin ﬁ bres 
calciﬁ ed from day 7 on, whereas the collagen ﬁ brils did not. COL did not show any 
calciﬁ cation.
Figure 3. Light microscopical evaluation of calciﬁ cation of scaffolds, 21 days after implantation in young 
Sprague Dawley rats. (A) COL, (B) COL-ELﬁ bre, (C) COL-ELsol scaffold. Calcium deposits have an intense black 
colour due to Von Kossa staining and are only found in COL-ELﬁ bre. Arrows indicate elastin ﬁ bres. Bar is 50 µm.
Cellular response to scaffolds
At day 3, cellular response to COL-ELsol showed moderate inﬁ ltration of neutrophilic 
granulocytes throughout the scaffold, whereas at day 7 ﬁ broblasts and other mononuclear 
cells,  and few giant cells were found. At day 21, an increased number of phagocytic 
cells was observed with strong proliferation of ﬁ broblasts. Cellular reactions to COL 
and COL-ELﬁ bre were considerably less. COL gave the mildest reaction; after 21 days 
macrophages and giant cells were present mainly at the periphery of the scaffolds. At 
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day 3, cellular response to COL-ELﬁ bre included some neutrophilic granulocytes which 
had entered the outer part of the scaffold. At day 7, ﬁ broblasts and other mononuclear 
cells were found in the scaffold with some giant cells at the periphery of the scaffold, 
and at day 21 phagocytic cells like macrophages and giant cells dominated the scaffold 
while the number of non-phagocytic cells increased at the periphery. Although more 
macrophages were found in COL-ELsol, the amount of giant cells in COL-ELsol and COL-
ELﬁ bre was similar.
Vascularisation of scaffolds
Staining for type IV collagen, present in endothelial basement membranes, was used 
to study the presence of blood vessels (Fig. 4). Blood vessels were most abundant in 
COL-ELsol, both at the periphery and within the scaffold. These scaffolds also contained 
more large blood vessels than COL-ELﬁ bre and COL. In COL-ELﬁ bre, vascularisation was 
also present at the periphery, but considerably less vessels were found within the 
scaffold. In COL, blood vessels were found only at the periphery of the scaffolds.
Figure 4. Light microscopical evaluation of angiogenesis in scaffolds, 21 days after implantation in young 
Sprague Dawley rats. Sections were stained for type IV collagen as a marker for blood vessels. (A) COL, (B) 
COL-ELﬁ bre, (C) periphery of COL-ELsol, (D) within COL-ELsol scaffold. Note increase in blood vessels in the 
COL-Elsol scaffold. Bar is 50 µm.
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Scaffold degradation and new matrix synthesis
Table 3 gives an overview of the immunostaining for scaffold components and newly 
formed extracellular matrix molecules at different time points.
Table 3. Overview of immunostaining results of explants for scaffold and rat extracellular matrix 
components.
Events were scored ranging from sporadic (sp) to abundant (++). -: not present.
Scaffold degradation
Scaffold degradation was studied using both conventional histology and 
immunohistochemistry with antibodies for scaffold elastin and collagen. From day 7, 
elastin staining in COL-ELsol decreased and after 21 days, elastin staining was reduced 
even more. Elastin spheres were still present at this time point, especially in the central 
part of the scaffolds (Fig. 5A, B). At the periphery of the scaffolds, staining intensity 
was less and spheres were smaller, suggesting resorption and degradation. Macrophages 
were able to incorporate elastin spheres (Fig. 5C). Collagen gradually decreased with 
time. Elastin ﬁ bre fragments (smaller than the implanted elastin ﬁ bres) were found 
from day 7 on in COL-ELﬁ bre. At day 21, less elastin staining and more elastin fragments 
were observed in these scaffolds. 
In COL-ELsol and COL-ELﬁ bre, thinner and fragmented collagen structures were visible 
mainly at the periphery of the scaffolds from day 7 on. More degraded collagen was 
found in COL-ELsol at this time point. At day 21, degraded collagen was also found 
more central in COL-ELsol and COL-ELﬁ bre, whereas only minor amounts of fragmented 
collagen were found in COL.
Collagen formation
Generally, most staining for rat type I and type III collagen was found in COL-ELsol,
somewhat less in COL-ELﬁ bre and the least in COL. In all scaffolds, staining for type I 
and III collagen started in the ﬁ brous capsule and at the periphery of the scaffolds from 
day 7 on. In general, new rat collagen ﬁ bres aligned with original scaffold components. 
However, in COL-ELsol ﬂ attened cells aligned only with the lamellar scaffold structures, 
and not with elastin spheres, and this was accompanied with extracellular matrix 
formation (Fig. 5D). Type IV collagen staining was present in blood vessels as shown 
under vascularisation (Fig. 4).
Elastic ﬁ bre formation
At day 21, COL-ELsol showed most new rat elastin, not only in blood vessels, but also as 
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thread-like structures within the scaffold. In COL-ELﬁ bre, rat elastin was found mainly 
in blood vessels present in the capsule around the implant and sporadically small 
amounts of thin elastic ﬁ bres were found at the periphery of the scaffolds. In COL, rat 
elastin was present only in blood vessels in the capsule. In blood vessels, rat elastin 
colocalised with ﬁ brillin-1 and ﬁ brillin-2 staining (Fig. 6). Fibrillin-2 staining was mainly 
present in blood vessels, but not all blood vessels contained elastin. Only ﬁ brillin-1 
staining colocalised with thin elastic ﬁ bres which were formed mainly in COL-ELsol, to 
less extent in COL-ELﬁ bre and scarcely in COL. Fibrillin-1 staining was found earlier in 
time than elastin and was more abundant than elastin staining (Fig. 6C, F).
Fig. 5. (A-B) Elastin Van Gieson stained parafﬁ n sections of COL-ELsol scaffolds shows that ELsol spheres from 
the scaffold are still present 21 days after implantation in young Sprague Dawley rats. Within the scaffolds, 
elastin spheres (arrowheads) are still quite large (A), but at the periphery of the scaffolds the elastin spheres 
have reduced sizes (B). Elastin Van Gieson stains elastin black and  collagen pink/red. (C-D) Semi-thin epon 
sections of crosslinked COL-ELsol 1:1 scaffolds that were implanted for 7 days in young Sprague Dawley rats 
stained with toluidine blue and basic fuchsin. Macrophages are able to incorporate solubilised elastin spheres 
(arrowheads) (C). Flattened cells aligned with the scaffold lamellar structures and were accompanied with 
extracellular matrix formation (D). Cells stain blue, new extracellular matrix stains light pink, and scaffold 
material stains dark pink. Bars represent 20 µm in A,B and 10 µm in C,D. Colour ﬁ gure on page 152.
DISCUSSION
In biomaterials, some principal difﬁ culties are observed including limited 
vascularisation and poor elastogenesis [1,34]. With regard to the application of 
elastin as a biomaterial, another difﬁ culty arises since elastin tends to calcify [13,35].
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Figure 6. Light microscopical evaluation of newly formed elastic ﬁ bres in scaffolds, 21 days after implantation 
in young Sprague Dawley rats. Sections were stained for rat elastin (A-C, G-I), ﬁ brillin-1 (D-F) and ﬁ brillin-2 
(J-L). Especially in COL-ELsol scaffolds, thread-like structures (arrows) positive for rat elastin and ﬁ brillin-1, 
but not for ﬁ brillin-2 were observed. Blood vessels mainly colocalised with ﬁ brillin-2, and to less extent with 
ﬁ brillin-1 staining. C= capsule; S= scaffold. Bar is 50 µm. Colour ﬁ gure on page 153.
In order to induce vascularisation and tissue formation, an initial tissue reaction seems 
to be necessary. COL scaffolds show less reaction than COL-ELﬁ bre or COL-ELsol, and little 
tissue formation was observed after three weeks. Tissue reaction is also dependent on 
the animal model that is used. In a previous study, we showed that (young and adult) 
Sprague Dawley rats showed more tissue reaction to subcutaneously implanted scaffolds 
compared to (adult) Wistar rats [13]. As a consequence, more vascularisation and collagen 
production was observed in the Sprague Dawley rats. In this study, COL-ELsol gave more 
tissue reaction than COL-ELﬁ bre, and vascularisation and tissue formation was further 
improved in COL-ELsol scaffolds. For example, in normal wound healing of the skin, 
chemotactic signals recruit inﬂ ammatory cells to the wound site, initiating the
process of reepithelialisation and connective tissue contraction, and stimulating the 
angiogenic response. It is important that this tissue reaction, including the presence of 
neutrophiles, does not persist over time since it is an indication of a grossly infected 
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wound [36]. In COL-ELsol, neutrophiles were only sporadically found at day 7. Soluble 
elastin seems to be able to trigger a cascade for angiogenesis and tissue regeneration. 
Robinet et al. [37] recently demonstrated that κ-elastin (solubilised elastin prepared by 
KOH treatment) triggered angiogenesis by promoting cell migration and tubulogenesis 
of human vascular endothelial cells through the elastin receptor.
COL-ELsol scaffolds were in particular able to stimulate the synthesis of elastic ﬁ bres 
in vivo, especially as thread-like structures to which ﬁ brillin-1 staining colocalised. 
Additional ﬁ brillin-1 staining was found surrounding these structures suggesting that 
ﬁ brillin-1 synthesis preceded elastin deposition and that elastin deposition was still 
in progress. Fibrillin-2 colocalised mainly with elastic ﬁ bres in blood vessels, and not 
with loose thread-like elastic ﬁ bres found in COL-ELsol. From mice experiments, it 
has been suggested that ﬁ brillin-2 directs elastogenesis during embryogenesis whereas 
ﬁ brillin-1 is more important in tissue homeostasis [38,39]. Our experimental setup 
may resemble tissue regeneration rather than embryogenesis. Furthermore, our results 
indicate that ﬁ brillin-2 may be more involved in cardiovascular aspects, while ﬁ brillin-
1 may be more signiﬁ cant in skin. Another study where skin biopsies were taken 
from healthy volunteers suggests a similar phenomenon: ﬁ brillin-1 was the major 
contributor to dermal elastic ﬁ bre formation during acute wound repair, whereas 
ﬁ brillin-2 was expressed only in wounds of the aged and expression was conﬁ ned to 
areas proximal to dermal blood vessels [40]. Fibrillin-1 may be the template for elastic 
ﬁ bre synthesis in thread-like (‘skin-like’) elastic ﬁ bres, whereas ﬁ brillin-2 may be the 
template for elastogenesis in blood vessels. However, time-resolved expression patterns 
of ﬁ brillin-1 and -2 would be necessary to further conﬁ rm this. Solubilised elastin 
may be a means to enhance elastic ﬁ bre synthesis. It has been suggested that elastin 
peptides stimulate elastin synthesis through the receptor [5]. In a porcine skin excision 
model, improved extracellular matrix remodelling (including elastin regeneration) 
was found with a collagen/solubilised elastin dermal substitute [41]. For a sustained 
effect of both angiogenesis and tissue formation in vivo, a depot of solubilised elastin 
is recommendatory. EDC/NHS-crosslinked COL-ELsol scaffolds contained solubilised 
elastin spheres that could still be detected 21 days after implantation and may thus 
accomplish their biological effect over a longer period of time.
Calciﬁ cation is an undesirable phenomenon in soft biomaterial application. Young 
Sprague Dawley rats have proven to be a sensitive model to study calciﬁ cation [13]. 
With COL-ELsol we could not detect any calciﬁ cation in the analysed time frame, 
whereas COL-ELﬁ bre showed calciﬁ cation starting at insoluble elastin ﬁ bres. This effect 
was not due to the presence of fewer macrophages and giant cells in COL-ELsol (and 
therefore a diminished release of extracellular enzymes involved in elastin degradation), 
as amounts of these cells were comparable in COL-ELﬁ bre and COL-ELsol scaffolds. 
Negative charges from C-terminal carboxylic groups may be involved in preventing 
positively charged calcium ions from precipitating, but other mechanisms cannot be 
excluded from this study alone. Others did observe calciﬁ cation of solubilised elastin 
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preparations. In a similar rat model, Singla and Lee found calciﬁ cation with collagen/
α-elastin ﬁ lms stabilised by glutaraldehyde ﬁ xation [35], but it is well-known that this 
treatment increases calciﬁ cation of biomaterials [42]. In a cranial lesion in adult rats, 
a polypentapeptide based on elastin with an amino acid sequence of (Val-Pro-Gly-Val-
Gly)n was also able to initiate calciﬁ cation in vivo [43], but it only calciﬁ ed in a rabbit 
tibial non-union model with  n>200 [44].
In conclusion, COL-ELsol scaffolds provide a non-calcifying biomaterial that stimulate 
angiogenesis and extracellular matrix formation (collagens and elastic ﬁ bres), and may 
be useful in soft tissue engineering.
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ABSTRACT
The preparation of vesicles from natural, biological macromolecules offers a major 
challenge in biomaterial and pharmacological science.  We here report on a novel, 
general method to prepare biovesicles combining freezing and lyophilisation procedures. 
The protein elastin, obtained by solubilisation of puriﬁ ed elastin ﬁ bres, was taken as 
an example. Vesicles ranging from 250 nm - 10 µm in diameter could be prepared 
and separated on basis of size. Vesicle features, such as diameter, were critically 
dependent on elastin concentration, type of solvent, and freezing/lyophilisation 
regime. Fluorescent-labelled (macro)molecules could be differentially incorporated in 
the vesicle wall and in the lumen, and were released by elastase digestion. Vesicles 
thus have potential as a binary delivery and release system. Vesicles were also obtained 
using other biomacromolecules such as albumin, atelocollagen and heparin, hence 
generalising the concept. Vesicle formation does not seem to rely on the amphiphilicity 
of the molecules used, thus establishing a new, widely applicable procedure.
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INTRODUCTION
Vesicle structures have found ample use as targetable drug carriers in pharmaceutics 
and cosmetics, and in special applications such as gene transfer [1]. A vesicle is 
deﬁ ned as a small sac that can contain gas or liquid. Vesicles in biological systems 
are usually lipid-based. Another class of self-assembled hollow spheres are protein-
based capsules such as virus capsids [2,3]. A new development involves polymeric 
and synthetic polypeptide vesicles (polymersomes) built up out of e.g. polyacrylic 
acid-polystyrene diblock copolymers or polymers based on ethylene glycol-modiﬁ ed 
amino acid residues [4,5]. Properties of polymersomal vesicles can be adjusted by 
the structure of the block copolymer [6] and solvent conditions [7], but are always 
based on the engineered amphiphilicity of the monomers [8]. In general, vesicles are 
prepared by mixing amphiphilic molecules in aqueous solutions, their formation being 
based on the tendency of hydrophobic parts of the molecules to self-associate while 
the more hydrophilic parts face the inner and outer water phase [2]. With respect 
to in vivo applications (biocompatiblity and biodegradability), it would be a major 
advantage if vesicles could be prepared from natural biomolecules. However, vesicles
from tissue-derived macromolecules such as (high molecular mass) proteins have not 
been reported yet. We here describe a general method to prepare vesicles by freezing 
and lyophilisation and which are solely based upon natural molecules. Solubilised 
elastin, obtained from puriﬁ ed elastin ﬁ bres by oxalic acid hydrolysis, was taken as a 
model compound, but the method works equally well with other macromolecules such 
as albumin, atelocollagen and heparin. To our knowledge, both the methodology for 
the preparation of vesicles and the use of natural proteins and other macromolecules 
for this purpose have never been realised before.
MATERIALS & METHODS
Materials
Puriﬁ ed insoluble elastin ﬁ bres were prepared as described [9] and hydrolysed with 
a procedure based on Partridge’s method [10]. Generally, elastin was solubilised after 
14 1 h hydrolysis steps with 0.25 M oxalic acid at 100°C. Supernatants were pooled, 
dialysed against 10 mM phosphate buffer pH 7.4 and then against MilliQ water. The 
solubilised elastin preparation (further called ‘elastin’) had a mean molecular mass of 
about 1100 kDa with a large molecular mass distribution and an isoelectric point of 
about 6. Amino acid composition of puriﬁ ed insoluble elastin ﬁ bres and solubilised 
elastin were similar, including the speciﬁ c crosslinks (iso)desmosine [11].
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Preparation of vesicles
The standard procedure for the preparation of vesicles was to drop 20 µl 2.0% (w/v) 
elastin in 0.25 M acetic acid in liquid nitrogen, keep the frozen droplets at -10 to -
20°C for about 3 h and then lyophilise the sample in a Zirbus lyophiliser (Bad Grund, 
Germany) using the program plotted in Fig. 1. Fixation of elastin vesicles was performed 
in vapour of 25% (w/v) glutaraldehyde/ 38% formaldehyde (w/v) 1:1 for 48 h, and 
was followed by wet ﬁ xation in 0.5% (v/v) glutaraldehyde in phosphate buffer pH 7.4 
(PB) for 4 h. Adaptations to this procedure included elastin concentration (0.2-5.0% 
(w/v)), solvent (0.25 M formic acid, propionic acid, butyric acid, oxalic acid or sodium 
acetate, and 50 mM and 0.25 M HCl), freezing temperature (-196 to -20°C), pressure 
settings during lyophilisation (20-400 Pa), and type of macromolecule, i.e. 0.25% type 
I atelocollagen (Symatese, Chaponost, France), 0.25% bovine serum albumin (Sigma, 
St. Louis, MO, USA) and 1.0% heparin (Sigma).
Figure 1. A representative run of the standard lyophiliser program for the preparation of elastin vesicles. Note 
that the pressure sensor can only accurately measure pressures under 1000 Pa.
Incorporation of ﬂ uorescent-labelled (macro)molecules into elastin vesicles
Incorporation of ﬂ uorescent probes in the vesicle wall was accomplished by addition 
of 50 µg probe/ml 2.0% (w/v) elastin solution prior to freezing and lyophilisation. 
Fluorescent probes included Alexa Fluor594 labelled goat anti-mouse antibody and 
Alexa Fluor488/594-labelled dextran (10,000 Da). Incorporation of ﬂ uorescent probes 
in the vesicle lumen was performed by a 96 h incubation of vapour-ﬁ xed vesicles in a 
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solution of 50 µg probe/ml in either MilliQ (dextrans) or ethanol (DiOC18 see below), 
followed by wet ﬁ xation, and 3 washings with MilliQ or 100% ethanol to remove non-
included probe. Probes included Alexa Fluor488 or 594-labelled dextran (10,000 Da) 
and 3,3’-dioctadecyloxacarbocyanine perchlorate DiOC18; all from Molecular Probes 
Europe (Leiden, The Netherlands).
Degradation studies with elastin vesicles containing ﬂ uorescent probes
Enzymatic degradation of vesicles containing ﬂ uorescent probes was assessed after 
incubation with elastase (Sigma) in 100 mM Tris-HCl pH 8.0 and analysed with confocal 
microscopy and scanning electron microscopy (SEM). Elastin vesicles containing Alexa 
Fluor488-labelled dextran in the vesicle wall and Alexa Fluor594-labelled dextran in the 
vesicle lumen were used for these experiments. In digestion experiments analysed by 
SEM, specimens were treated with 0.3 U/ml elastase and analysed after 0, 5, 10, 15, 20 
and 30 min at 22°C. In experiments analysed by confocal microscopy, specimens were 
digested with 0.4 U/ml elastase and analysed for 30 min at 22°C at 5 min intervals.
Fourier Transform Infrared (FT-IR) measurements
FT-IR spectra were obtained from 512 co-added double-sided interferograms at 2 cm-1
with a Bruker IFS-66 FT-IR spectrometer (Bruker, Karlsruhe, Germany). Spectroscopic 
grade deuterium oxide (D-content > 99.9 %) and tetradeuteroacetic acid (D-content 
> 99.5 %) were from Merck (Darmstadt, Germany). Freeze-induced changes were 
monitored by putting 5 µl elastin solution (2.0% in 0.25 M tetradeuteroacetic acid 
in D2O) between two AgCl windows and rapidly inserting this into a precooled (-
70ºC) variable temperature cell (Specac, Orpington, UK). This gave a temperature 
rise of about 25ºC that was restored within 10 min. After 30 min, infrared spectra 
were acquired in a continuous upward temperature gradient of 2.5ºC/min. Fourier 
self-deconvolution was applied, using a bandwidth of 18 cm-1 and a K-factor of up to 
K=2.3, to resolve overlapping bands while keeping overdeconvolution and noise to a 
minimum [12]. Curve ﬁ tting of absorbance spectra was performed as described before 
[13] using the OPUS NT 5.0 software.
Microscopical techniques
Transmission electron microscopy (TEM): Vapour and subsequently wet ﬁ xed samples 
were post ﬁ xed with 1% (w/v) osmium tetroxide in 0.1 M PB for 1 h. After a rinsing 
period of 3 h with 0.1 M PB, samples were dehydrated in an ascending series of 
ethanol in water solutions, embedded in epoxy resin (Epon 812), and microtomed. 
Ultrathin sections (60 nm) were picked up on formvar-coated grids, post stained with 
lead citrate and uranyl acetate, and examined in a JEOL 1010 electron microscope. 
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Frozen elastin specimens were freeze substituted at -90°C in acetone and embedded 
in lowicryl at -50°C [14,15].
Scanning electron microscopy (SEM): Lyophilised samples were sputtered with gold 
and studied with a JEOL JSM-6310 SEM apparatus with an accelerating voltage of 15 
kV. Wet samples ﬁ rst were critical point dried using CO2 (l).
Fluorescence-activated cell sorting (FACS): The average size of the stabilised vesicles 
was analysed by ﬂ ow cytometry (Epics Elite ﬂ ow cytometer, Coulter, Luton, UK). 
Vesicles were gated according to their forward and side scattering patterns. Fractions 
were collected on poly-D-lysine coated cover slips and left to attach for 60 min. Cover 
slips were critical point dried, sputtered with gold, and studied by SEM.
Freeze microscope: A preparation of 2.0% (w/v) elastin in 0.25 M acetic acid was 
frozen at -20°C/min until -70°C and analysed in the frozen state with a Lyostat 2 
microscope (Biopharma Technology Limited, Winchester, UK).
Confocal microscopy: Elastin vesicles with incorporated ﬂ uorescent probes were 
deposited on poly-D-lysine coated cover slips. Confocal images were made at 488 nm 
and 594 nm with a BioRad MRC1024 confocal laser scanning microscope, equipped 
with an argon/krypton laser, using a 60x 1.4 NA oil objective and LaserSharp2000 
acquisition software.
RESULTS
Vesicle formation
By quench-freezing at -196°C (liquid nitrogen), annealing and lyophilising of a 2.0% 
(w/v) solution of elastin in 0.25 M acetic acid, globular structures were formed ranging 
from 0.25-10 µm in diameter as revealed by scanning electron microscopy (SEM) (Fig.
2A). Further analysis using transmission electron microscopy (TEM) showed the 
vesicular nature of these spheres. Elastin vesicles with a perfect smooth and round 
morphology were obtained with elastin equally distributed throughout the vesicle wall. 
Images suggest that vesicles displayed some plasticity when in contact with each other 
(Fig. 2B). After preparation of the elastin vesicles, they were stabilised by treatment 
with a 25% glutaraldehyde / 38% formaldehyde 1:1 vapour for 48 h (‘vapour-ﬁ xation’). 
For further stabilisation, they were crosslinked in a solution of 0.5% glutaraldehyde in 
phosphate buffer of pH 7.4 for 4 h (‘wet ﬁ xation’). Diameters of stabilised vesicles up 
to 10 µm were found as analysed by ﬂ uorescence-activated cell sorting (FACS). Using 
FACS, it was possible to sort vesicles according to size (Fig. 2C).
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Figure 2. Elastin vesicles obtained by quench freezing at -196°C of 2.0% solubilised elastin in 0.25 M acetic acid 
followed by lyophilisation using the standard procedure (see M&M). (A) Scanning electron micrograph (SEM) 
shows that globular structures are formed upon freezing and lyophilisation. Bar is 5 µm. (B) Transmission 
electron micrograph (TEM) establishes vesicular nature of the globules in A. Inserts show that elastin is 
homogeneously distributed throughout the vesicle wall (left) and that vesicles may have some plasticity when 
in contact with each other (right). Bar is 1 µm. (C) SEM micrographs of stabilised vesicles that were sorted into 
four groups (A-D) based on their size using ﬂ uorescence-activated cell sorting (FACS). Bar is 2 µm.
Parameters inﬂ uencing vesicle formation
The standard methodology involved a 2.0% elastin in 0.25 M acetic acid solution 
which was quench frozen in liquid nitrogen (-196°C). The sample was subsequently 
placed in the lyophiliser with a plate temperature of -10°C that gradually decreased to 
-20°C within 3 h. When the plate temperature reached -20°C, pressure was reduced (80 
Pa) and these settings were kept constant for 8 h. Plate temperature was then increased 
to 0°C over a 5 h period. Next, plate temperature was increased to 20°C and pressure 
decreased to 30 Pa and kept for 1 h. Finally, the lyophiliser was slowly aerated and the 
samples were taken out of the lyophiliser (Fig. 1). Vesicle formation was dependent 
on many parameters, including elastin concentration, solvent composition, freezing 
temperature, annealing regime, pressure conditions during lyophilisation and type of 
biological macromolecule. Parameter modiﬁ cations resulted in an altered morphology 
of the structures obtained.
Elastin concentration: Elastin content inﬂ uenced the type of structures that were 
formed after freezing and lyophilisation (Fig. 3A). An optimum elastin concentration 
(2.0%) existed to obtain vesicles. At lower concentrations (0.2%) other self-assembled 
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structures were found, including tyroid-like structures and open vesicles, whereas at 
higher concentration (5.0%) sheets were predominantly found. At a concentration of 
2.0%, the majority of the structures in the preparation were vesicles.
Figure 3. The effect of different parameters on the morphology of structures formed after freezing and 
lyophilisation, as analysed by scanning electron microscopy. (A) Morphology as a function of elastin 
concentration. The optimum concentration of elastin for vesicle formation is 2.0% (w/v). (B) Morphology as 
a function of freezing regime. The optimum freezing medium to obtain vesicles is liquid nitrogen (-196°C). 
Bars are 5 µm.
Solvent composition: The solvent also inﬂ uenced the structure that was formed. In an 
acidic environment (0.25 M formic acid, acetic acid, propionic acid or butyric acid), 
globules were formed. Globule size was smaller with increasing alkyl chain of the 
acid solvent. Globules turned out to be vesicles when analysed with TEM (results 
not shown). No vesicles were formed from 0.25 M HCl, 0.25 M oxalic acid and 0.25 
M sodium acetate. Instead, ﬁ bres of several µm wide were formed in 0.25 M sodium 
acetate, resembling elastic ﬁ bre structures commonly found in vivo (results not 
shown).
Freezing temperature: Freezing temperature (freezing rate) was another important 
variable in vesicle formation. Freezing 2.0% elastin in 0.25 M acetic acid in liquid N2 (-
196°C) and subsequent lyophilisation yielded vesicles. When the freezing process was 
slowed down by using a solid CO2/ethanol mixture (-80°C) or by placing the sample 
in a -20°C freezer, more sheet-like structures were found (Fig. 3B).
Annealing regime: With the standard procedure for the preparation of vesicles, frozen 
specimens were left in a -10 to -20°C environment for about 3 h (annealing). When 
this time period was prolonged, more sheet-like structures (instead of vesicles) were 
found after lyophilisation, indicating that macromolecular motion occurred. At a 
lower annealing temperature (e.g. -80°C), the vesicles obtained after lyophilisation 
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were smaller, indicating that some macromolecular motion occurred with the standard 
procedure as well (results not shown). 
Annealing was required to obtain globules as shown by microscopical analysis of frozen 
elastin preparations. After freezing and annealing, but before lyophilisation, globular 
structures were found that could be attributed to elastin (Fig. 4) Using TEM, thread-like 
structures with globular extensions were found when the elastin solution was frozen 
in liquid N2 and freeze-substituted in acetone at -90°C. Using light microscopy, elastin 
globules (1-2 µm) were found when the elastin solution was frozen at -20°C/min until 
-70°C. Some of these globules were attached to a thread-like network. Globules formed 
out of the thread-like structures when the temperature was increased, as was shown 
by ﬂ uorescence microscopy of liquid nitrogen frozen samples that were left to thaw. 
When the elastin preparation was completely melted, no rounded structures could be 
observed.
Figure 4. Morphology of frozen 2.0% elastin in 0.25 M acetic acid. A, B Frozen at -20°C/min until -70°C 
and analysed by light microscopy without (A) and with elastin (B). Rounded structures only appeared when 
elastin was present. C Frozen in liquid nitrogen, freeze-substituted at -90°C in acetone, embedded in lowicryl 
and analysed by TEM. Thread-like structures showed globular extensions. D-F Elastin preparation containing 
Alexa Fluor594-labelled dextran before (D) and after (E-F) quench-freezing in liquid nitrogen, and analysed 
directly after freezing (E) and at a later time point (F) by ﬂ uorescence microscopy. Rounded structures formed 
out of sheets when the temperature increased. Bar is 10 µm in A and B, 1 µm in C, and 20 µm for D-F.
Pressure conditions during lyophilisation: The pressure settings during lyophilisation 
also inﬂ uenced vesicle formation. With the standard lyophilisation pressure (80 Pa), 
many vesicles were formed. At a lower pressure (20 Pa) more open vesicles were 
found, whereas at a higher pressure (400 Pa) more sheet-like structures were observed 
(results not shown).
Type of biological macromolecule : Applying the same freezing-annealing-lyophilisation 
technique as for elastin, vesicles could be prepared using macromolecules including 
serum albumin as an example of a spherical protein, type I atelocollagen, as an 
132
ch
ap
te
r 
7
pr
ep
ar
at
io
n 
of
 (
el
as
ti
n)
 b
io
ve
si
cl
es
example of a rod-like protein, and heparin as an example of a glycosaminoglycan (a 
polysaccharide) (Fig. 5).
Figure 5. Vesicle-like structures can be formed from other macromolecules than elastin in 0.25 M acetic acid. 
(A) 0.25% type I atelocollagen. (B) 0.25% bovine serum albumin (BSA). (C) 1.0% heparin. Heparin yielded 
the smallest structures. Bar is 10 µm.
Structural analysis by infrared spectroscopy
FT-IR spectra of quench-frozen 0.25 M tetradeuteroacetic acid in D2O without and with 
2.0% elastin were determined to give an indication of interactions in the frozen state. 
Without elastin (Fig. 6A), spectra were taken from -71 up to -5°C, and acetic acid 
displayed a temperature-dependent equilibrium between acetic acid monomeric and 
dimeric or polymeric structures. From -71 to -15°C, the carboxylic acid was present both 
in a dimer/polymer structure interacting with itself and as free, non-hydrogen bonded 
acetic acid monomers (C=O stretching band at 1648 cm-1 and 1733 cm-1, respectively) 
[16]. At -15°C, both bands collapsed and acetic acid acted only as a hydrogen bond 
acceptor, probably interacting with D2O (1704 cm
-1 band). With elastin present (Fig.
6B), spectra were taken from -68 up to 3°C. Acetic acid solely acted as a hydrogen 
bond acceptor at ﬁ rst, as observed from the relatively strong 1704 cm-1 band. This 
band gradually decreased at higher temperature (until approximately -22°C) when 
more acetic acid interacted with itself and free acetic acid monomers appeared as 
shown by the 1648 cm-1 band superimposed upon the amide I protein band (1645 cm-1)
and the 1726 cm-1 band, respectively. At -20°C and higher, acetic acid behaved only 
as a hydrogen bond acceptor again (collapse of bands at 1648 and 1726 cm-1 and re-
appearance of 1704 cm-1 band). Finally, at -68°C the amide I band was found at a lower 
frequency than at -22°C (1629 vs. 1645 cm-1), suggesting enhanced hydrogen bonding 
between elastin molecules. No evidence was found for changes in apolar VanderWaals 
interactions, since a bandshift around 1450 cm-1 was absent in the temperature range 
studied (data not shown).
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Figure 6. Expanded region of IR spectra of 0.25 M tetradeuteroacetic acid in D2O without (A) and with 2.0% 
(w/v) elastin (B), acquired in a temperature gradient from about -70°C (bottom) to 3°C (topmost spectrum). 
(A) The carboxylic acid vibrations were observed at 1648 cm-1 (C=O vibration in dimer or polymer), 1738 
cm-1 (non-hydrogen bonded or free carboxylic acid C=O group) and 1704 cm-1 (single hydrogen bond to 
carboxylic acid C=O group). (B) Superimposed upon the amide I protein band (1645 cm-1), the carboxylic 
acid vibrations were observed at the same frequencies as for A, with a distinct temperature dependency.
Incorporation of molecules into elastin vesicles
Fluorescent probes were encapsulated in the vesicles to study the potential of elastin 
vesicles as a molecular carrier. Fluorescent-labelled macromolecular molecules could 
be incorporated either in the vesicle wall and/or in the vesicle lumen based on the 
applied technique. Incorporation into the vesicle wall occurred when the probe was 
added to the elastin solution prior to the freezing step, similar to entrapment in a 
polymeric chitosan-based hydrogel [17]. Inclusion of the probe in the vesicle lumen 
occurred upon incubation of vapour-ﬁ xed vesicles in a probe solution, followed by wet 
ﬁ xation and washing of the vesicles to remove non-incorporated probe. In this fashion, 
it was possible to differentially incorporate similar substances in vesicle wall and/
or lumen (e.g. Fig. 7A, ﬂ uorescent-labelled dextrans) or to incorporate two distinct 
substances in vesicle wall and/or lumen, e.g. ﬂ uorescent-labelled antibodies in vesicle 
wall and ﬂ uorescent-labelled dextran in vesicle lumen, or a hydrophilic ﬂ uorescent 
labelled dextran probe in the vesicle wall, and a lipophilic DiOC18 probe in the vesicle 
lumen (results not shown).
Elastin vesicles with incorporated ﬂ uorescent probes were degraded by digestion with 
elastase as was shown by SEM at different time points. Elastin vesicle degradation 
resulted in the formation of elastin nanospheres (Fig. 7B). Elastase digestion also 
released the incorporated ﬂ uorescent macromolecules from the vesicles as was shown 
by confocal laser scanning microscopy (Fig. 7C).
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Figure 7. Fluorescent probes were differentially incorporated into the vesicle wall and the vesicle lumen as is 
shown in (A) for 10,000 Da dextran-conjugates labelled with Alexa Fluor488 (vesicle wall) or Alexa Fluor594 
(vesicle lumen). Upon degradation by elastase, elastin vesicles reassembled into nanoglobules and ﬂ uorescent 
probes were released in the process as evaluated at various time points by SEM (B) and confocal microscopy 
(C). Fluorescent molecules from the vesicle lumen released more rapidly than from the vesicle wall. Bar is 2 
µm in A, 1 µm in B, 20 µm in C. Colour ﬁ gure on page 153.
DISCUSSION
Plausible mechanisms for the formation of vesicles
Upon freezing a solution of 0.25 M acetic acid in water, pure ice crystals are formed 
initially, thereby increasing the concentration of acetic acid in the non-ice fraction [18]. 
In the presence of elastin, both acetic acid and elastin are concentrated in the non-
ice fraction as shown by microscopical analysis of frozen elastin preparations. Using 
quench-freezing at -196°C alone, a network of thread-like structures was obtained. 
Globular structures were principally formed when the temperature was increased after 
freezing (annealing). Globular structures are commonly found as a highly-concentrated 
liquid protein phase [19]. The rapid freezing procedure may ﬁ x a metastable phase 
rather than following thermodynamical equilibrium rules. Both freezing and annealing 
induce the phase separation process between water and elastin/acetic acid into 
135
rounded structures.
Once globular structures are present in a frozen elastin suspension, two mechanisms 
may explain the formation of the lumen in elastin globules using the freezing-
annealing-lyophilisation methodology, i.e. double phase separation and the coffee-
stain mechanism (Fig. 8).
Figure 8. Plausible mechanisms for the formation of vesicles by the freezing, annealing and lyophilisation 
methodology. Elastin is in solution at 4°C, but after freezing and annealing a primary phase separation into 
globular structures between ice and elastin/acetic acid was found. The mechanism of double phase separation 
explains the formation of the lumen in vesicles by a second phase separation between elastin and acetic acid, 
which probably also takes place during the freezing and annealing step. In the coffee-stain mechanism, the 
lumen is formed during lyophilisation because the globular fraction composed of concentrated elastin/acetic 
acid is not completely frozen and sublimation drives elastin molecules to the outer edge of the globule. For 
further details, see text.
Double phase separation explains the formation of the lumen by a second phase 
separation phenomenon prior to lyophilisation. As mentioned, the ﬁ rst phase separation 
results in globular structures after freezing and annealing. Concentrations due to 
freezing can rise up to 20-50 times the initial concentration and thus markedly increase 
molecular interactions that are negligible in the dilute solution and, concomitantly, add 
to the propensity for phase separation [20]. The second phase separation will then take 
place within the globular structures between concentrated elastin and concentrated 
acetic acid in such a way that elastin ends up at the ice interface. FT-IR results suggest 
that this phenomenon may be driven by the gradual increase of polymerised carboxylic 
groups in acetic acid when increasing the temperature of the frozen sample (and this 
may be applicable to other carboxylic acids and water, too). Finally, ice and acetic acid 
are removed by sublimation in the lyophilisation process resulting in elastin vesicles.
The second mechanism is a 3-dimensional analogue of the ‘coffee-stain mechanism’ 
[21] and can only occur when the contents of the highly concentrated globular 
structures remain liquid during the lyophilisation process (at -20°C). The original 
coffee-stain mechanism explains the formation of ring-like stains from solution 
droplets. During evaporation of the solvent the solute is concentrated at the edge of 
the droplet provided that the contact line of the solution with the solid substrate is 
pinned. To compensate for the evaporation losses, a capillary ﬂ uid ﬂ ow carries the 
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dispersed material from the interior out to the boundary of the drop and deposits as 
a solid ring [21,22]. In the 3-D analogue, the elastin molecules are driven to the outer 
edge of the globule by sublimation of acetic acid. The droplet may be ‘pinned’ because 
sublimation of ice subtracts heat from the outer part of the globule, allowing the acetic 
acid at the boundary of the globule to freeze which is necessary for sublimation during 
lyophilisation.
We are not able to discriminate between these two mechanisms as some uncertainties 
exist. For example, the ternary phase diagram of the water/acetic acid/elastin system 
is not known as are the concentrations of elastin and acetic acid in globular structures 
in the frozen samples, and the melting point of this concentrated fraction at low 
pressure.
Conditions that were varied in the methodology, e.g. elastin concentration, solvent 
composition, freezing rate and annealing regime, generally inﬂ uenced the initial phase 
separation and restructuring phase. The elastin starting concentration inﬂ uences the 
freeze-induced elastin concentration in the non-ice fraction. With a low freeze-induced 
elastin concentration, tyroid structures are formed. With a high freeze-induced elastin 
concentration, sheet-like structures are formed, because separate globules cannot be 
created. With a more hydrophobic carboxylic acid solvent, globule size is smaller, 
probably due to a higher propensity to phase separate from water. With a slower 
freezing rate, more sheets are present. Fast freezing may lead to a physical ﬁ xation of a 
metastable phase separation state, whereas slower freezing may favour thermodynamical 
equilibrium conditions. Annealing induced the formation of  globular structures as 
was found for frozen preparations by others [23]. However, a longer annealing time 
or a higher annealing temperature resulted in larger vesicles and ultimately sheet-like 
structures. That different circumstances inﬂ uence vesicle formation offers a means to 
control vesicle parameters such as diameter. Larger vesicles may be prepared with a 
less hydrophobic carboxylic acid, a slower freezing rate, a longer annealing period or 
a higher annealing temperature.
Elastin displays self-assembling characteristics, but these do not seem to be of importance 
in the preparation of vesicles. During coacervation, which is a reversible self-assembly 
process of enhanced folding of protein molecules with increasing temperature, the 
disruption of protein-solvent hydrogen bonds allows apolar VanderWaals elastin-elastin 
interactions, thus leading towards more protein folding [24]. However, no changes
in hydrophobic interactions were found with FT-IR. Furthermore, the ability of other 
biological macromolecules to form vesicles with the applied methodology indicates 
that it is a more common principle, unrelated to self-assembling behaviour elastin. 
Molecules that do not exhibit self-assembling behaviour can also yield vesicles.
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Potential of (elastin) biovesicles
Like certain polymersomes [25], elastin vesicles are able to encapsulate both aqueous 
solutions of proteins/drugs and lipophilic substances. In a pharmacological context, 
the simultaneous release of different materials is not easy and the preparation of multi-
component vesicles in a single delivery vehicle is beneﬁ cial in this respect [8]. With 
the possibility to incorporate different substances into the vesicle wall and the vesicle 
lumen, such a two-way system may be prepared with elastin vesicles. Furthermore, 
release of substances may be tailored by the extent of vesicle ﬁ xation and by the 
concentration of the substances to be incorporated.
Vesicles from biological proteins are especially interesting because they are biodegradable 
and biocompatible. They may form slow-release depots for therapeutics, may be 
directed to speciﬁ c locations in the body (e.g. by incorporating speciﬁ c antibodies into 
the vessel wall), and may release their content at speciﬁ c sites (e.g. in case of elastin 
vesicles at sites of high elastase concentrations).  Since vesicles can be prepared in 
large quantities application in tissue engineering is also possible.
CONCLUSION
We have shown that vesicles from natural macromolecules can be prepared by a 
freezing-annealing-lyophilisation methodology, as exempliﬁ ed by solubilised elastin. 
Vesicles could be differentially charged with various molecules either in the vesicle wall 
and/or the vesicle lumen depending on the moment of addition. The guest molecules 
were released upon elastase digestion. These vesicles may have great potential as a 
(binary) delivery and release system.
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Summary, general conclusions and future directions
Samenvatting, algemene conclusies en toekomstvisie 
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SUMMARY
Elastin in biomaterials
Extracellular matrix components are valuable building blocks for the preparation of 
biomaterials, especially if their biological, chemical and physical characteristics can 
be controlled. Elastin is present in elastic ﬁ bres as an insoluble, highly cross-linked 
protein, providing elasticity to organs like lung, aorta, and ligaments. Soluble elastin 
can be derived from elastin ﬁ bres by hydrolysis, and displays various biological effects, 
like enhancement of cell proliferation and induction of elastin synthesis. Despite its 
remarkable properties, elastin has found little use as a biomaterial. This thesis describes 
the preparation of puriﬁ ed insoluble elastin ﬁ bres and solubilised elastin, and their 
application as a biomaterial for tissue engineering purposes. The construction of tailor-
made (composite) scaffolds and the evaluation of their biocompatibility in vitro and 
in vivo, as well as the preparation of elastin biovesicles are assessed. In Chapter 1 an 
overview is given on the preparation and application of elastin-based biomaterials. 
Special attention is given to the different forms of elastin-based biomaterials that exist 
and some tissue engineering applications are highlighted.
Preparation of elastin ﬁ bres and solubilised elastin
Purity is of major importance when using extracellular matrix components as 
a biomaterial in order to be able to study the (cell-biological) effect of individual 
components. Puriﬁ cation of intact elastin from elastic ﬁ bres presents a major challenge, 
among others for the intimate interwoveness of elastin and microﬁ brils. Insoluble 
elastin -free of microﬁ brils- was isolated from equine ligamentum nuchae as described 
in Chapter 2. A modiﬁ ed procedure resulting in both intact and pure ﬁ bres is given in 
Chapter 3. The term ‘elastin ﬁ bre’ was introduced to indicate an elastic ﬁ bre in which 
the only component is elastin. Elastin ﬁ bres were used in the preparation of solubilised 
elastin by oxalic acid hydrolysis (Chapter 6).
Preparation and characterisation of collagen-elastin scaffolds
Tailor-made biomaterials for tissue engineering are designed to mimic the extracellular 
matrix composition of a speciﬁ c tissue. This is only possible when the characteristics 
of the biomaterials can be fully controlled. The development of molecularly-deﬁ ned 
scaffolds from puriﬁ ed type I collagen ﬁ brils, elastin ﬁ bres and chondroitin sulfate 
is described in Chapter 4. Collagen and elastin ﬁ bres physically interacted with each 
other in the scaffolds. Some collagen was necessary to obtain coherent scaffolds. The 
preparation of scaffolds containing crosslinked type I collagen ﬁ brils and solubilised 
elastin is described in Chapter 6. Solubilised elastin formed globular structures 
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that were incorporated in the collagenous part of the scaffolds. Many parameters 
determining the biochemical and mechanical properties of these scaffolds can be 
controlled, e.g. the composition (by the ECM components used and their ratio), the 
type and extent of chemical crosslinking, the pore size of the scaffold (by the freezing 
rate during the manufacturing process), the scaffold shape (by the mould), and the 
water-binding capacity (by the attachment of glycosaminoglycans). Scaffolds proved 
to be cytocompatible.
Tissue response to collagen-elastin scaffolds
Tissue response to porous scaffolds composed of crosslinked collagen-elastin ﬁ bres 
and collagen-solubilised elastin were studied after subcutaneous implantation in rats 
(Chapter 5 and 6, respectively). Collagen-elastin ﬁ bres scaffolds did not calcify in adult 
rats, but showed calciﬁ cation in young Sprague Dawley rats (a sensitive calciﬁ cation 
model). Collagen-solubilised elastin scaffolds, however, did not calcify. In scaffolds 
containing impure elastin (e.g. scaffolds containing pulverised ligament), calciﬁ cation 
was more severe. None of the implanted scaffolds calciﬁ ed in adult rats. Degradation 
of scaffolds and new matrix formation were related to cellular inﬂ ux and degree 
of vascularisation. Scaffolds containing solubilised elastin increased elastic ﬁ bre 
production and induced angiogenesis.
Preparation and characterisation of vesicles from solubilised elastin
The preparation of vesicles from biological macromolecules offers a major challenge 
in material science. Vesicles (250 nm – 10 µm in diameter) could be obtained from 
solubilised puriﬁ ed elastin using a novel approach combining freezing and lyophilisation 
procedures (Chapter 7). Vesicle formation was critically dependent on elastin 
concentration, solvent, freezing mode and pressure conditions during lyophilisation. 
The elastin vesicles could be fractionated based on their size. Fluorescent-labelled 
(macro)molecules were differentially incorporated into the vesicle wall and/or vesicle 
lumen and were released by elastase digestion. Vesicles can thus create a potential 
two-phase delivery system.
GENERAL CONCLUSIONS
Highly puriﬁ ed and intact elastin ﬁ bres were prepared which were devoid of microﬁ brils 
and could be solubilised by oxalic acid hydrolysis. Various elastin biomaterials were 
developed from these elastin preparations. At ﬁ rst, scaffolds were designed to mimic 
the extracellular matrix constitution and were composed of type I collagen, elastin 
ﬁ bres and glycosaminoglycans, or type I collagen and solubilised elastin. Particularly, 
scaffolds composed of collagen and solubilised elastin showed improved tissue 
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regeneration after subcutaneous implantation, i.e. increased elastic ﬁ bre production 
and induced angiogenesis without calciﬁ cation. In addition, new features could be 
given to elastin biomaterials as in the case of elastin biovesicles that were able to 
incorporate and release ﬂ uorescent macromolecules. It was thus shown that elastin is 
a valuable component of biomaterials for tissue engineering.
FUTURE DIRECTIONS
Elastin-based materials are promising in the ﬁ eld of biomaterials, tissue engineering 
and controlled release, especially because they exhibit interesting biological, 
biomechanical, biochemical and biophysical properties, and may comprise novel 
approaches for improving tissue regeneration. Extracellular matrix mimicking scaffolds 
are especially interesting when variables like chemical composition and architecture 
can be controlled, as shown in this thesis. Self-assembling elastin-based materials are 
an emerging and promising theme within the biomaterials ﬁ eld. A bottom-up approach 
may lead to well-deﬁ ned biomaterials when proteins are used as building blocks for 
the fabrication of higher order structures via (self-)assembly [1].
From the preparation of biomaterials and the evaluation of their biocompatibility the 
next step can now be taken towards deﬁ ned in vivo applications. Scaffolds can be 
designed to speciﬁ cally mimic or regenerate a speciﬁ c organ. One example is to make 
a bilayered skin construct that may not need the incorporation of cells outside the 
body, but attracts and controls the desired cells in vivo. The dermal element can be 
composed of a porous collagen-elastin scaffold with attached glycosaminoglycans that 
allow binding of growth factors that speciﬁ cally promote angiogenesis and ﬁ broblast 
proliferation. It can be covered by a collagen ﬁ lm containing heparan sulfate and a 
growth factor that stimulates keratinocyte proliferation (Fig. 1).
Elastin may also be valuable in vascular grafts, providing both desired mechanical 
properties (e.g. elasticity) and biological effects on speciﬁ c cell types. Another 
application may be elastic cartilage present in e.g. auricle (external ear) and epiglottis. 
By combining different extracellular matrix components (including growth factors and 
morphogens), even the embryonic microenvironment may be mimicked. Embryonic 
scaffolds may provide the correct signals to the body to start the formation of new 
tissues. Elastin-based biomaterials thus have great potential for tissue engineering 
applications.
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Figure 1. Design of a bilayered scaffold as a full-thickness skin graft.  The scaffold contains elements for the 
inﬂ ux and differentiation of cells. Population of the matrix by cells of the body should lead to the formation 
of intact skin.
Figuur 1. Ontwerp van een dubbellaags matrix voor een huidsubstituut dat zowel de dermale als de epidermale 
component bevat. De matrix bevat bouwstenen voor de instroom en differentiatie van cellen. Ingroei door 
lichaamseigen cellen in de matrix moet aanleiding geven tot de vorming van intacte huid.
SAMENVATTING
Elastine in biomaterialen
Extracellulaire matrix componenten zijn waardevolle bouwstenen om biomaterialen mee 
te bereiden, in het bijzonder als de biologische, chemische en fysische eigenschappen 
van deze materialen beheersbaar zijn. Elastine is aanwezig in elastische vezels als een 
onoplosbaar, verknoopt eiwit en het geeft elasticiteit aan organen zoals long, aorta 
en ligamenten. Oplosbaar elastine kan bereid worden uit elastinevezels door middel 
van hydrolyse. Het vertoont verscheidene biologische effecten zoals een verbeterde 
celproliferatie en verhoogde elastineproductie. Ondanks de bijzondere eigenschappen 
van elastine, kent het nog weinig toepassing als biomateriaal. Dit proefschrift beschrijft 
de zuivering van onoplosbare elastinevezels, de bereiding van oplosbaar elastine en de 
toepassing als biomateriaal voor weefseltechnologie (tissue engineering). De bereiding 
van op maat gemaakte matrices, de evaluatie van hun biocompatibiliteit en de 
bereiding van biovesicles worden hier beschreven. In Hoofdstuk 1 wordt een overzicht 
gegeven van de bereiding en toepassing van op elastine gebaseerde biomaterialen. 
Speciale aandacht wordt hierbij geschonken aan de verschillende vormen van 
elastine als biomateriaal en er wordt nader ingegaan op enkele toepassingen in de 
weefseltechnologie.
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Bereiding van elastinevezels en oplosbaar elastine
Bij het gebruik van extracellulaire matrixcomponenten als biomateriaal is zuiverheid 
van groot belang om in staat te zijn het (celbiologische) effect van de afzonderlijke 
componenten te bestuderen. Isolatie van intact elastine uit elastische vezels biedt een 
grote uitdaging, mede doordat elastine en microﬁ brillen hierin sterk verweven zijn. 
Onoplosbaar elastine werd gezuiverd uit paardennekligamenten zoals beschreven in 
Hoofdstuk 2. Een aangepaste methode (Hoofdstuk 3) resulteerde in zowel intacte als 
zuivere vezels. De term ‘elastinevezel’ werd geïntroduceerd om een elastische vezel 
aan te duiden met als enige bestanddeel elastine. Deze elastinevezels werden gebruikt 
om oplosbaar elastine te maken door middel van oxaalzuurhydrolyse (Hoofdstuk 6).
Bereiding en karakterisering van collageen-elastine matrices
Op maat gemaakte biomaterialen voor tissue engineering werden zodanig ontwikkeld 
dat zij de extracellulaire matrixcompositie van speciﬁ eke weefsels nabootsten. Dit is 
alleen mogelijk als de eigenschappen van deze biomaterialen beheerst kunnen worden. 
De ontwikkeling van moleculair-gedeﬁ nieerde matrices uit collageen type I ﬁ brillen, 
elastinevezels en chondroïtinesulfaat staat beschreven in Hoofdstuk 4. Collageen 
en elastinevezels gingen een fysieke interactie met elkaar aan in deze matrices. Een 
kleine hoeveelheid collageen was nodig om stabiele matrices te maken. De bereiding 
van matrices met collageen type I ﬁ brillen en oplosbaar elastine wordt beschreven in 
Hoofdstuk 6. Oplosbaar elastine vormde bolvormige structuren die deel uitmaakten 
van het collagene deel van de matrices. Diverse parameters die de biochemische en 
mechanische eigenschappen van deze matrices bepalen, kunnen beheerst worden, 
zoals de samenstelling (door de gebruikte extracellulaire matrixcomponenten en hun 
ratio), het type en de mate van chemische crosslinking, de poriegrootte van de matrix 
(door de invriessnelheid tijdens het bereidingsproces), de vorm van de matrix (door de 
mal) en de waterbindende eigenschappen (door koppeling van glycosaminoglycanen). 
Cellen konden op de gevormde matrices groeien en zich ontwikkelen.
Weefselreactie op collageen-elastine matrices
De weefselreactie op poreuze matrices, bestaande uit collageen met elastinevezels en 
collageen met oplosbaar elastine, is bestudeerd na onderhuidse implantatie in ratten 
(Hoofdstuk 5, respectievelijk 6). Collageen-elastinevezels matrices calciﬁ ceerden niet 
in volwassen ratten, maar wel in jonge Sprague Dawley ratten (een gevoelig model 
voor de bestudering van calciﬁ catie). Matrices opgebouwd uit onzuivere componenten 
(bijvoorbeeld matrices met verpulverd ligament) vertoonden meer calciﬁ catie, terwijl 
collageen-oplosbaar elastine matrices helemaal niet calciﬁ ceerden. De afbraak van 
de matrices en de vorming van nieuwe extracellulaire matrixcomponenten konden 
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worden gerelateerd aan de mate van cellulaire instroming en bloedvatvorming. Vooral 
in matrices die oplosbaar elastine bevatten, werden nieuwe elastische vezels en 
bloedvaten waargenomen.
Bereiding en karakterisering van vesicles uit oplosbaar elastine
De bereiding van vesicles uit biologische macromoleculen biedt een grote uitdaging 
binnen de materiaalwetenschappen. Vesicles (250 nm – 10 µm in diameter) konden 
vervaardigd worden uit oplosbaar elastine door middel van een nieuwe aanpak die 
invriezen en vriesdrogen combineert (Hoofdstuk 7). De vorming van vesicles was 
afhankelijk van elastineconcentratie, oplosmiddel, vriesprocedure en vacuümcondities. 
De vesicles konden gesorteerd worden op basis van hun grootte. Fluorescent-gelabelde 
(macro)moleculen werden opgesloten in de vesicle wand en/of de vesicleholte en 
kwamen vrij door digestie met het enzym elastase. Deze vesicles kunnen mogelijk als 
twee-fasen afgiftesysteem toegepast worden.
ALGEMENE CONCLUSIES
Hoog-gezuiverde intacte elastinevezels, die geen microﬁ brillen meer bevatten, zijn 
bereid. Deze elastinevezels konden oplosbaar worden gemaakt door middel van 
oxaalzuurhydrolyse. Verschillende elastinebiomaterialen werden ontwikkeld met zowel 
elastinevezels als oplosbaar elastine. Matrices bootsten de extracellulaire matrix na en 
waren opgebouwd uit collageen type I, elastinevezels en glycosaminoglycanen of uit 
collageen type I en opgelost elastine. Met name de laatstgenoemde matrices lieten een 
verbeterde weefselregeneratie zien na onderhuidse implantatie, dat wil zeggen dat deze 
een verhoogde elastinevezelproductie en bloedvatvorming gaven en geen calciﬁ catie. 
Daarnaast werden nieuwe eigenschappen gevonden voor elastinebiomaterialen zoals 
de vorming van elastinevesicles waarmee het mogelijk was om ﬂ uorescente moleculen 
op te sluiten en te laten vrijkomen. Er is dus aangetoond dat elastine een waardevolle 
bouwsteen is van biomaterialen voor tissue engineering.
TOEKOMSTVISIE
Materialen gebaseerd op elastine zijn veelbelovend in het veld van biomaterialen 
weefseltechnologie en gedoseerde afgifte, vooral omdat deze materialen interessante 
biologische, biomechanische, biochemische en biofysische eigenschappen bezitten 
en nieuwe mogelijkheden bieden om weefselherstel te verbeteren. Matrices die op 
de werkelijke extracellulaire matrix gebaseerd zijn, worden vooral interessant indien 
variabelen, zoals chemische samenstelling en vorm, beheerst kunnen worden, 
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hetgeen in dit proefschrift is aangetoond. Elastine-achtige materialen die gebaseerd 
zijn op het zelf-aggregerende gedrag van elastine zijn een opkomend en veelbelovend 
thema binnen het biomaterialenveld. Een ‘bottom-up approach’ kan leiden tot goed 
gedeﬁ nieerde biomaterialen indien eiwitmoleculen worden gebruikt als bouwstenen 
om tot grotere structuren te komen door middel van (zelf-)aggregatie [1].
Na de bereiding van biomaterialen en de evaluatie van hun biocompatibiliteit kan 
nu de volgende stap gezet worden in de richting van in vivo toepassingen. Matrices 
kunnen dusdanig ontworpen worden dat ze een bepaald orgaan nabootsen of kunnen 
regenereren. Een voorbeeld hiervan is een dubbellaags huidvervanging dat in het 
lichaam de gewenste cellen aantrekt en laat ontwikkelen in plaats van dit buiten 
het lichaam te bewerkstelligen. De dermale component kan bestaan uit een poreuze 
collageen-elastine matrix met glycosaminoglycanen die binding van groeifactoren 
mogelijk maakt die speciﬁ ek de bloedvatvorming of ﬁ broblastengroei bevorderen. Deze 
laag wordt bedekt met een collageenvlies dat heparansulfaat bevat en een groeifactor 
die de groei van keratinocyten stimuleert (Fig. 1).
Elastine kan ook een waardevolle component zijn in bloedvatconstructen, en hierbij 
zowel de gewenste mechanische eigenschappen (elasticiteit) als celbiologische 
effecten geven. Een andere toepassing ligt mogelijk in de regeneratie van elastisch 
kraakbeen zoals dat aanwezig is in bijvoorbeeld de oorschelp en het strotklepje. Door 
verschillende extracellulaire matrixcomponenten (in combinatie met groeifactoren 
en morfogenen) te combineren, zou mogelijk zelfs de embryonale micro-omgeving 
nagebootst kunnen worden. Embryonale matrices zouden op deze manier de juiste 
signalen aan het lichaam kunnen geven om een aanzet te geven tot de vorming van 
nieuwe weefsels. Biomaterialen gebaseerd op elastine bieden dus grote mogelijkheden 
voor toepassing in de weefseltechnologie.
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